

Exhibit 16



US012285261B2

(12) **United States Patent**
Bishay et al.

(10) **Patent No.: US 12,285,261 B2**
(45) **Date of Patent: *Apr. 29, 2025**

(54) **MOISTURE-RESISTANT
ELECTROCARDIOGRAMY MONITOR**

(71) Applicant: **Bardy Diagnostics, Inc.**, Bellevue, WA
(US)

(72) Inventors: **Jon Mikalson Bishay**, Lexington, KY
(US); **Jason Felix**, Vashon Island, WA
(US); **Gust H. Bardy**, Carnation, WA
(US)

(73) Assignee: **Bardy Diagnostics, Inc.**

(*) Notice: Subject to any disclaimer, the term of this
patent is extended or adjusted under 35
U.S.C. 154(b) by 49 days.

This patent is subject to a terminal dis-
claimer.

(21) Appl. No.: **18/318,641**

(22) Filed: **May 16, 2023**

(65) **Prior Publication Data**
US 2023/0301576 A1 Sep. 28, 2023

Related U.S. Application Data

(63) Continuation of application No. 17/959,174, filed on
Oct. 3, 2022, now Pat. No. 11,653,869, which is a
(Continued)

(51) **Int. Cl.**
A61B 5/05 (2021.01)
A61B 5/00 (2006.01)
(Continued)

(52) **U.S. Cl.**
CPC **A61B 5/349** (2021.01); **A61B 5/0006**
(2013.01); **A61B 5/0205** (2013.01); **A61B**
5/259 (2021.01);
(Continued)

(58) **Field of Classification Search**
CPC . A61B 5/04085; A61B 5/0006; A61B 5/6833;
A61B 5/04087; A61B 5/0402;
(Continued)

(56) **References Cited**

U.S. PATENT DOCUMENTS

5,862,803 A 1/1999 Besson et al.
7,197,357 B2 3/2007 Istvan et al.

(Continued)

FOREIGN PATENT DOCUMENTS

WO WO 03/065926 A2 8/2003
WO WO 2008/005015 A1 1/2008
WO WO 2010/104952 A2 9/2010

OTHER PUBLICATIONS

Anand et al., "Design of the Multi-Sensor Monitoring in Congestive
Heart Failure (MUSIC) Study: Prospective Trial to Assess the
Utility of Continuous Wireless Physiologic Monitoring in Heart
Failure", Journal of Cardiac Failure, vol. 17, No. 1, Jan. 1, 2011, pp.
11-16 (6 pages).

(Continued)

Primary Examiner — Joseph A Stoklosa


Assistant Examiner — Brian M Antiskay

(74) *Attorney, Agent, or Firm* — K&L Gates LLP

(57) **ABSTRACT**

Physiological monitoring can be provided through a light-
weight wearable monitor that includes two components, a
flexible extended wear electrode patch and a reusable moni-
tor recorder that removably snaps into a receptacle on the
electrode patch. The wearable monitor sits centrally on the
patient's chest along the sternum oriented top-to-bottom.
The placement of the wearable monitor in a location at the
sternal midline, with its unique narrow "hourglass"-like
shape, significantly improves the ability of the wearable
monitor to cutaneously sense cardiac electrical potential
signals, particularly the P-wave and the QRS interval signals
indicating ventricular activity in the ECG waveforms. In
particular, the ECG electrodes on the electrode patch are
tailored to be positioned axially along the midline of the
sternum for capturing action potential propagation in an
orientation that corresponds to the aVF lead used in a

(Continued)



US 12,285,261 B2

Page 2

conventional 12-lead ECG that is used to sense positive or upright P-waves.

19 Claims, 15 Drawing Sheets

Related U.S. Application Data

continuation of application No. 16/782,951, filed on Feb. 5, 2020, now Pat. No. 11,457,852, which is a continuation of application No. 16/404,562, filed on May 6, 2019, now Pat. No. 10,561,328, which is a continuation of application No. 16/174,122, filed on Oct. 29, 2018, now Pat. No. 10,278,606, which is a continuation of application No. 15/645,708, filed on Jul. 10, 2017, now Pat. No. 10,111,601, which is a continuation of application No. 14/488,230, filed on Sep. 16, 2014, now Pat. No. 9,700,227, which is a continuation-in-part of application No. 14/080,725, filed on Nov. 14, 2013, now Pat. No. 9,730,593.

(60) Provisional application No. 61/882,403, filed on Sep. 25, 2013.

(51) **Int. Cl.**
A61B 5/0205 (2006.01)
A61B 5/259 (2021.01)
A61B 5/282 (2021.01)
A61B 5/349 (2021.01)

(52) **U.S. Cl.**
CPC *A61B 5/282* (2021.01); *A61B 5/6823* (2013.01); *A61B 5/7225* (2013.01); *A61B 2560/0406* (2013.01); *A61B 2560/0443* (2013.01)

(58) **Field of Classification Search**
CPC A61B 2018/00351; A61N 1/04; A61N 1/0484
USPC 600/372, 382, 384, 386, 388, 390–393, 600/508–509
See application file for complete search history.

(56) **References Cited**

U.S. PATENT DOCUMENTS

7,206,630	B1	4/2007	Tarler	
7,212,849	B2	5/2007	Zhang et al.	
7,395,106	B2	7/2008	Ryu et al.	
7,468,032	B2	12/2008	Stahmann et al.	
8,150,502	B2	4/2012	Kumar et al.	
8,214,007	B2	7/2012	Baker et al.	
8,315,695	B2	11/2012	Sebelius et al.	
8,483,809	B2	7/2013	Kim et al.	
8,538,503	B2	9/2013	Kumar et al.	
8,611,980	B2	12/2013	Choe et al.	
8,647,268	B2	2/2014	Tran	
8,718,742	B2	5/2014	Beck et al.	
8,926,509	B2	1/2015	Magar et al.	
9,211,073	B2	12/2015	Banet et al.	
9,277,864	B2	3/2016	Yang et al.	
9,510,755	B2	12/2016	Fong et al.	
9,669,212	B2	6/2017	Mueller et al.	
10,327,660	B2	6/2019	Gallego et al.	
10,413,251	B2	9/2019	Golda et al.	
10,441,185	B2	10/2019	Rogers et al.	
11,051,743	B2	7/2021	Felix et al.	
11,116,447	B2	9/2021	Yang et al.	
11,445,967	B2	9/2022	Felix et al.	
2006/0111636	A1 *	5/2006	Jacober	A61B 5/021 600/490

2007/0270921	A1 *	11/2007	Strother	A61N 1/3787 607/60
2008/0091089	A1	4/2008	Guillory et al.	
2008/0139953	A1 *	6/2008	Baker	A61B 5/024 600/509
2008/0288026	A1 *	11/2008	Cross	H01R 13/5224 607/60
2009/0062670	A1	3/2009	Sterling et al.	
2009/0099469	A1	4/2009	Flores	
2009/0177073	A1	7/2009	Sonnenborg	
2009/0182204	A1	7/2009	Semler et al.	
2011/0009729	A1	1/2011	Shin et al.	
2011/0054285	A1	3/2011	Searle et al.	
2011/0077497	A1	3/2011	Oster et al.	
2011/0125040	A1	5/2011	Crawford et al.	
2011/0237924	A1 *	9/2011	McGusty	A61B 5/335 600/391
2012/0323098	A1	12/2012	Moein et al.	
2013/0225967	A1	8/2013	Esposito	
2014/0005737	A1 *	1/2014	Kozin	A61N 1/046 607/7
2015/0022372	A1	1/2015	Vosch	
2015/0087950	A1	3/2015	Felix et al.	
2015/0250422	A1 *	9/2015	Bay	A61B 5/0533 600/391
2019/0223806	A1	7/2019	Bennet et al.	

OTHER PUBLICATIONS

Cesario et al., “Arrhythmia Detection with a Low-Profile Wireless Adherent Cardiac Monitor: Results from the Adam and Eve Studies”, The Journal of Innovations in Cardiac Rhythm Management, 2 (2011) Sep. 2011, pp. 476-482, (7 pages).
Corventis Nuvant, “Nuvant Mobile Cardiac Telemetry (MTC) System”, Corventis, 2009, last printed Jul. 18, 2024, <https://web.archive.org/web/20100127193736/http://corventis.com/AP/nuvant.asp>.
Corventis Avivo, “Avivo Mobile Patient Management System”, Corventis, 2008, last printed Jul. 18, 2024, <https://web.archive.org/web/20100118155329/http://www.corventis.com/AP/avivo.asp>.
iRhythm Zio XT Patch/Event Card, “Zio Patch”, iRhythm, 2011, last printed Jul. 18, 2024, <https://web.archive.org/web/20111017074139/http://irhythmtech.com/media/files/Z100A4020.04%20-%20ZIO%20PATCH%20DATA%20SHEET.pdf>.
Bardy Diagnostics, Inc. v. Vital Connect, Inc., Defendant’s Identification of Supplemental Prior Art References, C.A. No. 22-351 (CJV), May 22, 2024.
International Preliminary Report on Patentability and Written Opinion, PCT/US2019/064331, Jun. 8, 2021.
First Examination Report, Communication pursuant to Article 94(3) EPC, 19 828 053.9-1113, dated Apr. 15, 2024.
[Corrected] Chart CC-2 Invalidity Contentions: U.S. Pat. No. 11,445,967; Case No. 22-351-CJB (Delaware); Invalidity of U.S. Patent No. by U.S. Pat. Pub. No. 2011/0077497 (“Oster”) and U.S. Pat. No. 11,116,447 (“Yang”); Oct. 25, 2023; 16 pages.
[Corrected] Chart C-2 Invalidity Contentions: U.S. Pat. No. 11,051,743; Case No. 22-351-CJB (Delaware); Invalidity of U.S. Pat. No. 11,051,743 by U.S. Pat. Pub. No. 2011/0077497 (“Oster”) and U.S. Pat. No. 11,116,447 (“Yang”); Oct. 25, 2023; 22 pages.
Chart AA-1 Invalidity Contentions: U.S. Pat. No. 11,445,967; Case No. 22-351-CJB (Delaware); Invalidity of U.S. Pat. No. 11,445,967 by International Publication No. WO 2010/104952 to Mazar (“Mazar”) and U.S. Pat. No. 11,116,447 (“Yang”); Oct. 25, 2023; 24 pages.
Chart C-1 Invalidity Contentions: U.S. Pat. No. 11,051,743; Case No. 22-351-CJB (Delaware); Invalidity of U.S. Pat. No. 11,051,743 by International Publication No. WO 2010/104952 to Mazar (“Mazar”) and U.S. Pat. No. 11,116,447 (“Yang”); Oct. 25, 2023; 32 pages.
Chart B-7 Invalidity Contentions: U.S. Pat. No. 11,051,743 and U.S. Pat. No. 11,445,967; Case No. 22-351-CJB (Delaware); A Patch Comprising Adhered Layers; Oct. 25, 2023; 16 pages.
Chart B-6 Invalidity Contentions: U.S. Pat. No. 11,051,743 and U.S. Pat. No. 11,445,967; Case No. 22-351-CJB (Delaware); Hydrocolloid Adhesives on a Portion of the Backing; Oct. 25, 2023; 5 pages.

US 12,285,261 B2

Page 3

(56)

References Cited

OTHER PUBLICATIONS

Chart B-5 Invalidity Contentions: U.S. Pat. No. 11,051,743 and U.S. Pat. No. 11,445,967; Case No. 22-351-CJB (Delaware); Conversion of Electrocardiogramals From One Format to Another; Oct. 25, 2023; 6 pages.

Chart B-4 Invalidity Contentions: U.S. Pat. No. 11,051,743 and U.S. Pat. No. 11,445,967; The Case No. 22-351-CJB (Delaware); Rounded Outer Edge of Backing Ends; Oct. 25, 2023; 5 pages.

Chart B-3 Invalidity Contentions: U.S. Pat. No. 11,051,743 and U.S. Pat. No. 11,445,967; Case No. 22-351-CJB (Delaware); Flexible Circuit Comprising a Pair of Circuit Traces to Couple Electrodes; Oct. 25, 2023; 8 pages.

Chart B-2 Invalidity Contentions: U.S. Pat. No. 11,051,743 and U.S. Pat. No. 11,445,967; Case No. 22-351-CJB (Delaware); An Electrocardiogramactrode on Each End of the Backing; Oct. 25, 2023; 8 pages.

Chart B-1 Invalidity Contentions: U.S. Pat. No. 11,051,743 and U.S. Pat. No. 11,445,967; Case No. 22-351-CJB (Delaware); Elongated Strip With Narrowed Midsection; Oct. 25, 2023; 8 pages.

Chart AA-10 Invalidity Contentions: U.S. Pat. No. 11,445,967; Case No. 22-351-CJB (Delaware); Invalidity of U.S. Pat. No. 11,445,967 by WO 2003/065926 (“Ozguz”); Oct. 25, 2023; 6 pages.

Chart AA-9 Invalidity Contentions: U.S. Pat. No. 11,445,967; Case No. 22-351-CJB (Delaware); Invalidity of U.S. Pat. No. 11,445,967 by U.S. Pat. Pub. No. 2011/0009729 (“Shin”); Oct. 25, 2023; 6 pages.

Chart AA-8 Invalidity Contentions: U.S. Pat. No. 11,445,967; Case No. 22-351-CJB (Delaware); Invalidity of U.S. Pat. No. 11,445,967 by WO 2008/005015 (“Shennib”); Oct. 25, 2023; 6 pages.

Chart AA-7 Invalidity Contentions: U.S. Pat. No. 11,445,967; Case No. 22-351-CJB (Delaware); Invalidity of U.S. Pat. No. 11,445,967 by U.S. Pat. No. 7,206,630 (“Tarler”); Oct. 25, 2023; 7 pages.

Chart AA-6 Invalidity Contentions: U.S. Pat. No. 11,445,967; Case No. 22-351-CJB (Delaware); Invalidity of U.S. Pat. No. 11,445,967 by U.S. Pat. No. 9,669,212 (“Mueller”); Oct. 25, 2023; 6 pages.

Chart AA-5 Invalidity Contentions: U.S. Pat. No. 11,445,967; Case No. 22-351-CJB (Delaware); Invalidity of U.S. Pat. No. 11,445,967 by U.S. Pat. No. 10,413,251 (“Golda”); Oct. 25, 2023; 6 pages.

Chart A-4 Invalidity Contentions: U.S. Pat. No. 11,445,967; Case No. 22-351-CJB (Delaware); Invalidity of U.S. Pat. No. 11,445,967 by U.S. Pat. Pub. No. 2011/0077497 (“Oster”); Oct. 25, 2023; 6 pages.

Chart A-3 Invalidity Contentions: U.S. Pat. No. 11,445,967; Case No. 22-351-CJB (Delaware); Invalidity of U.S. Pat. No. 11,445,967 by U.S. Pat. No. 10,327,660 (“Gallego”); Oct. 25, 2023; 7 pages.

Chart AA-2 Invalidity Contentions: U.S. Pat. No. 11,445,967; Case No. 22-351-CJB (Delaware); Invalidity of U.S. Pat. No. 11,445,967 by U.S. Pat. No. 11,116,447 (“Yang”); Oct. 25, 2023; 14 pages.

Chart AA-1 Invalidity Contentions: U.S. Pat. No. 11,445,967; Case No. 22-351-CJB (Delaware); Invalidity of U.S. Pat. No. 11,445,967 by International Publication No. WO 2010/104952 to Mazar (“Mazar”); Oct. 25, 2023; 13 pages.

Chart A-10 Invalidity Contentions: U.S. Pat. No. 11,051,743; Case No. 22-351-CJB (Delaware); Invalidity of U.S. Pat. No. 11,051,743 by WO 2003/065926 (“Ozguz”); Oct. 25, 2023; 12 pages.

Chart A-9 Invalidity Contentions: U.S. Pat. No. 11,051,743; Case No. 22-351-CJB (Delaware); Invalidity of U.S. Pat. No. 11,051,743 by U.S. Pat. Pub. No. 2011/0009729 (“Shin”); Oct. 25, 2023; 12 pages.

Chart A-8 Invalidity Contentions: U.S. Pat. No. 11,051,743; Case No. 22-351-CJB (Delaware); Invalidity of U.S. Pat. No. 11,051,743 by WO 2008/005015 (“Shennib”); Oct. 25, 2023; 12 pages.

Chart A-7 Invalidity Contentions: U.S. Pat. No. 11,051,743; Case No. 22-351-CJB (Delaware); Invalidity of U.S. Pat. No. 11,051,743 by U.S. Pat. No. 7,206,630 (“Tarler”); Oct. 25, 2023; 12 pages.

Chart A-6 Invalidity Contentions: U.S. Pat. No. 11,051,743; Case No. 22-351-CJB (Delaware); Invalidity of U.S. Pat. No. 11,051,743 by U.S. Pat. No. 9,669,212 (“Mueller”); Oct. 25, 2023; 11 pages.

Chart A-5 Invalidity Contentions: U.S. Pat. No. 11,051,743; Case No. 22-351-CJB (Delaware); Invalidity of U.S. Pat. No. 11,051,743 by U.S. Pat. No. 10,413,251 (“Golda”); Oct. 25, 2023; 11 pages.

Chart A-4 Invalidity Contentions: U.S. Pat. No. 11,051,743; Case No. 22-351-CJB (Delaware); Invalidity of U.S. Pat. No. 11,051,743 by U.S. Pat. Pub. No. 2011/0077497 (“Oster”); Oct. 25, 2023; 11 pages.

Chart A-3 Invalidity Contentions: U.S. Pat. No. 11,051,743; Case No. 22-351-CJB (Delaware); Invalidity of U.S. Pat. No. 11,051,743 by U.S. Pat. No. 10,327,660 (“Gallego”); Oct. 25, 2023; 12 pages.

Chart A-2 Invalidity Contentions: U.S. Pat. No. 11,051,743; Case No. 22-351-CJB (Delaware); Invalidity of U.S. Pat. No. 11,051,743 by U.S. Pat. No. 11,116,447 (“Yang”); Oct. 25, 2023; 19 pages.

Chart A-1 Invalidity Contentions: U.S. Pat. No. 11,051,743; Case No. 22-351-CJB (Delaware); Invalidity of U.S. Pat. No. 11,051,743 by International Publication No. WO 2010/104952 to Mazar (“Mazar”); Oct. 25, 2023; 19 pages.

Bardy Diagnostics, Inc., Plaintiff v. *Vital Connect, Inc.*; The United States District Court for the District of Delaware; C.A. No. 22-351 (CJB); Vitalconnect’s Preliminary Invalidity Contentions; filed Oct. 25, 2023.

Wolf, “The Data-Driven Life,” New York Times Magazine, Apr. 28, 2010, 13 pages.

Hill, “Adventures in Self-Surveillance: Fitbit, Tracking My Movement and Sleep,” Forbes, Feb. 25, 2011, 11 pages.

Mehen, “Open health with the quantified self,” Opensource.com, Aug. 25, 2011, 7 pages.

“23 Personal Tools to Learn More About Yourself,” Flowingdata.com, Sep. 18, 2008, 18 pages.

Puurtinen et al., “Estimation of ECG Signal of closely separated bipolar electrodes using thorax models,” Proceedings of the 26th Annual International Conference of the IEEE EMBS pp. 801-804, San Francisco, Calif., USA, Sep. 1-5, 2004, 4 pages.

Trägårdh et al., How many ECG leads do we need? *Cardiol Clin.* Aug. 2006;24(3):317-30, vii. doi: 10.1016/j.ccl.2006.04.005. PMID: 16939826; 14 pages.

Adams et al., U.S. Appl. No. 61/755,623, filed Jan. 23, 2013, 48 pages.

Toth et al., U.S. Appl. No. 61/832,131, filed Jun. 6, 2013, 82 pages.

Vishnubhotla, “Pre-processing of ECG signals for ambulatory use,” Jan. 2009; 5 pages.

Chaimanonart et al., “A wireless batteryless in vivo EKG and body temperature sensing microsystem with adaptive RF powering for genetically engineered mice monitoring,” Jul. 2009; 4 pages.

Alzaidi et al., “Smart Textiles Based Wireless ECG System,” May 2012; 5 pages.

Saeed et al., “A Scalable Wireless Body Area Sensor Network for Health-Care Monitoring,” Jun. 2009, 4 pages.

Pandian et al., “Wireless Sensor Network for Wearable Physiological Monitoring,” *Journal of Networks*, vol. 3, No. 5, May 2008; 15 pages.

Mukala et al., “A Novel Zigbee-based Low-cost, Low-Power Wireless EKG system,” *IEEE*, May 2010; 4 pages.

Aventyn, Inc., “Vital Connect, Aventyn Launch Wearable Biosensor Platform for Mobile Patient Monitoring”, Dec. 12, 2013, 5 pages.

* cited by examiner

Fig. 1.




Fig. 2.




Fig. 3.




Fig. 4.




Fig. 5.




Fig. 6.




Fig. 7.




Fig. 8.




Fig. 9.




Fig. 10.




Fig. 11.

80




Fig. 12.

100




Fig. 13.




Fig. 14.




Fig. 15.




Fig. 16A.

150




Fig. 16B.

160





Fig. 16C.

170






Fig. 18.




Fig. 19.




Fig. 20.





Fig. 21.



US 12,285,261 B2

1

**MOISTURE-RESISTANT
ELECTROCARDIOGRAMY MONITOR**

FIELD

This application relates in general to electrocardiographic monitoring and, in particular, to a moisture-resistant electrocardiography monitor.

BACKGROUND

The first electrocardiogram (ECG) was invented by a Dutch physiologist, Willem Einthoven, in 1903, who used a string galvanometer to measure the electrical activity of the heart. Generations of physicians around the world have since used ECGs, in various forms, to diagnose heart problems and other potential medical concerns. Although the basic principles underlying Dr. Einthoven's original work, including his naming of various waveform deflections (Einthoven's triangle), are still applicable today, ECG machines have evolved from his original three-lead ECG, to ECGs with unipolar leads connected to a central reference terminal starting in 1934, to augmented unipolar leads beginning in 1942, and finally to the 12-lead ECG standardized by the American Heart Association in 1954 and still in use today. Further advances in portability and computerized interpretation have been made, yet the electronic design of the ECG recording apparatuses has remained fundamentally the same for much of the past 40 years.

Essentially, an ECG measures the electrical signals emitted by the heart as generated by the propagation of the action potentials that trigger depolarization of heart fibers. Physiologically, transmembrane ionic currents are generated within the heart during cardiac activation and recovery sequences. Cardiac depolarization originates high in the right atrium in the sinoatrial (SA) node before spreading leftward towards the left atrium and inferiorly towards the atrioventricular (AV) node. After a delay occasioned by the AV node, the depolarization impulse transits the Bundle of His and moves into the right and left bundle branches and Purkinje fibers to activate the right and left ventricles.

During each cardiac cycle, the ionic currents create an electrical field in and around the heart that can be detected by ECG electrodes placed on the skin. Cardiac electrical activity is then visually represented in an ECG trace by PQRSTU-waveforms. The P-wave represents atrial electrical activity, and the QRSTU components represent ventricular electrical activity. Specifically, a P-wave represents atrial depolarization, which causes atrial contraction.

P-wave analysis based on ECG monitoring is critical to accurate cardiac rhythm diagnosis and focuses on localizing the sites of origin and pathways of arrhythmic conditions. P-wave analysis is also used in the diagnosis of other medical disorders, including imbalance of blood chemistry. Cardiac arrhythmias are defined by the morphology of P-waves and their relationship to QRS intervals. For instance, atrial fibrillation (AF), an abnormally rapid heart rhythm, can be confirmed by an absence of P-waves and an irregular ventricular rate. Similarly, sinoatrial block is characterized by a delay in the onset of P-waves, while junctional rhythm, an abnormal heart rhythm resulting from impulses coming from a locus of tissue in the area of the AV node, usually presents without P-waves or with inverted P-waves. Also, the amplitudes of P-waves are valuable for diagnosis. The presence of broad, notched P-waves can indicate left atrial enlargement. Conversely, the presence of tall, peaked P-waves can indicate right atrial enlargement.

2

Finally, P-waves with increased amplitude can indicate hypokalemia, caused by low blood potassium, whereas P-waves with decreased amplitude can indicate hyperkalemia, caused by elevated blood potassium.

Cardiac rhythm disorders may present with lightheadedness, fainting, chest pain, hypoxia, syncope, palpitations, and congestive heart failure (CHF), yet rhythm disorders are often sporadic in occurrence and may not show up in-clinic during a conventional 12-second ECG. Continuous ECG monitoring with P-wave-centric action potential acquisition over an extended period is more apt to capture sporadic cardiac events. However, recording sufficient ECG and related physiological data over an extended period remains a significant challenge, despite an over 40-year history of ambulatory ECG monitoring efforts combined with no appreciable improvement in P-wave acquisition techniques since Dr. Einthoven's original pioneering work over a 110 years ago.

Electrocardiographic monitoring over an extended period provides a physician with the kinds of data essential to identifying the underlying cause of sporadic cardiac conditions, especially rhythm disorders, and other physiological events of potential concern. A 30-day observation period is considered the "gold standard" of monitoring, yet a 14-day observation period is currently pitched as being achievable by conventional ECG monitoring approaches. Realizing a 30-day observation period has proven unworkable with existing ECG monitoring systems, which are arduous to employ; cumbersome, uncomfortable and not user-friendly to the patient; and costly to manufacture and deploy. Still, if a patient's ECG could be recorded in an ambulatory setting over a prolonged time periods, particularly for more than 14 days, thereby allowing the patient to engage in activities of daily living, the chances of acquiring meaningful medical information and capturing an abnormal event while the patient is engaged in normal activities are greatly improved.

The location of the atria and their low amplitude, low frequency content electrical signals make P-waves difficult to sense, particularly through ambulatory ECG monitoring. The atria are located posteriorly within the chest, and their physical distance from the skin surface adversely affects current strength and signal fidelity. Cardiac electrical potentials measured dermally have an amplitude of only one-percent of the amplitude of transmembrane electrical potentials. The distance between the heart and ECG electrodes reduces the magnitude of electrical potentials in proportion to the square of change in distance, which compounds the problem of sensing low amplitude P-waves. Moreover, the tissues and structures that lie between the activation regions within the heart and the body's surface alter the cardiac electrical field due to changes in the electrical resistivity of adjacent tissues. Thus, surface electrical potentials, when even capable of being accurately detected, are smoothed over in aspect and bear only a general spatial relationship to actual underlying cardiac events, thereby complicating diagnosis. Conventional 12-lead ECGs attempt to compensate for weak P-wave signals by monitoring the heart from multiple perspectives and angles, while conventional ambulatory ECGs primarily focus on monitoring higher amplitude ventricular activity that can be readily sensed. Both approaches are unsatisfactory with respect to the P-wave and the accurate, medically actionable diagnosis of the myriad cardiac rhythm disorders that exist.

Additionally, maintaining continual contact between ECG electrodes and the skin after a day or two of ambulatory ECG monitoring has been a problem. Time, dirt, moisture, and other environmental contaminants, as well as perspira-

US 12,285,261 B2

3

tion, skin oil, and dead skin cells from the patient's body, can get between an ECG electrode's non-conductive adhesive and the skin's surface. These factors adversely affect electrode adhesion and the quality of cardiac signal recordings. Furthermore, the physical movements of the patient and their clothing impart various compressional, tensile, bending, and torsional forces on the contact point of an ECG electrode, especially over long recording times, and an inflexibly fastened ECG electrode will be prone to becoming dislodged. Moreover, dislodgment may occur unbeknownst to the patient, making the ECG recordings worthless. Further, some patients may have skin that is susceptible to itching or irritation, and the wearing of ECG electrodes can aggravate such skin conditions. Thus, a patient may want or need to periodically remove or replace ECG electrodes during a long-term ECG monitoring period, whether to replace a dislodged electrode, reestablish better adhesion, alleviate itching or irritation, allow for cleansing of the skin, allow for showering and exercise, or for other purpose. Such replacement or slight alteration in electrode location actually facilitates the goal of recording the ECG signal for long periods of time.

Conventionally, multi-week or multi-month monitoring can be performed by implantable ECG monitors, such as the Reveal LINQ insertable cardiac monitor, manufactured by Medtronic, Inc., Minneapolis, MN. This monitor can detect and record paroxysmal or asymptomatic arrhythmias for up to three years. However, like all forms of implantable medical device (IMD), use of this monitor requires invasive surgical implantation, which significantly increases costs; requires ongoing follow up by a physician throughout the period of implantation; requires specialized equipment to retrieve monitoring data; and carries complications attendant to all surgery, including risks of infection, injury or death.

Holter monitors are widely used for extended ECG monitoring. Typically, they are often used for only 24-48 hours. A typical Holter monitor is a wearable and portable version of an ECG that include cables for each electrode placed on the skin and a separate battery-powered ECG recorder. The leads are placed in the anterior thoracic region in a manner similar to what is done with an in-clinic standard ECG machine using electrode locations that are not specifically intended for optimal P-wave capture. The duration of monitoring depends on the sensing and storage capabilities of the monitor. A "looping" Holter (or event) monitor can operate for a longer period of time by overwriting older ECG tracings, thence "recycling" storage in favor of extended operation, yet at the risk of losing event data. Although capable of extended ECG monitoring, Holter monitors are cumbersome, expensive and typically only available by medical prescription, which limits their usability. Further, the skill required to properly place the electrodes on the patient's chest precludes a patient from replacing or removing the sensing leads and usually involves moving the patient from the physician office to a specialized center within the hospital or clinic.

U.S. Pat. No. 8,460,189, to Libbus et al. ("Libbus") discloses an adherent wearable cardiac monitor that includes at least two measurement electrodes and an accelerometer. The device includes a reusable electronics module and a disposable adherent patch that includes the electrodes. ECG monitoring can be conducted using multiple disposable patches adhered to different locations on the patient's body. The device includes a processor configured to control collection and transmission of data from ECG circuitry, including generating and processing of ECG signals and data

4

acquired from two or more electrodes. The ECG circuitry can be coupled to the electrodes in many ways to define an ECG vector, and the orientation of the ECG vector can be determined in response to the polarity of the measurement electrodes and orientation of the electrode measurement axis. The accelerometer can be used to determine the orientation of the measurement electrodes in each of the locations. The ECG signals measured at different locations can be rotated based on the accelerometer data to modify amplitude and direction of the ECG features to approximate a standard ECG vector. The signals recorded at different locations can be combined by summing a scaled version of each signal. Libbus further discloses that inner ECG electrodes may be positioned near outer electrodes to increase the voltage of measured ECG signals. However, Libbus treats ECG signal acquisition as the measurement of a simple aggregate directional data signal without differentiating between the distinct kinds of cardiac electrical activities presented with an ECG waveform, particularly atrial (P-wave) activity.

The ZIO XT Patch and ZIO Event Card devices, manufactured by iRhythm Tech., Inc., San Francisco, CA, are wearable monitoring devices that are typically worn on the upper left pectoral region to respectively provide continuous and looping ECG recording. The location is used to simulate surgically implanted monitors, but without specifically enhancing P-wave capture. Both of these devices are prescription-only and for single patient use. The ZIO XT Patch device is limited to a 14-day period, while the electrodes only of the ZIO Event Card device can be worn for up to 30 days. The ZIO XT Patch device combines both electronic recordation components and physical electrodes into a unitary assembly that adheres to the patient's skin. The ZIO XT Patch device uses adhesive sufficiently strong to support the weight of both the monitor and the electrodes over an extended period and to resist disadherence from the patient's body, albeit at the cost of disallowing removal or relocation during the monitoring period. The ZIO Event Card device is a form of downsized Holter monitor with a recorder component that must be removed temporarily during baths or other activities that could damage the non-waterproof electronics. Both devices represent compromises between length of wear and quality of ECG monitoring, especially with respect to ease of long term use, female-friendly fit, and quality of cardiac electrical potential signals, especially atrial (P-wave) signals.

Therefore, a need remains for a low cost extended wear continuously recording ECG monitor attuned to capturing low amplitude cardiac action potential propagation for arrhythmia diagnosis, particularly atrial activation P-waves, and practicably capable of being worn for a long period of time, especially in patient's whose breast anatomy or size can interfere with signal quality in both women and men.

SUMMARY

Physiological monitoring can be provided through a lightweight wearable monitor that includes two components, a flexible extended wear electrode patch and a reusable monitor recorder that removably snaps into a receptacle on the electrode patch. The wearable monitor sits centrally (in the midline) on the patient's chest along the sternum oriented top-to-bottom. The ECG electrodes on the electrode patch are tailored to be positioned axially along the midline of the sternum for capturing action potential propagation in an orientation that corresponds to the aVF lead used in a conventional 12-lead ECG that is used to sense positive or

US 12,285,261 B2

5

upright P-waves. The placement of the wearable monitor in a location at the sternal midline (or immediately to either side of the sternum), with its unique narrow “hourglass”-like shape, significantly improves the ability of the wearable monitor to cutaneously sense cardiac electrical potential signals, particularly the P-wave (or atrial activity) and, to a lesser extent, the QRS interval signals indicating ventricular activity in the ECG waveforms.

Moreover, the electrocardiography monitor offers superior patient comfort, convenience and user-friendliness. The electrode patch is specifically designed for ease of use by a patient (or caregiver); assistance by professional medical personnel is not required. The patient is free to replace the electrode patch at any time and need not wait for a doctor’s appointment to have a new electrode patch placed. Patients can easily be taught to find the familiar physical landmarks on the body necessary for proper placement of the electrode patch. Empowering patients with the knowledge to place the electrode patch in the right place ensures that the ECG electrodes will be correctly positioned on the skin, no matter the number of times that the electrode patch is replaced. In addition, the monitor recorder operates automatically and the patient only need snap the monitor recorder into place on the electrode patch to initiate ECG monitoring. Thus, the synergistic combination of the electrode patch and monitor recorder makes the use of the electrocardiography monitor a reliable and virtually foolproof way to monitor a patient’s ECG and physiology for an extended, or even open-ended, period of time.

In one embodiment, a moisture-resistant electrocardiography monitor is provided. The monitor includes an electrocardiography monitor recorder and an extended wear electrode patch. The electrocardiography monitor recorder includes a wearable housing molded out of one or more materials and sealed against moisture; a plurality of electrical contacts protruding from the wearable housing; a seal coupling positioned on the wearable housing and surrounding the electrical contacts; and electronic circuitry provided within the wearable housing. The electronic circuitry includes an electrocardiographic front end circuit under a control of a micro-controller and adapted to sense cardiac electrical potential differentials through electrocardiographic electrodes via some of the electrical contacts, which are provided to the micro-controller as an analog signal; the micro-controller configured to sample the analog signal; and a memory electrically interfaced with the micro-controller and operable to store the samples. The extended wear electrode patch includes a flexible backing including a plurality of adhesive contact surfaces; the electrocardiographic electrodes, each included on one of the adhesive contact surfaces; a receptacle affixed to a non-contacting surface of the flexible backing into which the wearable housing can be removably secured, the receptacle including a compartment within which a component interfaced to the electronic circuitry is positioned via some of the electrical contacts; a plurality of electrical pads positioned on the receptacle, each of the pads configured to interface with one of the electrical contacts when the wearable housing is secured within the receptacle; and a moisture-resistant seal formed on the receptacle and surrounding the electrical pads, wherein the moisture-resistant seal mates the seal coupling when the wearable housing is secured within the receptacle.

In a further embodiment, a moisture-resistant patient-interfacing electrocardiography monitor is provided. The monitor includes an electrocardiography monitor recorder and an extended wear electrode patch. The electrocardiography monitor recorder includes a wearable housing molded

6

out of one or more materials and sealed against moisture; a waterproof patient-operable tactile feedback button positioned on an outside of the wearable housing; a plurality of electrical contacts protruding the wearable housing; a seal coupling positioned on the wearable housing and surrounding the electrical contacts; and electronic circuitry provided within the wearable housing. The electronic circuitry includes an electrocardiographic front end circuit under a control of a micro-controller and adapted to sense cardiac electrical potential differentials through electrocardiographic electrodes via some of the electrical contacts, which are provided to the micro-controller as an analog signal; the micro-controller configured to sample the analog signal; and a memory electrically interfaced with the micro-controller and operable to store the samples. The extended wear electrode patch includes: a flexible backing including a plurality of adhesive contact surfaces; the electrocardiographic electrodes, each included on one of the adhesive contact surfaces; a receptacle affixed to a non-contacting surface of the flexible backing into which the wearable housing can be removably secured, the receptacle including a compartment within which a battery, wherein the electronic circuitry is powered by the battery via at least some of the electrical contacts; a plurality of electrical pads positioned on the receptacle, each of the pads configured to interface with one of the electrical contacts when the wearable housing is secured within the receptacle; and a moisture-resistant seal formed on the receptacle and surrounding the electrical pads, wherein the moisture-resistant seal mates the seal coupling when the wearable housing is secured within the receptacle.

The monitoring patch is especially suited to the female anatomy, although also easily used over the male sternum. The narrow longitudinal midsection can fit nicely within the inter-mammary cleft of the breasts without inducing discomfort, whereas conventional patch electrodes are wide and, if adhered between the breasts, would cause chafing, irritation, discomfort, and annoyance, leading to low patient compliance.

In addition, the foregoing aspects enhance comfort in women (and certain men), but not irritation of the breasts, by placing the monitoring patch in the best location possible for optimizing the recording of cardiac signals from the atrium, particularly P-waves, which is another feature critical to proper arrhythmia and cardiac rhythm disorder diagnoses.

Still other embodiments will become readily apparent to those skilled in the art from the following detailed description, wherein are described embodiments by way of illustrating the best mode contemplated. As will be realized, other and different embodiments are possible and the embodiments’ several details are capable of modifications in various obvious respects, all without departing from their spirit and the scope. Accordingly, the drawings and detailed description are to be regarded as illustrative in nature and not as restrictive.

BRIEF DESCRIPTION OF THE DRAWINGS

FIGS. 1 and 2 are diagrams showing, by way of examples, an extended wear electrocardiography monitor, including an extended wear electrode patch, in accordance with one embodiment, respectively fitted to the sternal region of a female patient and a male patient.

FIG. 3 is a front anatomical view showing, by way of illustration, the locations of the heart and lungs within the rib cage of an adult human.

US 12,285,261 B2

7

FIG. 4 is a perspective view showing an extended wear electrode patch in accordance with one embodiment with a monitor recorder inserted.

FIG. 5 is a perspective view showing the monitor recorder of FIG. 4.

FIG. 6 is a perspective view showing the extended wear electrode patch of FIG. 4 without a monitor recorder inserted.

FIG. 7 is a bottom plan view of the monitor recorder of FIG. 4.

FIG. 8 is a top view showing the flexible circuit of the extended wear electrode patch of FIG. 4.

FIG. 9 is a functional block diagram showing the component architecture of the circuitry of the monitor recorder of FIG. 4.

FIG. 10 is a functional block diagram showing the circuitry of the extended wear electrode patch of FIG. 4.

FIG. 11 is a schematic diagram showing the ECG front end circuit of the circuitry of the monitor recorder of FIG. 9.

FIG. 12 is a flow diagram showing a monitor recorder-implemented method for monitoring ECG data for use in the monitor recorder of FIG. 4.

FIG. 13 is a graph showing, by way of example, a typical ECG waveform.

FIG. 14 is a functional block diagram showing the signal processing functionality of the microcontroller.

FIG. 15 is a functional block diagram showing the operations performed by the download station.

FIGS. 16A-C are functional block diagrams respectively showing practical uses of the extended wear electrocardiography monitors of FIGS. 1 and 2.

FIG. 17 is a perspective view of an extended wear electrode patch with a flexile wire electrode assembly in accordance with a still further embodiment.

FIG. 18 is perspective view of the flexile wire electrode assembly from FIG. 17, with a layer of insulating material shielding a bare distal wire around the midsection of the flexible backing.

FIG. 19 is a bottom view of the flexile wire electrode assembly as shown in FIG. 17.

FIG. 20 is a bottom view of a flexile wire electrode assembly in accordance with a still yet further embodiment.

FIG. 21 is a perspective view showing the longitudinal midsection of the flexible backing of the electrode assembly from FIG. 17.

DETAILED DESCRIPTION

ECG and physiological monitoring can be provided through a wearable ambulatory monitor that includes two components, a flexible extended wear electrode patch and a removable reusable (or single use) monitor recorder. Both the electrode patch and the monitor recorder are optimized to capture electrical signals from the propagation of low amplitude, relatively low frequency content cardiac action potentials, particularly the P-waves generated during atrial activation. FIGS. 1 and 2 are diagrams showing, by way of examples, an extended wear electrocardiography monitor 12, including a monitor recorder 14, in accordance with one embodiment, respectively fitted to the sternal region of a female patient 10 and a male patient 11. The wearable monitor 12 sits centrally, positioned axially along the sternal midline 16, on the patient's chest along the sternum 13 and oriented top-to-bottom with the monitor recorder 14 preferably situated towards the patient's head. In a further embodiment, the orientation of the wearable monitor 12 can be

8

corrected post-monitoring, as further described infra, for instance, if the wearable monitor 12 is inadvertently fitted upside down.

The electrode patch 15 is shaped to fit comfortably and conformal to the contours of the patient's chest approximately centered on the sternal midline 16 (or immediately to either side of the sternum 13). The distal end of the electrode patch 15, under which a lower or inferior pole (ECG electrode) is adhered, extends towards the Xiphoid process and lower sternum and, depending upon the patient's build, may straddle the region over the Xiphoid process and lower sternum. The proximal end of the electrode patch 15, located under the monitor recorder 14, under which an upper or superior pole (ECG electrode) is adhered, is below the manubrium and, depending upon patient's build, may straddle the region over the manubrium.

During ECG monitoring, the amplitude and strength of action potentials sensed on the body's surface are affected to varying degrees by cardiac, cellular, extracellular, vector of current flow, and physical factors, like obesity, dermatitis, large breasts, and high impedance skin, as can occur in dark-skinned individuals. Sensing along the sternal midline 16 (or immediately to either side of the sternum 13) significantly improves the ability of the wearable monitor 12 to cutaneously sense cardiac electric signals, particularly the P-wave (or atrial activity) and, to a lesser extent, the QRS interval signals in the ECG waveforms that indicate ventricular activity by countering some of the effects of these factors.

The ability to sense low amplitude, low frequency content body surface potentials is directly related to the location of ECG electrodes on the skin's surface and the ability of the sensing circuitry to capture these electrical signals. FIG. 3 is a front anatomical view showing, by way of illustration, the locations of the heart 4 and lungs 5 within the rib cage of an adult human. Depending upon their placement locations on the chest, ECG electrodes may be separated from activation regions within the heart 4 by differing combinations of internal tissues and body structures, including heart muscle, intracardiac blood, the pericardium, intrathoracic blood and fluids, the lungs 5, skeletal muscle, bone structure, subcutaneous fat, and the skin, plus any contaminants present between the skin's surface and electrode signal pickups. The degree of amplitude degradation of cardiac transmembrane potentials increases with the number of tissue boundaries between the heart 4 and the skin's surface that are encountered. The cardiac electrical field is degraded each time the transmembrane potentials encounter a physical boundary separating adjoining tissues due to differences in the respective tissues' electrical resistances. In addition, other non-spatial factors, such as pericardial effusion, emphysema or fluid accumulation in the lungs, as further explained infra, can further degrade body surface potentials.

Internal tissues and body structures can adversely affect the current strength and signal fidelity of all body surface potentials, yet low amplitude cardiac action potentials, particularly the P-wave with a normative amplitude of less than 0.25 microvolts (mV) and a normative duration of less than 120 milliseconds (ms), are most apt to be negatively impacted. The atria 6 are generally located posteriorly within the thoracic cavity (with the exception of the anterior right atrium and right atrial appendage), and, physically, the left atrium constitutes the portion of the heart 4 furthest away from the surface of the skin on the chest. Conversely, the ventricles 7, which generate larger amplitude signals, generally are located anteriorly with the anterior right ventricle and most of the left ventricle situated relatively close

US 12,285,261 B2

9

to the skin surface on the chest, which contributes to the relatively stronger amplitudes of ventricular waveforms. Thus, the quality of P-waves (and other already-low amplitude action potential signals) is more susceptible to weakening from intervening tissues and structures than the waveforms associated with ventricular activation.

The importance of the positioning of ECG electrodes along the sternal midline **15** has largely been overlooked by conventional approaches to ECG monitoring, in part due to the inability of their sensing circuitry to reliably detect low amplitude, low frequency content electrical signals, particularly in P-waves. In turn, that inability to keenly sense P-waves has motivated ECG electrode placement in other non-sternal midline thoracic locations, where the QRSTU components that represent ventricular electrical activity are more readily detectable by their sensing circuitry than P-waves. In addition, ECG electrode placement along the sternal midline **15** presents major patient wearability challenges, such as fitting a monitoring ensemble within the narrow confines of the inter-mammary cleft between the breasts, that to large extent drive physical packaging concerns, which can be incompatible with ECG monitors intended for placement, say, in the upper pectoral region or other non-sternal midline thoracic locations. In contrast, the wearable monitor **12** uses an electrode patch **15** that is specifically intended for extended wear placement in a location at the sternal midline **16** (or immediately to either side of the sternum **13**). When combined with a monitor recorder **14** that uses sensing circuitry optimized to preserve the characteristics of low amplitude cardiac action potentials, especially those signals from the atria, as further described infra with reference to FIG. **11**, the electrode patch **15** helps to significantly improve atrial activation (P-wave) sensing through placement in a body location that robustly minimizes the effects of tissue and body structure.

Referring back to FIGS. **1** and **2**, the placement of the wearable monitor **12** in the region of the sternal midline **13** puts the ECG electrodes of the electrode patch **15** in locations better adapted to sensing and recording low amplitude cardiac action potentials during atrial propagation (P-wave signals) than placement in other locations, such as the upper left pectoral region, as commonly seen in most conventional ambulatory ECG monitors. The sternum **13** overlies the right atrium of the heart **4**. As a result, action potential signals have to travel through fewer layers of tissue and structure to reach the ECG electrodes of the electrode patch **15** on the body's surface along the sternal midline **13** when compared to other monitoring locations, a distinction that is of critical importance when capturing low frequency content electrical signals, such as P-waves.

Moreover, cardiac action potential propagation travels simultaneously along a north-to-south and right-to-left vector, beginning high in the right atrium and ultimately ending in the posterior and lateral region of the left ventricle. Cardiac depolarization originates high in the right atrium in the SA node before concurrently spreading leftward towards the left atrium and inferiorly towards the AV node. The ECG electrodes of the electrode patch **15** are placed with the upper or superior pole (ECG electrode) along the sternal midline **13** in the region of the manubrium and the lower or inferior pole (ECG electrode) along the sternal midline **13** in the region of the Xiphoid process **9** and lower sternum. The ECG electrodes are placed primarily in a north-to-south orientation along the sternum **13** that corresponds to the north-to-south waveform vector exhibited during atrial acti-

10

vation. This orientation corresponds to the aVF lead used in a conventional 12-lead ECG that is used to sense positive or upright P-waves.

Furthermore, the thoracic region underlying the sternum **13** along the midline **16** between the manubrium **8** and Xiphoid process **9** is relatively free of lung tissue, musculature, and other internal body structures that could occlude the electrical signal path between the heart **4**, particularly the atria, and ECG electrodes placed on the surface of the skin. Fewer obstructions means that cardiac electrical potentials encounter fewer boundaries between different tissues. As a result, when compared to other thoracic ECG sensing locations, the cardiac electrical field is less altered when sensed dermally along the sternal midline **13**. As well, the proximity of the sternal midline **16** to the ventricles **7** facilitates sensing of right ventricular activity and provides superior recordation of the QRS interval, again, in part due to the relatively clear electrical path between the heart **4** and the skin surface.

Finally, non-spatial factors can affect transmembrane action potential shape and conductivity. For instance, myocardial ischemia, an acute cardiac condition, can cause a transient increase in blood perfusion in the lungs **5**. The perfused blood can significantly increase electrical resistance across the lungs **5** and therefore degrade transmission of the cardiac electrical field to the skin's surface. However, the placement of the wearable monitor **12** along the sternal midline **16** in the inter-mammary cleft between the breasts is relatively resilient to the adverse effects to cardiac action potential degradation caused by ischemic conditions as the body surface potentials from a location relatively clear of underlying lung tissue and fat help compensate for the loss of signal amplitude and content. The monitor recorder **14** is thus able to record the P-wave morphology that may be compromised by myocardial ischemia and therefore make diagnosis of the specific arrhythmias that can be associated with myocardial ischemia more difficult.

During use, the electrode patch **15** is first adhered to the skin along the sternal midline **16** (or immediately to either side of the sternum **13**). A monitor recorder **14** is then snapped into place on the electrode patch **15** using an electro mechanical docking interface to initiate ECG monitoring. FIG. **4** is a perspective view showing an extended wear electrode patch **15** in accordance with one embodiment with a monitor recorder **14** inserted. The body of the electrode patch **15** is preferably constructed using a flexible backing **20** formed as an elongated strip **21** of wrap knit or similar stretchable material about 145 mm long and 32 mm at the widest point with a narrow longitudinal mid-section **23** evenly tapering inward from both sides. A pair of cut-outs **22** between the distal and proximal ends of the electrode patch **15** create a narrow longitudinal midsection **23** or "isthmus" and defines an elongated "hourglass"-like shape, when viewed from above, such as described in commonly-assigned U.S. Design Patent No. D744,659, issued Dec. 1, 2015, the disclosure of which is incorporated by reference. The upper part of the "hourglass" is sized to allow an electrically non-conductive receptacle **25**, sits on top of the outward-facing surface of the electrode patch **15**, to be affixed to the electrode patch **15** with an ECG electrode placed underneath on the patient-facing underside, or contact, surface of the electrode patch **15**; the upper part of the "hourglass" has a longer and wider profile (but still rounded and tapered to fit comfortably between the breasts) than the lower part of the "hourglass," which is sized primarily to allow just the placement of an ECG electrode of appropriate

US 12,285,261 B2

11

shape and surface area to record the P-wave and the QRS signals sufficiently given the inter-electrode spacing.

The electrode patch **15** incorporates features that significantly improve wearability, performance, and patient comfort throughout an extended monitoring period. The entire electrode patch **15** is lightweight in construction, which allows the patch to be resilient to disadhering or falling off and, critically, to avoid creating distracting discomfort to the patient, even when the patient is asleep. In contrast, the weight of a heavy ECG monitor impedes patient mobility and will cause the monitor to constantly tug downwards and press on the patient's body that can generate skin inflammation with frequent adjustments by the patient needed to maintain comfort.

During every day wear, the electrode patch **15** is subjected to pushing, pulling, and torsional movements, including compressional and torsional forces when the patient bends forward, or tensile and torsional forces when the patient leans backwards. To counter these stress forces, the electrode patch **15** incorporates crimp and strain reliefs, such as described in commonly-assigned U.S. Pat. No. 9,545,204, issued Jan. 17, 2017, the disclosure of which is incorporated by reference. In addition, the cut-outs **22** and longitudinal midsection **23** help minimize interference with and discomfort to breast tissue, particularly in women (and gynecomastic men). The cut-outs **22** and longitudinal midsection **23** further allow better conformity of the electrode patch **15** to sternal bowing and to the narrow isthmus of flat skin that can occur along the bottom of the inter-mammary cleft between the breasts, especially in buxom women. The cut-outs **22** and narrow and flexible longitudinal midsection **23** help the electrode patch **15** fit nicely between a pair of female breasts in the inter-mammary cleft. In one embodiment, the cut-outs **22** can be graduated to form the longitudinal midsection **23** as a narrow in-between stem or isthmus portion about 7 mm wide. In a still further embodiment, tabs **24** can respectively extend an additional 8 mm to 12 mm beyond the distal and proximal ends of the flexible backing **20** to facilitate with adhering the electrode patch **15** to or removing the electrode patch **15** from the sternum **13**. These tabs preferably lack adhesive on the underside, or contact, surface of the electrode patch **15**. Still other shapes, cut-outs and conformities to the electrode patch **15** are possible.

The monitor recorder **14** removably and reusably snaps into an electrically non-conductive receptacle **25** during use. The monitor recorder **14** contains electronic circuitry for recording and storing the patient's electrocardiography as sensed via a pair of ECG electrodes provided on the electrode patch **15**, as further described infra beginning with reference to FIG. **9**. The non-conductive receptacle **25** is provided on the top surface of the flexible backing **20** with a retention catch **26** and tension clip **27** molded into the non-conductive receptacle **25** to conformably receive and securely hold the monitor recorder **14** in place.

The monitor recorder **14** includes a sealed housing that snaps into place in the non-conductive receptacle **25**. FIG. **5** is a perspective view showing the monitor recorder **14** of FIG. **4**. The sealed housing **50** of the monitor recorder **14** intentionally has a rounded isosceles trapezoidal-like shape **52**, when viewed from above, such as described in commonly-assigned U.S. Design Patent No. D717,955, issued Nov. 18, 2014, the disclosure of which is incorporated by reference. The edges **51** along the top and bottom surfaces are rounded for patient comfort. The sealed housing **50** is approximately 47 mm long, 23 mm wide at the widest point, and 7 mm high, excluding a patient-operable tactile-feed-back button **55**. The sealed housing **50** can be molded out of

12

polycarbonate, ABS, or an alloy of those two materials. The button **55** is waterproof and the button's top outer surface is molded silicon rubber or similar soft pliable material. A retention detent **53** and tension detent **54** are molded along the edges of the top surface of the housing **50** to respectively engage the retention catch **26** and the tension clip **27** molded into non-conductive receptacle **25**. Other shapes, features, and conformities of the sealed housing **50** are possible.

The electrode patch **15** is intended to be disposable, while the monitor recorder **14** is designed for reuse and can be transferred to successive electrode patches **15** to ensure continuity of monitoring, if so desired. The monitor recorder **14** can be used only once, but single use effectively wastes the synergistic benefits provided by the combination of the disposable electrode patch and reusable monitor recorder, as further explained infra with reference to FIGS. **16A-C**. The placement of the wearable monitor **12** in a location at the sternal midline **16** (or immediately to either side of the sternum **13**) benefits long-term extended wear by removing the requirement that ECG electrodes be continually placed in the same spots on the skin throughout the monitoring period. Instead, the patient is free to place an electrode patch **15** anywhere within the general region of the sternum **13**.

As a result, at any point during ECG monitoring, the patient's skin is able to recover from the wearing of an electrode patch **15**, which increases patient comfort and satisfaction, while the monitor recorder **14** ensures ECG monitoring continuity with minimal effort. A monitor recorder **14** is merely unsnapped from a worn out electrode patch **15**, the worn out electrode patch **15** is removed from the skin, a new electrode patch **15** is adhered to the skin, possibly in a new spot immediately adjacent to the earlier location, and the same monitor recorder **14** is snapped into the new electrode patch **15** to reinitiate and continue the ECG monitoring.

During use, the electrode patch **15** is first adhered to the skin in the sternal region. FIG. **6** is a perspective view showing the extended wear electrode patch **15** of FIG. **4** without a monitor recorder **14** inserted. A flexible circuit **32** is adhered to each end of the flexible backing **20**. A distal circuit trace **33** from the distal end **30** of the flexible backing **20** and a proximal circuit trace (not shown) from the proximal end **31** of the flexible backing **20** electrically couple ECG electrodes (not shown) with a pair of electrical pads **34**. In a further embodiment, the distal and proximal circuit traces are replaced with interlaced or sewn-in flexible wires, as further described infra beginning with reference to FIG. **17**. The electrical pads **34** are provided within a moisture-resistant seal **35** formed on the bottom surface of the non-conductive receptacle **25**. When the monitor recorder **14** is securely received into the non-conductive receptacle **25**, that is, snapped into place, the electrical pads **34** interface to electrical contacts (not shown) protruding from the bottom surface of the monitor recorder **14**. The moisture-resistant seal **35** enables the monitor recorder **14** to be worn at all times, even during showering or other activities that could expose the monitor recorder **14** to moisture or adverse conditions.

In addition, a battery compartment **36** is formed on the bottom surface of the non-conductive receptacle **25**. A pair of battery leads (not shown) from the battery compartment **36** to another pair of the electrical pads **34** electrically interface the battery to the monitor recorder **14**. The battery contained within the battery compartment **35** is a direct current (DC) power cell and can be replaceable, rechargeable or disposable.

US 12,285,261 B2

13

The monitor recorder **14** draws power externally from the battery provided in the non-conductive receptacle **25**, thereby uniquely obviating the need for the monitor recorder **14** to carry a dedicated power source. FIG. **7** is a bottom plan view of the monitor recorder **14** of FIG. **4**. A cavity **58** is formed on the bottom surface of the sealed housing **50** to accommodate the upward projection of the battery compartment **36** from the bottom surface of the non-conductive receptacle **25**, when the monitor recorder **14** is secured in place on the non-conductive receptacle **25**. A set of electrical contacts **56** protrude from the bottom surface of the sealed housing **50** and are arranged in alignment with the electrical pads **34** provided on the bottom surface of the non-conductive receptacle **25** to establish electrical connections between the electrode patch **15** and the monitor recorder **14**. In addition, a seal coupling **57** circumferentially surrounds the set of electrical contacts **56** and securely mates with the moisture-resistant seal **35** formed on the bottom surface of the non-conductive receptacle **25**. The battery contained within the battery compartment **36** can be replaceable, rechargeable or disposable. In a further embodiment, the ECG sensing circuitry of the monitor recorder **14** can be supplemented with additional sensors, including an SpO₂ sensor, a blood pressure sensor, a temperature sensor, respiratory rate sensor, a glucose sensor, an air flow sensor, and a volumetric pressure sensor, which can be incorporated directly into the monitor recorder **14** or onto the non-conductive receptacle **25**.

The placement of the flexible backing **20** on the sternal midline **16** (or immediately to either side of the sternum **13**) also helps to minimize the side-to-side movement of the wearable monitor **12** in the left- and right-handed directions during wear. However, the wearable monitor **12** is still susceptible to pushing, pulling, and torqueing movements, including compressional and torsional forces when the patient bends forward, and tensile and torsional forces when the patient leans backwards or twists. To counter the dislodgment of the flexible backing **20** due to compressional and torsional forces, a layer of non-irritating adhesive, such as hydrocolloid, is provided at least partially on the underside, or contact, surface of the flexible backing **20**, but only on the distal end **30** and the proximal end **31**. As a result, the underside, or contact surface of the longitudinal midsection **23** does not have an adhesive layer and remains free to move relative to the skin. Thus, the longitudinal midsection **23** forms a crimp relief that respectively facilitates compression and twisting of the flexible backing **20** in response to compressional and torsional forces. Other forms of flexible backing crimp reliefs are possible.

Unlike the flexible backing **20**, the flexible circuit **32** is only able to bend and cannot stretch in a planar direction. The flexible circuit **32** can be provided either above or below the flexible backing **20**. FIG. **8** is a top view showing the flexible circuit **32** of the extended wear electrode patch **15** of FIG. **4** when mounted above the flexible backing **20**. A distal ECG electrode **38** and proximal ECG electrode **39** are respectively coupled to the distal and proximal ends of the flexible circuit **32** to serve as electrode signal pickups. The flexible circuit **32** preferably does not extend to the outside edges of the flexible backing **20**, thereby avoiding gouging or discomforting the patient's skin during extended wear, such as when sleeping on the side. During wear, the ECG electrodes **38**, **39** must remain in continual contact with the skin. A strain relief **40** is defined in the flexible circuit **32** at a location that is partially underneath the battery compartment **36** when the flexible circuit **32** is affixed to the flexible backing **20**. The strain relief **40** is laterally extendable to

14

counter dislodgment of the ECG electrodes **38**, **39** due to bending, tensile and torsional forces. A pair of strain relief cutouts **41** partially extend transversely from each opposite side of the flexible circuit **32** and continue longitudinally towards each other to define in 'S'-shaped pattern, when viewed from above. The strain relief respectively facilitates longitudinal extension and twisting of the flexible circuit **32** in response to tensile and torsional forces. Other forms of circuit board strain relief are possible.

ECG monitoring and other functions performed by the monitor recorder **14** are provided through a micro controlled architecture. FIG. **9** is a functional block diagram showing the component architecture of the circuitry **60** of the monitor recorder **14** of FIG. **4**. The circuitry **60** is externally powered through a battery provided in the non-conductive receptacle **25** (shown in FIG. **6**). Both power and raw ECG signals, which originate in the pair of ECG electrodes **38**, **39** (shown in FIG. **8**) on the distal and proximal ends of the electrode patch **15**, are received through an external connector **65** that mates with a corresponding physical connector on the electrode patch **15**. The external connector **65** includes the set of electrical contacts **56** that protrude from the bottom surface of the sealed housing **50** and which physically and electrically interface with the set of pads **34** provided on the bottom surface of the non-conductive receptacle **25**. The external connector includes electrical contacts **56** for data download, microcontroller communications, power, analog inputs, and a peripheral expansion port. The arrangement of the pins on the electrical connector **65** of the monitor recorder **14** and the device into which the monitor recorder **14** is attached, whether an electrode patch **15** or download station (not shown), follow the same electrical pin assignment convention to facilitate interoperability. The external connector **65** also serves as a physical interface to a download station that permits the retrieval of stored ECG monitoring data, communication with the monitor recorder **14**, and performance of other functions. The download station is further described infra with reference to FIG. **15**.

Operation of the circuitry **60** of the monitor recorder **14** is managed by a microcontroller **61**, such as the EFM32 Tiny Gecko 32-bit microcontroller, manufactured by Silicon Laboratories Inc., Austin, TX. The microcontroller **61** has flexible energy management modes and includes a direct memory access controller and built-in analog-to-digital and digital-to-analog converters (ADC and DAC, respectively). The microcontroller **61** also includes a program memory unit containing internal flash memory that is readable and writeable. The internal flash memory can also be programmed externally. The microcontroller **61** operates under modular micro program control as specified in firmware stored in the internal flash memory. The functionality and firmware modules relating to signal processing by the microcontroller **61** are further described infra with reference to FIG. **14**. The microcontroller **61** draws power externally from the battery provided on the electrode patch **15** via a pair of the electrical contacts **56**. The microcontroller **61** connects to the ECG front end circuit **63** that measures raw cutaneous electrical signals using a driven reference that eliminates common mode noise, as further described infra with reference to FIG. **11**.

The circuitry **60** of the monitor recorder **14** also includes a flash memory **62**, which the microcontroller **61** uses for storing ECG monitoring data and other physiology and information. The flash memory **62** also draws power externally from the battery provided on the electrode patch **15** via a pair of the electrical contacts **56**. Data is stored in a serial flash memory circuit, which supports read, erase and pro-

US 12,285,261 B2

15

gram operations over a communications bus. The flash memory 62 enables the microcontroller 61 to store digitized ECG data. The communications bus further enables the flash memory 62 to be directly accessed externally over the external connector 65 when the monitor recorder 14 is interfaced to a download station.

The microcontroller 61 includes functionality that enables the acquisition of samples of analog ECG signals, which are converted into a digital representation, as further described infra with reference to FIG. 14. In one mode, the microcontroller 61 will acquire, sample, digitize, signal process, and store digitized ECG data into available storage locations in the flash memory 62 until all memory storage locations are filled, after which the digitized ECG data needs to be downloaded or erased to restore memory capacity. Data download or erasure can also occur before all storage locations are filled, which would free up memory space sooner, albeit at the cost of possibly interrupting monitoring while downloading or erasure is performed. In another mode, the microcontroller 61 can include a loop recorder feature that will overwrite the oldest stored data once all storage locations are filled, albeit at the cost of potentially losing the stored data that was overwritten, if not previously downloaded. Still other modes of data storage and capacity recovery are possible.

The circuitry 60 of the monitor recorder 14 further includes an actigraphy sensor 64 implemented as a 3-axis accelerometer. The accelerometer may be configured to generate interrupt signals to the microcontroller 61 by independent initial wake up and free fall events, as well as by device position. In addition, the actigraphy provided by the accelerometer can be used during post-monitoring analysis to correct the orientation of the monitor recorder 14 if, for instance, the monitor recorder 14 has been inadvertently installed upside down, that is, with the monitor recorder 14 oriented on the electrode patch 15 towards the patient's feet, as well as for other event occurrence analyses.

The microcontroller 61 includes an expansion port that also utilizes the communications bus. External devices, separately drawing power externally from the battery provided on the electrode patch 15 or other source, can interface to the microcontroller 61 over the expansion port in half duplex mode. For instance, an external physiology sensor can be provided as part of the circuitry 60 of the monitor recorder 14, or can be provided on the electrode patch 15 with communication with the microcontroller 61 provided over one of the electrical contacts 56. The physiology sensor can include an SpO₂ sensor, blood pressure sensor, temperature sensor, respiratory rate sensor, glucose sensor, airflow sensor, volumetric pressure sensing, or other types of sensor or telemetric input sources. In a further embodiment, a wireless interface for interfacing with other wearable (or implantable) physiology monitors, as well as data offload and programming, can be provided as part of the circuitry 60 of the monitor recorder 14, or can be provided on the electrode patch 15 with communication with the microcontroller 61 provided over one of the electrical contacts 56.

Finally, the circuitry 60 of the monitor recorder 14 includes patient-interfaceable components, including a tactile feedback button 66, which a patient can press to mark events or to perform other functions, and a buzzer 67, such as a speaker, magnetic resonator or piezoelectric buzzer. The buzzer 67 can be used by the microcontroller 61 to output feedback to a patient such as to confirm power up and initiation of ECG monitoring. Still other components as part of the circuitry 60 of the monitor recorder 14 are possible.

16

While the monitor recorder 14 operates under micro control, most of the electrical components of the electrode patch 15 operate passively. FIG. 10 is a functional block diagram showing the circuitry 70 of the extended wear electrode patch 15 of FIG. 4. The circuitry 70 of the electrode patch 15 is electrically coupled with the circuitry 60 of the monitor recorder 14 through an external connector 74. The external connector 74 is terminated through the set of pads 34 provided on the bottom of the non-conductive receptacle 25, which electrically mate to corresponding electrical contacts 56 protruding from the bottom surface of the sealed housing 50 to electrically interface the monitor recorder 14 to the electrode patch 15.

The circuitry 70 of the electrode patch 15 performs three primary functions. First, a battery 71 is provided in a battery compartment formed on the bottom surface of the non-conductive receptacle 25. The battery 71 is electrically interfaced to the circuitry 60 of the monitor recorder 14 as a source of external power. The unique provisioning of the battery 71 on the electrode patch 15 provides several advantages. First, the locating of the battery 71 physically on the electrode patch 15 lowers the center of gravity of the overall wearable monitor 12 and thereby helps to minimize shear forces and the effects of movements of the patient and clothing. Moreover, the housing 50 of the monitor recorder 14 is sealed against moisture and providing power externally avoids having to either periodically open the housing 50 for the battery replacement, which also creates the potential for moisture intrusion and human error, or to recharge the battery, which can potentially take the monitor recorder 14 off line for hours at a time. In addition, the electrode patch 15 is intended to be disposable, while the monitor recorder 14 is a reusable component. Each time that the electrode patch 15 is replaced, a fresh battery is provided for the use of the monitor recorder 14, which enhances ECG monitoring performance quality and duration of use. Also, the architecture of the monitor recorder 14 is open, in that other physiology sensors or components can be added by virtue of the expansion port of the microcontroller 61. Requiring those additional sensors or components to draw power from a source external to the monitor recorder 14 keeps power considerations independent of the monitor recorder 14. This approach also enables a battery of higher capacity to be introduced when needed to support the additional sensors or components without effecting the monitor recorder's circuitry 60.

Second, the pair of ECG electrodes 38, 39 respectively provided on the distal and proximal ends of the flexible circuit 32 are electrically coupled to the set of pads 34 provided on the bottom of the non-conductive receptacle 25 by way of their respective circuit traces 33, 37. The signal ECG electrode 39 includes a protection circuit 72, which is an inline resistor that protects the patient from excessive leakage current should the front end circuit fail.

Last, in a further embodiment, the circuitry 70 of the electrode patch 15 includes a cryptographic circuit 73 to authenticate an electrode patch 15 for use with a monitor recorder 14. The cryptographic circuit 73 includes a device capable of secure authentication and validation. The cryptographic device 73 ensures that only genuine, non-expired, safe, and authenticated electrode patches 15 are permitted to provide monitoring data to a monitor recorder 14 and for a specific patient.

The ECG front end circuit 63 measures raw cutaneous electrical signals using a driven reference that effectively reduces common mode noise, power supply noise and system noise, which is critical to preserving the character-

US 12,285,261 B2

17

istics of low amplitude cardiac action potentials, especially those signals from the atria. FIG. 11 is a schematic diagram 80 showing the ECG front end circuit 63 of the circuitry 60 of the monitor recorder 14 of FIG. 9. The ECG front end circuit 63 senses body surface potentials through a signal lead (“Si”) and reference lead (“REF”) that are respectively connected to the ECG electrodes of the electrode patch 15. Power is provided to the ECG front end circuit 63 through a pair of DC power leads (“VCC” and “GND”). An analog ECG signal (“ECG”) representative of the electrical activity of the patient’s heart over time is output, which the microcontroller 11 converts to digital representation and filters, as further described infra.

The ECG front end circuit 63 is organized into five stages, a passive input filter stage 81, a unity gain voltage follower stage 82, a passive high pass filtering stage 83, a voltage amplification and active filtering stage 84, and an anti-aliasing passive filter stage 85, plus a reference generator. Each of these stages and the reference generator will now be described.

The passive input filter stage 81 includes the parasitic impedance of the ECG electrodes 38, 39 (shown in FIG. 8), the protection resistor that is included as part of the protection circuit 72 of the ECG electrode 39 (shown in FIG. 10), an AC coupling capacitor 87, a termination resistor 88, and filter capacitor 89. This stage passively shifts the frequency response poles downward there is a high electrode impedance from the patient on the signal lead Si and reference lead REF, which reduces high frequency noise.

The unity gain voltage follower stage 82 provides a unity voltage gain that allows current amplification by an Operational Amplifier (“Op Amp”) 90. In this stage, the voltage stays the same as the input, but more current is available to feed additional stages. This configuration allows a very high input impedance, so as not to disrupt the body surface potentials or the filtering effect of the previous stage.

The passive high pass filtering stage 83 is a high pass filter that removes baseline wander and any offset generated from the previous stage. Adding an AC coupling capacitor 91 after the Op Amp 90 allows the use of lower cost components, while increasing signal fidelity.

The voltage amplification and active filtering stage 84 amplifies the voltage of the input signal through Op Amp 92, while applying a low pass filter. The DC bias of the input signal is automatically centered in the highest performance input region of the Op Amp 92 because of the AC coupling capacitor 91.

The anti-aliasing passive filter stage 85 provides an anti-aliasing low pass filter. When the microcontroller 61 acquires a sample of the analog input signal, a disruption in the signal occurs as a sample and hold capacitor that is internal to the microcontroller 61 is charged to supply signal for acquisition.

The reference generator in subcircuit 86 drives a driven reference containing power supply noise and system noise to the reference lead REF. A coupling capacitor 87 is included on the signal lead Si and a pair of resistors 93a, 93b inject system noise into the reference lead REF. The reference generator is connected directly to the patient, thereby avoiding the thermal noise of the protection resistor that is included as part of the protection circuit 72.

In contrast, conventional ECG lead configurations try to balance signal and reference lead connections. The conventional approach suffers from the introduction of differential thermal noise, lower input common mode rejection, increased power supply noise, increased system noise, and differential voltages between the patient reference and the

18

reference used on the device that can obscure, at times, extremely, low amplitude body surface potentials.

Here, the parasitic impedance of the ECG electrodes 38, 39, the protection resistor that is included as part of the protection circuit 72 and the coupling capacitor 87 allow the reference lead REF to be connected directly to the skin’s surface without any further components. As a result, the differential thermal noise problem caused by pairing protection resistors to signal and reference leads, as used in conventional approaches, is avoided.

The monitor recorder 14 continuously monitors the patient’s heart rate and physiology. FIG. 12 is a flow diagram showing a monitor recorder-implemented method 100 for monitoring ECG data for use in the monitor recorder 14 of FIG. 4. Initially, upon being connected to the set of pads 34 provided with the non-conductive receptacle 25 when the monitor recorder 14 is snapped into place, the microcontroller 61 executes a power up sequence (step 101). During the power up sequence, the voltage of the battery 71 is checked, the state of the flash memory 62 is confirmed, both in terms of operability check and available capacity, and microcontroller operation is diagnostically confirmed. In a further embodiment, an authentication procedure between the microcontroller 61 and the electrode patch 15 are also performed.

Following satisfactory completion of the power up sequence, an iterative processing loop (steps 102-110) is continually executed by the microcontroller 61. During each iteration (step 102) of the processing loop, the ECG frontend 63 (shown in FIG. 9) continually senses the cutaneous ECG electrical signals (step 103) via the ECG electrodes 38, 29 and is optimized to maintain the integrity of the P-wave. A sample of the ECG signal is read (step 104) by the microcontroller 61 by sampling the analog ECG signal that is output by the ECG front end circuit 63. FIG. 13 is a graph showing, by way of example, a typical ECG waveform 120. The x-axis represents time in approximate units of tenths of a second. The y-axis represents cutaneous electrical signal strength in approximate units of millivolts. The P-wave 121 has a smooth, normally upward, that is, positive, waveform that indicates atrial depolarization. The QRS complex often begins with the downward deflection of a Q-wave 122, followed by a larger upward deflection of an R-wave 123, and terminated with a downward waveform of the S-wave 124, collectively representative of ventricular depolarization. The T-wave 125 is normally a modest upward waveform, representative of ventricular depolarization, while the U-wave 126, often not directly observable, indicates the recovery period of the Purkinje conduction fibers.

Sampling of the R-to-R interval enables heart rate information derivation. For instance, the R-to-R interval represents the ventricular rate and rhythm, while the P-to-P interval represents the atrial rate and rhythm. Importantly, the PR interval is indicative of atrioventricular (AV) conduction time and abnormalities in the PR interval can reveal underlying heart disorders, thus representing another reason why the P-wave quality achievable by the ambulatory electrocardiography monitoring patch optimized for capturing low amplitude cardiac action potential propagation described herein is medically unique and important. The long-term observation of these ECG indicia, as provided through extended wear of the wearable monitor 12, provides valuable insights to the patient’s cardiac function symptoms, and overall well-being.

Referring back to FIG. 12, each sampled ECG signal, in quantized and digitized form, is processed by signal processing modules as specified in firmware (step 105), as

US 12,285,261 B2

19

described infra, and temporarily staged in a buffer (step 106), pending compression preparatory to storage in the flash memory 62 (step 107). Following compression, the compressed ECG digitized sample is again buffered (step 108), then written to the flash memory 62 (step 109) using the communications bus. Processing continues (step 110), so long as the monitoring recorder 14 remains connected to the electrode patch 15 (and storage space remains available in the flash memory 62), after which the processing loop is exited (step 110) and execution terminates. Still other operations and steps are possible.

The microcontroller 61 operates under modular micro program control as specified in firmware, and the program control includes processing of the analog ECG signal output by the ECG front end circuit 63. FIG. 14 is a functional block diagram showing the signal processing functionality 130 of the microcontroller 61. The microcontroller 61 operates under modular micro program control as specified in firmware 132. The firmware modules 132 include high and low pass filtering 133, and compression 134. Other modules are possible. The microcontroller 61 has a built-in ADC, although ADC functionality could also be provided in the firmware 132.

The ECG front end circuit 63 first outputs an analog ECG signal, which the ADC 131 acquires, samples and converts into an uncompressed digital representation. The microcontroller 61 includes one or more firmware modules 133 that perform filtering. In one embodiment, three low pass filters and two high pass filters are used. Following filtering, the digital representation of the cardiac activation wave front amplitudes are compressed by a compression module 134 before being written out to storage 135.

The download station executes a communications or offload program ("Offload") or similar program that interacts with the monitor recorder 14 via the external connector 65 to retrieve the stored ECG monitoring data. FIG. 15 is a functional block diagram showing the operations 140 performed by the download station. The download station could be a server, personal computer, tablet or handheld computer, smart mobile device, or purpose-built programmer designed specific to the task of interfacing with a monitor recorder 14. Still other forms of download station are possible, including download stations connected through wireless interfacing using, for instance, a smart phone connected to the monitor recorder 14 through Bluetooth or Wi-Fi.

The download station is responsible for offloading stored ECG monitoring data from a monitor recorder 14 and includes an electro mechanical docking interface by which the monitor recorder 14 is connected at the external connector 65. The download station operates under programmable control as specified in software 141. The stored ECG monitoring data retrieved from storage 142 on a monitor recorder 14 is first decompressed by a decompression module 143, which converts the stored ECG monitoring data back into an uncompressed digital representation more suited to signal processing than a compressed signal. The retrieved ECG monitoring data may be stored into local storage for archival purposes, either in original compressed form, or as uncompressed.

The download station can include an array of filtering modules. For instance, a set of phase distortion filtering tools 144 may be provided, where corresponding software filters can be provided for each filter implemented in the firmware executed by the microcontroller 61. The digital signals are run through the software filters in a reverse direction to remove phase distortion. For instance, a 45 Hertz high pass filter in firmware may have a matching reverse 45 Hertz high

20

pass filter in software. Most of the phase distortion is corrected, that is, canceled to eliminate noise at the set frequency, but data at other frequencies in the waveform remain unaltered. As well, bidirectional impulse infinite response (IIR) high pass filters and reverse direction (symmetric) IIR low pass filters can be provided. Data is run through these filters first in a forward direction, then in a reverse direction, which generates a square of the response and cancels out any phase distortion. This type of signal processing is particularly helpful with improving the display of the ST-segment by removing low frequency noise.

An automatic gain control (AGC) module 145 can also be provided to adjust the digital signals to a usable level based on peak or average signal level or other metric. AGC is particularly critical to single-lead ECG monitors, where physical factors, such as the tilt of the heart, can affect the electrical field generated. On three-lead Holter monitors, the leads are oriented in vertical, horizontal and diagonal directions. As a result, the horizontal and diagonal leads may be higher amplitude and ECG interpretation will be based on one or both of the higher amplitude leads. In contrast, the electrocardiography monitor 12 has only a single lead that is oriented in the vertical direction, so variations in amplitude will be wider than available with multi-lead monitors, which have alternate leads to fall back upon.

In addition, AGC may be necessary to maintain compatibility with existing ECG interpretation software, which is typically calibrated for multi-lead ECG monitors for viewing signals over a narrow range of amplitudes. Through the AGC module 145, the gain of signals recorded by the monitor recorder 14 of the electrocardiography monitor 12 can be attenuated up (or down) to work with FDA-approved commercially available ECG interpretation.

AGC can be implemented in a fixed fashion that is uniformly applied to all signals in an ECG recording, adjusted as appropriate on a recording-by-recording basis. Typically, a fixed AGC value is calculated based on how an ECG recording is received to preserve the amplitude relationship between the signals. Alternatively, AGC can be varied dynamically throughout an ECG recording, where signals in different segments of an ECG recording are amplified up (or down) by differing amounts of gain.

Typically, the monitor recorder 14 will record a high resolution, low frequency signal for the P-wave segment. However, for some patients, the result may still be a visually small signal. Although high resolution is present, the unaided eye will normally be unable to discern the P-wave segment. Therefore, gaining the signal is critical to visually depicting P-wave detail. This technique works most efficaciously with a raw signal with low noise and high resolution, as generated by the monitor recorder 14. Automatic gain control applied to a high noise signal will only exacerbate noise content and be self-defeating.

Finally, the download station can include filtering modules specifically intended to enhance P-wave content. For instance, a P-wave base boost filter 146, which is a form of pre-emphasis filter, can be applied to the signal to restore missing frequency content or to correct phase distortion. Still other filters and types of signal processing are possible.

Conventional ECG monitors, like Holter monitors, invariably require specialized training on proper placement of leads and on the operation of recording apparatuses, plus support equipment purpose-built to retrieve, convert, and store ECG monitoring data. In contrast, the electrocardiography monitor 12 simplifies monitoring from end to end, starting with placement, then with use, and finally with data retrieval. FIGS. 16A-C are functional block diagrams

US 12,285,261 B2

21

respectively showing practical uses **150**, **160**, **170** of the extended wear electrocardiography monitors **12** of FIGS. **1** and **2**. The combination of a flexible extended wear electrode patch and a removable reusable (or single use) monitor recorder empowers physicians and patients alike with the ability to readily perform long-term ambulatory monitoring of the ECG and physiology.

Especially when compared to existing Holter-type monitors and monitoring patches placed in the upper pectoral region, the electrocardiography monitor **12** offers superior patient comfort, convenience and user-friendliness. To start, the electrode patch **15** is specifically designed for ease of use by a patient (or caregiver); assistance by professional medical personnel is not required. Moreover, the patient is free to replace the electrode patch **15** at any time and need not wait for a doctor's appointment to have a new electrode patch **15** placed. In addition, the monitor recorder **14** operates automatically and the patient only need snap the monitor recorder **14** into place on the electrode patch **15** to initiate ECG monitoring. Thus, the synergistic combination of the electrode patch **15** and monitor recorder **14** makes the use of the electrocardiography monitor **12** a reliable and virtually foolproof way to monitor a patient's ECG and physiology for an extended, or even open-ended, period of time.

In simplest form, extended wear monitoring can be performed by using the same monitor recorder **14** inserted into a succession of fresh new electrode patches **15**. As needed, the electrode patch **15** can be replaced by the patient (or caregiver) with a fresh new electrode patch **15** throughout the overall monitoring period. Referring first to FIG. **16A**, at the outset of monitoring, a patient adheres a new electrode patch **15** in a location at the sternal midline **16** (or immediately to either side of the sternum **13**) oriented top-to-bottom (step **151**). The placement of the wearable monitor in a location at the sternal midline (or immediately to either side of the sternum), with its unique narrow "hourglass"-like shape, significantly improves the ability of the wearable monitor to cutaneously sense cardiac electrical potential signals, particularly the P-wave (or atrial activity) and, to a lesser extent, the QRS interval signals indicating ventricular activity in the ECG waveforms.

Placement involves simply adhering the electrode patch **15** on the skin along the sternal midline **16** (or immediately to either side of the sternum **13**). Patients can easily be taught to find the physical landmarks on the body necessary for proper placement of the electrode patch **15**. The physical landmarks are locations on the surface of the body that are already familiar to patients, including the inter-mammary cleft between the breasts above the manubrium (particularly easily locatable by women and gynecomastic men), the sternal notch immediately above the manubrium, and the Xiphoid process located at the bottom of the sternum. Empowering patients with the knowledge to place the electrode patch **15** in the right place ensures that the ECG electrodes will be correctly positioned on the skin, no matter the number of times that the electrode patch **15** is replaced.

A monitor recorder **14** is snapped into the non-conductive receptacle **25** on the outward-facing surface of the electrode patch **15** (step **152**). The monitor recorder **14** draws power externally from a battery provided in the non-conductive receptacle **25**. In addition, the battery is replaced each time that a fresh new electrode patch **15** is placed on the skin, which ensures that the monitor recorder **14** is always operating with a fresh power supply and minimizing the chances of a loss of monitoring continuity due to a depleted battery source.

22

By default, the monitor recorder **14** automatically initiates monitoring upon sensing body surface potentials through the pair of ECG electrodes (step **153**). In a further embodiment, the monitor recorder **14** can be configured for manual operation, such as by using the tactile feedback button **66** on the outside of the sealed housing **50**, or other user-operable control. In an even further embodiment, the monitor recorder **14** can be configured for remotely-controlled operation by equipping the monitor recorder **14** with a wireless transceiver, such as described in commonly-assigned U.S. Pat. No. 9,433,367, issued Sep. 6, 2016, the disclosure of which is incorporated by reference. The wireless transceiver allows wearable or mobile communications devices to wirelessly interface with the monitor recorder **14**.

A key feature of the extended wear electrocardiography monitor **12** is the ability to monitor ECG and physiological data for an extended period of time, which can be well in excess of the 14 days currently pitched as being achievable by conventional ECG monitoring approaches. In a further embodiment, ECG monitoring can even be performed over an open-ended time period, as further explained infra. The monitor recorder **14** is reusable and, if so desired, can be transferred to successive electrode patches **15** to ensure continuity of monitoring. At any point during ECG monitoring, a patient (or caregiver) can remove the monitor recorder **14** (step **154**) and replace the electrode patch **15** currently being worn with a fresh new electrode patch **15** (step **151**). The electrode patch **15** may need to be replaced for any number of reasons. For instance, the electrode patch **15** may be starting to come off after a period of wear or the patient may have skin that is susceptible to itching or irritation. The wearing of ECG electrodes can aggravate such skin conditions. Thus, a patient may want or need to periodically remove or replace ECG electrodes during a long-term ECG monitoring period, whether to replace a dislodged electrode, reestablish better adhesion, alleviate itching or irritation, allow for cleansing of the skin, allow for showering and exercise, or for other purpose.

Following replacement, the monitor recorder **14** is again snapped into the electrode patch **15** (step **152**) and monitoring resumes (step **153**). The ability to transfer the same monitor recorder **14** to successive electrode patches **15** during a period of extended wear monitoring is advantageous not to just diagnose cardiac rhythm disorders and other physiological events of potential concern, but to do extremely long term monitoring, such as following up on cardiac surgery, ablation procedures, or medical device implantation. In these cases, several weeks of monitoring or more may be needed. In addition, some IMDs, such as pacemakers or implantable cardioverter defibrillators, incorporate a loop recorder that will capture cardiac events over a fixed time window. If the telemetry recorded by the IMD is not downloaded in time, cardiac events that occurred at a time preceding the fixed time window will be overwritten by the IMD and therefore lost. The monitor recorder **14** provides continuity of monitoring that acts to prevent loss of cardiac event data. In a further embodiment, the firmware executed by the microcontroller **61** of the monitor recorder **14** can be optimized for minimal power consumption and additional flash memory for storing monitoring data can be added to achieve a multi-week monitor recorder **14** that can be snapped into a fresh new electrode patch **15** every seven days, or other interval, for weeks or even months on end.

Upon the conclusion of monitoring, the monitor recorder **14** is removed (step **154**) and recorded ECG and physiological telemetry are downloaded (step **155**). For instance, a download station can be physically interfaced to the external

US 12,285,261 B2

23

connector **65** of the monitor recorder **14** to initiate and conduct downloading, as described supra with reference to FIG. **15**.

In a further embodiment, the monitoring period can be of indeterminate duration. Referring next to FIG. **16B**, a similar series of operations are followed with respect to replacement of electrode patches **15**, reinsertion of the same monitor recorder **14**, and eventual download of ECG and physiological telemetry (steps **161-165**), as described supra with reference to FIG. **16A**. However, the flash memory **62** (shown in FIG. **9**) in the circuitry **60** of the monitor recorder **14** has a finite capacity. Following successful downloading of stored data, the flash memory **62** can be cleared to restore storage capacity and monitoring can resume once more, either by first adhering a new electrode patch **15** (step **161**) or by snapping the monitor recorder **14** into an already-adhered electrode patch **15** (step **162**). The foregoing expanded series of operations, to include reuse of the same monitor recorder **14** following data download, allows monitoring to continue indefinitely and without the kinds of interruptions that often affect conventional approaches, including the retrieval of monitoring data only by first making an appointment with a medical professional.

In a still further embodiment, when the monitor recorder **14** is equipped with a wireless transceiver, the use of a download station can be skipped. Referring last to FIG. **16C**, a similar series of operations are followed with respect to replacement of electrode patches **15** and reinsertion of the same monitor recorder **14** (steps **171-174**), as described supra with reference to FIG. **16A**. However, recorded ECG and physiological telemetry are downloaded wirelessly (step **175**), such as described in commonly-assigned U.S. Pat. No. 9,433,367, cited supra. The recorded ECG and physiological telemetry can even be downloaded wirelessly directly from a monitor recorder **14** during monitoring while still snapped into the non-conductive receptacle **25** on the electrode patch **15**. The wireless interfacing enables monitoring to continue for an open-ended period of time, as the downloading of the recorded ECG and physiological telemetry will continually free up onboard storage space. Further, wireless interfacing simplifies patient use, as the patient (or caregiver) only need worry about placing (and replacing) electrode patches **15** and inserting the monitor recorder **14**. Still other forms of practical use of the extended wear electrocardiography monitors **12** are possible.

The circuit trace and ECG electrodes components of the electrode patch **15** can be structurally simplified. In a still further embodiment, the flexible circuit **32** (shown in FIG. **5**) and distal ECG electrode **38** and proximal ECG electrode **39** (shown in FIG. **6**) are replaced with a pair of interlaced flexile wires. The interlacing of flexile wires through the flexible backing **20** reduces both manufacturing costs and environmental impact, as further described infra. The flexible circuit and ECG electrodes are replaced with a pair of flexile wires that serve as both electrode circuit traces and electrode signal pickups. FIG. **17** is a perspective view **180** of an extended wear electrode patch **15** with a flexile wire electrode assembly in accordance with a still further embodiment. The flexible backing **20** maintains the unique narrow "hourglass"-like shape that aids long term extended wear, particularly in women, as described supra with reference to FIG. **4**. For clarity, the non-conductive receptacle **25** is omitted to show the exposed battery printed circuit board **182** that is adhered underneath the non-conductive receptacle **25** to the proximal end **31** of the flexible backing **20**. Instead of employing flexible circuits, a pair of flexile wires are separately interlaced or sewn into the flexible backing **20**

24

to serve as circuit connections for an anode electrode lead and for a cathode electrode lead.

To form a distal electrode assembly, a distal wire **181** is interlaced into the distal end **30** of the flexible backing **20**, continues along an axial path through the narrow longitudinal midsection of the elongated strip, and electrically connects to the battery printed circuit board **182** on the proximal end **31** of the flexible backing **20**. The distal wire **181** is connected to the battery printed circuit board **182** by stripping the distal wire **181** of insulation, if applicable, and interlacing or sewing the uninsulated end of the distal wire **181** directly into an exposed circuit trace **183**. The distal wire-to-battery printed circuit board connection can be made, for instance, by back stitching the distal wire **181** back and forth across the edge of the battery printed circuit board **182**. Similarly, to form a proximal electrode assembly, a proximal wire (not shown) is interlaced into the proximal end **31** of the flexible backing **20**. The proximal wire is connected to the battery printed circuit board **182** by stripping the proximal wire of insulation, if applicable, and interlacing or sewing the uninsulated end of the proximal wire directly into an exposed circuit trace **184**. The resulting flexile wire connections both establish electrical connections and help to affix the battery printed circuit board **182** to the flexible backing **20**.

The battery printed circuit board **182** is provided with a battery compartment **36**. A set of electrical pads **34** are formed on the battery printed circuit board **182**. The electrical pads **34** electrically interface the battery printed circuit board **182** with a monitor recorder **14** when fitted into the non-conductive receptacle **25**. The battery compartment **36** contains a spring **185** and a clasp **186**, or similar assembly, to hold a battery (not shown) in place and electrically interfaces the battery to the electrical pads **34** through a pair of battery leads **187** for powering the electrocardiography monitor **14**. Other types of battery compartment are possible. The battery contained within the battery compartment **36** can be replaceable, rechargeable, or disposable.

In a yet further embodiment, the circuit board and non-conductive receptacle **25** are replaced by a combined housing that includes a battery compartment and a plurality of electrical pads. The housing can be affixed to the proximal end of the elongated strip through the interlacing or sewing of the flexile wires or other wires or threads.

The core of the flexile wires may be made from a solid, stranded, or braided conductive metal or metal compounds. In general, a solid wire will be less flexible than a stranded wire with the same total cross-sectional area, but will provide more mechanical rigidity than the stranded wire. The conductive core may be copper, aluminum, silver, or other material. The pair of the flexile wires may be provided as insulated wire. In one embodiment, the flexile wires are made from a magnet wire from Belden Cable, catalogue number 8051, with a solid core of AWG 22 with bare copper as conductor material and insulated by polyurethane or nylon. Still other types of flexile wires are possible. In a further embodiment, conductive ink or graphene can be used to print electrical connections, either in combination with or in place of the flexile wires.

In a still further embodiment, the flexile wires are uninsulated. FIG. **18** is perspective view of the flexile wire electrode assembly from FIG. **17**, with a layer of insulating material **189** shielding a bare uninsulated distal wire **181** around the midsection on the contact side of the flexible backing. On the contact side of the proximal and distal ends of the flexible backing, only the portions of the flexile wires serving as electrode signal pickups are electrically exposed

US 12,285,261 B2

25

and the rest of the flexile wire on the contact side outside of the proximal and distal ends are shielded from electrical contact. The bare uninsulated distal wire **181** may be insulated using a layer of plastic, rubber-like polymers, or varnish, or by an additional layer of gauze or adhesive (or non-adhesive) gel. The bare uninsulated wire **181** on the non-contact side of the flexible backing may be insulated or can simply be left uninsulated.

Both end portions of the pair of flexile wires are typically placed uninsulated on the contact surface of the flexible backing **20** to form a pair of electrode signal pickups. FIG. **19** is a bottom view **190** of the flexile wire electrode assembly as shown in FIG. **17**. When adhered to the skin during use, the uninsulated end portions of the distal wire **181** and the proximal wire **191** enable the monitor recorder **14** to measure dermal electrical potential differentials. At the proximal and distal ends of the flexible backing **20**, the uninsulated end portions of the flexile wires may be configured into an appropriate pattern to provide an electrode signal pickup, which would typically be a spiral shape formed by guiding the flexile wire along an inwardly spiraling pattern. The surface area of the electrode pickups can also be variable, such as by selectively removing some or all of the insulation on the contact surface. For example, an electrode signal pickup arranged by sewing insulated flexile wire in a spiral pattern could have a crescent-shaped cutout of uninsulated flexile wire facing towards the signal source.

In a still yet further embodiment, the flexile wires are left freely riding on the contact surfaces on the distal and proximal ends of the flexible backing, rather than being interlaced into the ends of the flexible backing **20**. FIG. **20** is a bottom view **200** of a flexile wire electrode assembly in accordance with a still yet further embodiment. The distal wire **181** is interlaced onto the midsection and extends an exposed end portion **192** onto the distal end **30**. The proximal wire **191** extends an exposed end portion **193** onto the proximal end **31**. The exposed end portions **192** and **193**, not shielded with insulation, are further embedded within an electrically conductive adhesive **201**. The adhesive **201** makes contact to skin during use and conducts skin electrical potentials to the monitor recorder **14** (not shown) via the flexile wires. The adhesive **201** can be formed from electrically conductive, non-irritating adhesive, such as hydrocolloid.

The distal wire **181** is interlaced or sewn through the longitudinal midsection of the flexible backing **20** and takes the place of the flexible circuit **32**. FIG. **21** is a perspective view showing the longitudinal midsection of the flexible backing of the electrode assembly from FIG. **17**. Various stitching patterns may be adopted to provide a proper combination of rigidity and flexibility. In simplest form, the distal wire **181** can be manually threaded through a plurality of holes provided at regularly-spaced intervals along an axial path defined between the battery printed circuit board **182** (not shown) and the distal end **30** of the flexible backing **20**. The distal wire **181** can be threaded through the plurality of holes by stitching the flexile wire as a single "thread." Other types of stitching patterns or stitching of multiple "threads" could also be used, as well as using a sewing machine or similar device to machine-stitch the distal wire **181** into place, as further described infra. Further, the path of the distal wire **181** need not be limited to a straight line from the distal to the proximal end of the flexible backing **20**.

While the invention has been particularly shown and described as referenced to the embodiments thereof, those skilled in the art will understand that the foregoing and other

26

changes in form and detail may be made therein without departing from the spirit and scope.

What is claimed is:

1. A moisture-resistant electrocardiography monitor, comprising:

an electrocardiography monitor recorder, comprising:

a wearable housing molded out of one or more materials and sealed against moisture;

a plurality of electrical contacts protruding from the wearable housing;

a seal coupling positioned on the wearable housing and surrounding the electrical contacts; and

electronic circuitry provided within the wearable housing, the electronic circuitry further comprising:

an electrocardiographic front end circuit under a control of a micro-controller and adapted to sense cardiac electrical potential differentials through electrocardiographic electrodes via some of the electrical contacts, which are provided to the micro-controller as an analog signal;

the micro-controller configured to sample the analog signal; and

a memory electrically interfaced with the micro-controller and operable to store the samples; and

an extended wear electrode patch, comprising:

a flexible backing comprising a plurality of adhesive contact surfaces;

the electrocardiographic electrodes, each comprised on one of the adhesive contact surfaces;

a receptacle affixed to a non-contacting surface of the flexible backing into which the wearable housing can be removably secured, the receptacle comprising a compartment within which a component interfaced to the electronic circuitry is positioned via some of the electrical contacts, wherein the component is a battery;

a plurality of electrical pads positioned on the receptacle, each of the pads configured to interface with one of the electrical contacts when the wearable housing is secured within the receptacle; and

a moisture-resistant seal formed on the receptacle and surrounding the electrical pads, wherein the moisture-resistant seal mates the seal coupling when the wearable housing is secured within the receptacle.

2. A monitor according to claim **1**, wherein the one or more materials comprise at least one of polycarbonate and ABS.

3. A monitor according to claim **1**, wherein the one or more materials comprise an alloy of polycarbonate and ABS.

4. A monitor according to claim **1**, the housing further comprising a waterproof patient-operable tactile-feedback button.

5. A monitor according to claim **4**, wherein an outer surface of the button is molded out of a soft pliable material.

6. A monitor according to claim **5**, wherein the soft pliable material comprises silicon rubber.

7. A monitor according to claim **1**, wherein the seal coupling and the moisture resistant seal are circular.

8. A monitor according to claim **1**, wherein the battery is replaceable without opening the wearable housing.

9. A monitor according to claim **1**, wherein the compartment is formed on a bottom surface of the receptacle.

US 12,285,261 B2

27

10. A moisture-resistant patient-interfacing electrocardiography monitor, comprising:

an electrocardiography monitor recorder, comprising:

a wearable housing molded out of one or more materials and sealed against moisture;

a waterproof patient-operable tactile feedback button positioned on an outside of the wearable housing;

a plurality of electrical contacts protruding the wearable housing;

a seal coupling positioned on the wearable housing and surrounding the electrical contacts; and

electronic circuitry provided within the wearable housing, the electronic circuitry further comprising:

an electrocardiographic front end circuit under a control of a micro-controller and adapted to sense cardiac electrical potential differentials through electrocardiographic electrodes via some of the electrical contacts, which are provided to the micro-controller as an analog signal;

the micro-controller configured to sample the analog signal; and

a memory electrically interfaced with the micro-controller and operable to store the samples; and

an extended wear electrode patch, comprising:

a flexible backing comprising a plurality of adhesive contact surfaces;

the electrocardiographic electrodes, each comprised on one of the adhesive contact surfaces;

a receptacle affixed to a non-contacting surface of the flexible backing into which the wearable housing can be removably secured, the receptacle comprising a compartment within which a battery, wherein the electronic circuitry is powered by the battery via at least some of the electrical contacts;

28

a plurality of electrical pads positioned on the receptacle, each of the pads configured to interface with one of the electrical contacts when the wearable housing is secured within the receptacle; and

a moisture-resistant seal formed on the receptacle and surrounding the electrical pads, wherein the moisture-resistant seal mates the seal coupling when the wearable housing is secured within the receptacle.

11. A monitor according to claim **10**, wherein the one or more materials comprise at least one of polycarbonate and ABS.

12. A monitor according to claim **10**, wherein the one or more materials comprise an alloy of polycarbonate and ABS.

13. A monitor according to claim **10**, wherein the waterproof patient-operable tactile feedback button is positioned on a side of the housing opposite to a further side on which the electrical contacts are positioned.

14. A monitor according to claim **13**, wherein an outer surface of the button is molded out of a soft pliable material.

15. A monitor according to claim **14**, wherein the soft pliable material comprises silicon rubber.

16. A monitor according to claim **10**, wherein the seal coupling and the moisture resistant seal are circular.

17. A monitor according to claim **10**, wherein the battery is one of a replaceable, rechargeable, and disposable battery.

18. A monitor according to claim **10**, wherein the compartment is formed on a bottom surface of the receptacle.

19. A monitor according to claim **10**, wherein the battery is replaceable without opening the wearable housing.

* * * * *

Exhibit 17



US012310735B2

(12) **United States Patent**
Felix et al.

(10) **Patent No.:** **US 12,310,735 B2**
(45) **Date of Patent:** ***May 27, 2025**

(54) **EXTENDED WEAR AMBULATORY
ELECTROCARDIOGRAPHY MONITOR**

(71) Applicant: **Bardy Diagnostics, Inc.**, Bellevue, WA
(US)

(72) Inventors: **Jason Felix**, Vashon Island, WA (US);
Jon Mikalson Bishay, Lexington, KY
(US); **Gust H. Bardy**, Carnation, WA
(US)

(73) Assignee: **Bardy Diagnostics, Inc.**

(*) Notice: Subject to any disclaimer, the term of this
patent is extended or adjusted under 35
U.S.C. 154(b) by 0 days.

This patent is subject to a terminal dis-
claimer.

(21) Appl. No.: **18/353,407**

(22) Filed: **Jul. 17, 2023**

(65) **Prior Publication Data**

US 2023/0355154 A1 Nov. 9, 2023

Related U.S. Application Data

(63) Continuation of application No. 17/691,004, filed on
Mar. 9, 2022, now Pat. No. 11,701,045, which is a
(Continued)

(51) **Int. Cl.**
A61B 5/05 (2021.01)
A61B 5/00 (2006.01)
(Continued)

(52) **U.S. Cl.**
CPC **A61B 5/282** (2021.01); **A61B 5/0006**
(2013.01); **A61B 5/0022** (2013.01);
(Continued)

(58) **Field of Classification Search**

CPC A61B 5/282; A61B 5/0006; A61B
2560/0412; A61B 5/6833; A61B 5/259;
(Continued)

(56) **References Cited**

U.S. PATENT DOCUMENTS

3,215,136 A 11/1965 Holter et al.
3,569,852 A 3/1971 Berkovits
(Continued)

FOREIGN PATENT DOCUMENTS

DE 19955211 5/2001
EP 1859833 11/2007
(Continued)

OTHER PUBLICATIONS

US 6,527,714 B2, 03/2003, Bardy (withdrawn)
(Continued)

Primary Examiner — Joseph A Stoklosa


Assistant Examiner — Brian M Antiskay

(74) *Attorney, Agent, or Firm* — K&L Gates LLP

(57) **ABSTRACT**

An electrocardiography monitor is provided. A sealed hous-
ing includes one end wider than an opposite end of the
sealed housing. Electronic circuitry is provided within the
sealed housing. The electronic circuitry includes an electro-
graphic front end circuit to sense electrocardiographic sig-
nals and a micro-controller interfaced to the electrocardio-
graphic front end circuit to sample the electrocardiographic
signals. A buzzer within the housing outputs feedback to a
wearer of the sealed housing.

20 Claims, 6 Drawing Sheets



US 12,310,735 B2

Related U.S. Application Data			4,532,934 A	8/1985	Kelen
continuation of application No. 16/684,386, filed on			4,546,342 A	10/1985	Weaver et al.
Nov. 14, 2019, now Pat. No. 11,272,872, which is a			4,550,502 A	11/1985	Grayzel
continuation of application No. 15/676,896, filed on			4,580,572 A	4/1986	Granek et al.
Aug. 14, 2017, now Pat. No. 10,478,083, which is a			4,635,646 A	1/1987	Gilles et al.
continuation of application No. 14/080,725, filed on			4,653,022 A	3/1987	Koro
Nov. 14, 2013, now Pat. No. 9,730,593.			4,716,903 A	1/1988	Hansen
			4,763,660 A	8/1988	Kroll et al.
			4,788,983 A	12/1988	Brink et al.
			4,809,705 A	3/1989	Ascher
			4,915,656 A	4/1990	Alferness
(60)	Provisional application No. 61/882,403, filed on Sep.		5,007,429 A	4/1991	Treatch et al.
25, 2013.			5,025,794 A	6/1991	Albert et al.
			5,107,480 A	4/1992	Naus
(51)	Int. Cl.		5,168,876 A	12/1992	Quedens et al.
	<i>A61B 5/0205</i>	(2006.01)	5,215,098 A	6/1993	Steinhaus
	<i>A61B 5/11</i>	(2006.01)	5,231,990 A	8/1993	Gauglitz
	<i>A61B 5/259</i>	(2021.01)	D341,423 S	11/1993	Bible
	<i>A61B 5/282</i>	(2021.01)	5,263,481 A	11/1993	Axelgaard
	<i>A61B 5/316</i>	(2021.01)	5,265,579 A	11/1993	Ferrari
	<i>A61B 5/335</i>	(2021.01)	5,312,446 A	5/1994	Holschbach et al.
	<i>A61B 5/349</i>	(2021.01)	5,314,453 A	5/1994	Jeutter
	<i>A61B 5/35</i>	(2021.01)	5,331,966 A	7/1994	Bennett et al.
	<i>A61B 5/01</i>	(2006.01)	5,333,615 A	8/1994	Craelius et al.
	<i>A61B 5/021</i>	(2006.01)	5,341,806 A	8/1994	Gadsby et al.
	<i>A61B 5/08</i>	(2006.01)	5,348,008 A	9/1994	Bornn et al.
	<i>A61B 5/087</i>	(2006.01)	5,355,891 A	10/1994	Wateridge et al.
	<i>A61B 5/091</i>	(2006.01)	5,365,934 A	11/1994	Leon et al.
	<i>A61B 5/145</i>	(2006.01)	5,365,935 A	11/1994	Righter et al.
	<i>A61B 5/1455</i>	(2006.01)	5,392,784 A	2/1995	Gudaitis
	<i>G01N 27/30</i>	(2006.01)	D357,069 S	4/1995	Plahn et al.
(52)	U.S. Cl.		5,402,780 A	4/1995	Faasse, Jr.
	CPC	<i>A61B 5/02055</i> (2013.01); <i>A61B 5/1116</i>	5,402,884 A	4/1995	Gilman et al.
		(2013.01); <i>A61B 5/1117</i> (2013.01); <i>A61B</i>	5,450,845 A	9/1995	Axelgaard
		<i>5/1118</i> (2013.01); <i>A61B 5/259</i> (2021.01);	5,451,876 A	9/1995	Senford et al.
		<i>A61B 5/316</i> (2021.01); <i>A61B 5/335</i> (2021.01);	5,458,141 A	10/1995	Neil
		<i>A61B 5/349</i> (2021.01); <i>A61B 5/35</i> (2021.01);	5,473,537 A	12/1995	Glazer et al.
		<i>A61B 5/4809</i> (2013.01); <i>A61B 5/6801</i>	5,479,922 A	1/1996	Reichl
		(2013.01); <i>A61B 5/6823</i> (2013.01); <i>A61B</i>	5,483,969 A	1/1996	Testerman et al.
		<i>5/6833</i> (2013.01); <i>A61B 5/01</i> (2013.01); <i>A61B</i>	5,511,553 A	4/1996	Segalowitz
		<i>5/021</i> (2013.01); <i>A61B 5/0816</i> (2013.01);	5,540,733 A	7/1996	Testerman et al.
		<i>A61B 5/087</i> (2013.01); <i>A61B 5/091</i> (2013.01);	5,546,952 A	8/1996	Erickson
		<i>A61B 5/14532</i> (2013.01); <i>A61B 5/14542</i>	5,549,655 A	8/1996	Erickson
		(2013.01); <i>A61B 5/14551</i> (2013.01); <i>A61B</i>	5,579,919 A	12/1996	Gilman et al.
		<i>5/7455</i> (2013.01); <i>A61B 2505/07</i> (2013.01);	5,582,181 A	12/1996	Ruess
		<i>A61B 2560/0271</i> (2013.01); <i>A61B 2560/0412</i>	D377,983 S	2/1997	Sabri et al.
		(2013.01); <i>A61B 2560/045</i> (2013.01); <i>A61B</i>	5,601,089 A	2/1997	Bledsoe et al.
		<i>2562/0219</i> (2013.01); <i>A61B 2562/164</i>	5,623,935 A	4/1997	Faisandier
		(2013.01); <i>G01N 27/307</i> (2013.01)	5,682,901 A	11/1997	Kamen
(58)	Field of Classification Search		5,697,955 A	12/1997	Stolte
	CPC	A61B 5/28; A61B 5/1118; A61B 5/1117;	5,724,967 A	3/1998	Venkatachalam
		A61B 2560/0468; A61B 5/02405; A61B	5,749,902 A	5/1998	Olsen et al.
		5/256; A61B 5/6804	5,788,633 A	8/1998	Mahoney
	USPC	600/372, 382, 384, 386, 388, 390–393,	5,817,151 A	10/1998	Olsen et al.
		600/508–509	5,819,741 A	10/1998	Karlsson et al.
	See application file for complete search history.		5,850,920 A	12/1998	Gilman et al.
			5,860,918 A	1/1999	Schradi et al.
(56)	References Cited		5,862,803 A	1/1999	Besson et al.
	U.S. PATENT DOCUMENTS		D407,159 S	3/1999	Roberg
	3,602,215 A	8/1971 Parnell	5,876,351 A	3/1999	Rohde
	3,699,948 A	10/1972 Ota et al.	5,906,583 A	5/1999	Rogel
	3,718,772 A	2/1973 Sanctuary	5,951,598 A	9/1999	Bishay et al.
	3,893,453 A	7/1975 Goldberg	5,956,013 A	9/1999	Raj et al.
	4,123,785 A	10/1978 Cherry et al.	5,957,857 A	9/1999	Hartley
	4,151,513 A	4/1979 Menken et al.	5,984,102 A	11/1999	Tay
	4,328,814 A	5/1982 Arkans	5,987,352 A	11/1999	Klein et al.
	4,441,500 A	4/1984 Sessions et al.	6,032,064 A	2/2000	Devlin et al.
	4,506,678 A	3/1985 Russell et al.	6,038,469 A	3/2000	Karlsson et al.
			6,101,413 A	8/2000	Olsen et al.
			6,115,638 A	9/2000	Groenke
			6,117,077 A	9/2000	Del Mar et al.
			6,134,479 A	10/2000	Brewer et al.
			6,148,233 A	11/2000	Owen et al.
			6,149,602 A	11/2000	Arcelus
			6,149,781 A	11/2000	Forand
			6,185,452 B1	2/2001	Schulman et al.
			6,188,407 B1	2/2001	Smith et al.
			6,223,080 B1	4/2001	Thompson
			D443,063 S	5/2001	Pisani et al.

US 12,310,735 B2

Page 3

(56)

References Cited

U.S. PATENT DOCUMENTS

6,238,338	B1	5/2001	DeLuca et al.	D606,656	S	12/2009	Kobayashi et al.
6,245,025	B1	6/2001	Torok et al.	7,672,714	B2	3/2010	Kuo et al.
6,246,330	B1	6/2001	Nielsen	7,706,870	B2	4/2010	Shieh et al.
6,249,696	B1	6/2001	Olson et al.	7,756,721	B1	7/2010	Falchuk et al.
D445,507	S	7/2001	Pisani et al.	7,787,943	B2	8/2010	McDonough
6,269,267	B1	7/2001	Bardy et al.	7,874,993	B2	1/2011	Bardy
6,272,385	B1	8/2001	Bishay et al.	7,881,785	B2	2/2011	Nassif et al.
6,298,255	B1	10/2001	Cordero et al.	D639,437	S	6/2011	Bishay et al.
6,301,502	B1	10/2001	Owen et al.	7,959,574	B2	6/2011	Bardy
6,304,773	B1	10/2001	Taylor et al.	8,108,035	B1	1/2012	Bharmi
6,304,780	B1	10/2001	Owen et al.	8,116,841	B2	2/2012	Bly et al.
6,304,783	B1	10/2001	Lyster et al.	8,135,459	B2	3/2012	Bardy et al.
6,374,138	B1	4/2002	Owen et al.	8,150,502	B2	4/2012	Kumar et al.
6,381,482	B1	4/2002	Jayaraman et al.	8,160,682	B2	4/2012	Kumar et al.
6,416,471	B1	7/2002	Kumar et al.	8,172,761	B1	5/2012	Rulkov et al.
6,418,342	B1	7/2002	Owen et al.	8,180,425	B2	5/2012	Selvitelli et al.
6,424,860	B1	7/2002	Karlsson et al.	8,200,320	B2	6/2012	Kovacs
6,427,083	B1	7/2002	Owen et al.	8,214,007	B2	7/2012	Baker et al.
6,427,085	B1	7/2002	Boon et al.	8,231,539	B2	7/2012	Bardy
6,434,410	B1	8/2002	Cordero	8,231,540	B2	7/2012	Bardy
6,450,845	B1	9/2002	Snyder et al.	8,239,012	B2	8/2012	Felix et al.
6,454,708	B1	9/2002	Ferguson et al.	8,249,686	B2	8/2012	Libbus et al.
6,456,256	B1	9/2002	Amundson et al.	8,260,414	B2	9/2012	Nassif et al.
6,456,872	B1	9/2002	Faisandier	8,266,008	B1	9/2012	Siegal et al.
6,463,320	B1	10/2002	Xue et al.	8,277,378	B2	10/2012	Bardy
6,546,285	B1	4/2003	Owen et al.	8,285,356	B2	10/2012	Bly et al.
6,605,046	B1	8/2003	Del Mar	8,285,370	B2	10/2012	Felix et al.
6,607,485	B2	8/2003	Bardy	8,308,650	B2	11/2012	Bardy
6,611,705	B2	8/2003	Hopman et al.	8,315,695	B2	11/2012	Sebelius et al.
6,671,545	B2	12/2003	Fincke	8,366,629	B2	2/2013	Bardy
6,671,547	B2	12/2003	Lyster et al.	8,374,688	B2	2/2013	Libbus et al.
6,694,186	B2	2/2004	Bardy	8,412,317	B2	4/2013	Mazar
6,704,595	B2	3/2004	Bardy	8,460,189	B2	6/2013	Libbus et al.
6,705,991	B2	3/2004	Bardy	8,473,047	B2	6/2013	Chakravarthy et al.
6,719,701	B2	4/2004	Lade	8,478,418	B2	7/2013	Fahey
6,754,523	B2	6/2004	Toole	8,483,809	B2	7/2013	Kim et al.
6,782,293	B2	8/2004	Dupelle et al.	8,538,503	B2	9/2013	Kumar et al.
6,856,832	B1	2/2005	Matsumura et al.	8,545,416	B1	10/2013	Kayyali et al.
6,860,897	B2	3/2005	Bardy	8,554,311	B2	10/2013	Warner et al.
6,866,629	B2	3/2005	Bardy	8,560,046	B2	10/2013	Kumar et al.
6,887,201	B2	5/2005	Bardy	8,591,430	B2	11/2013	Amurthur et al.
6,893,397	B2	5/2005	Bardy	8,594,763	B1	11/2013	Bibian et al.
6,895,261	B1	5/2005	Palamides	8,600,486	B2	12/2013	Kaib et al.
6,904,312	B2	6/2005	Bardy	8,611,980	B2	12/2013	Choe et al.
6,908,431	B2	6/2005	Bardy	8,613,708	B2	12/2013	Bishay et al.
6,913,577	B2	7/2005	Bardy	8,613,709	B2	12/2013	Bishay et al.
6,944,498	B2	9/2005	Owen et al.	8,620,418	B1	12/2013	Kuppuraj et al.
6,960,167	B2	11/2005	Bardy	8,626,277	B2	1/2014	Felix et al.
6,970,731	B1	11/2005	Jayaraman et al.	8,628,020	B2	1/2014	Beck
6,978,169	B1	12/2005	Guerra	8,630,699	B2	1/2014	Baker et al.
6,993,377	B2	1/2006	Flick et al.	8,647,268	B2	2/2014	Tran
7,020,508	B2	3/2006	Stivoric et al.	8,668,653	B2	3/2014	Nagata et al.
7,027,864	B2	4/2006	Snyder et al.	8,684,925	B2	4/2014	Manicka et al.
7,052,472	B1	5/2006	Miller et al.	8,688,190	B2	4/2014	Libbus et al.
7,065,401	B2	6/2006	Worden	8,718,742	B2	5/2014	Beck et al.
7,085,601	B1	8/2006	Bardy et al.	8,718,752	B2	5/2014	Libbus et al.
7,104,955	B2	9/2006	Bardy	8,744,561	B2	6/2014	Fahey
7,134,996	B2	11/2006	Bardy	8,750,974	B2	6/2014	Baker et al.
7,137,389	B2	11/2006	Berthon-Jones	8,774,932	B2	7/2014	Fahey
7,147,600	B2	12/2006	Bardy	8,790,257	B2	7/2014	Libbus et al.
7,197,357	B2	3/2007	Istvan et al.	8,790,259	B2	7/2014	Katra et al.
7,206,630	B1	4/2007	Tarler	8,795,174	B2	8/2014	Manicka et al.
7,212,849	B2	5/2007	Zhang et al.	8,798,729	B2	8/2014	Kaib et al.
7,215,991	B2	5/2007	Besson et al.	8,798,734	B2	8/2014	Kuppuraj et al.
7,248,916	B2	7/2007	Bardy	8,818,478	B2	8/2014	Scheffler et al.
7,257,438	B2	8/2007	Kinast	8,818,481	B2	8/2014	Bly et al.
7,277,752	B2	10/2007	Matos	8,823,490	B2	9/2014	Libbus et al.
7,294,108	B1	11/2007	Bornzin et al.	8,858,432	B2	10/2014	Robertson et al.
D558,882	S	1/2008	Brady	8,926,509	B2	1/2015	Magar et al.
7,328,061	B2	2/2008	Rowlandson et al.	8,938,287	B2	1/2015	Felix et al.
7,395,106	B2	7/2008	Ryu et al.	8,948,935	B1	2/2015	Peeters et al.
7,412,395	B2	8/2008	Rowlandson et al.	8,965,492	B2	2/2015	Baker et al.
7,429,938	B1	9/2008	Corndorf	9,066,664	B2	6/2015	Karjalainen
7,468,032	B2	12/2008	Stahmann et al.	9,135,608	B2	9/2015	Herlitz
7,552,031	B2	6/2009	Vock et al.	9,149,229	B1	10/2015	Tarler
				9,155,484	B2	10/2015	Baker et al.
				9,204,813	B2	12/2015	Kaib et al.
				9,211,073	B2	12/2015	Banet et al.
				9,241,649	B2	1/2016	Kumar et al.

US 12,310,735 B2

Page 4

(56)

References Cited

U.S. PATENT DOCUMENTS

9,259,154 B2

2/2016

Miller et al.

9,277,864 B2

3/2016

Yang et al.

9,339,202 B2

5/2016

Brockway et al.

9,375,179 B2

6/2016

Schultz et al.

9,414,786 B1

8/2016

Brockway et al.

9,433,366 B2

9/2016

Baker et al.

9,439,566 B2

9/2016

Arne et al.

9,510,755 B2

12/2016

Fong et al.

9,603,542 B2

3/2017

Veen et al.

9,669,212 B2

6/2017

Mueller et al.

9,693,732 B1

7/2017

Tarler

9,700,222 B2

7/2017

Quinlan et al.

9,770,182 B2

9/2017

Bly et al.

9,877,663 B2

1/2018

Baker et al.

10,034,614 B2

7/2018

Edic et al.

10,045,708 B2

8/2018

Dusan

10,049,182 B2

8/2018

Chefles et al.

10,159,422 B2

12/2018

Baker et al.

10,271,754 B2

4/2019

Bahney et al.

10,327,660 B2

6/2019

Gallego et al.

10,405,799 B2

9/2019

Kumar et al.

10,413,251 B2

9/2019

Golda et al.

10,441,185 B2

10/2019

Rogers et al.

10,517,500 B2

12/2019

Kumar et al.

10,555,683 B2

2/2020

Bahney et al.

10,939,839 B2

3/2021

Baker et al.

11,051,743 B2

7/2021

Felix et al.

11,116,447 B2

9/2021

Yang et al.

11,141,091 B2

10/2021

Kumar et al.

11,445,967 B2

9/2022

Felix et al.

11,627,902 B2

4/2023

Bahney et al.

2001/0051766 A1

12/2001

Gazdzinski

2002/0013538 A1

1/2002

Teller

2002/0013717 A1

1/2002

Ando et al.

2002/0016798 A1

2/2002

Sakai et al.

2002/0072682 A1

6/2002

Hopman

2002/0082867 A1

6/2002

MacCarter et al.

2002/0103422 A1

8/2002

Harder et al.

2002/0109621 A1

8/2002

Khair et al.

2002/0120310 A1

8/2002

Linden et al.

2002/0128686 A1

9/2002

Minogue et al.

2002/0184055 A1

12/2002

Naghavi et al.

2002/0193668 A1

12/2002

Munneke

2003/0004547 A1

1/2003

Owen et al.

2003/0028811 A1

2/2003

Walker et al.

2003/0073916 A1

4/2003

Yonce

2003/0083559 A1

5/2003

Thompson

2003/0097078 A1

5/2003

Maeda

2003/0139785 A1

7/2003

Riff et al.

2003/0149349 A1

8/2003

Jensen

2003/0174881 A1

9/2003

Simard et al.

2003/0176802 A1

9/2003

Galen et al.

2003/0211797 A1

11/2003

Hill et al.

2004/0008123 A1

1/2004

Carrender

2004/0019288 A1

1/2004

Kinast

2004/0034284 A1

2/2004

Aversano et al.

2004/0049120 A1

3/2004

Cao et al.

2004/0049132 A1

3/2004

Barron et al.

2004/0073127 A1

4/2004

Istvan et al.

2004/0087836 A1

5/2004

Green et al.

2004/0088019 A1

5/2004

Rueter et al.

2004/0093192 A1

5/2004

Hasson et al.

2004/0116784 A1

6/2004

Gavish

2004/0148194 A1

7/2004

Wellons et al.

2004/0163034 A1

8/2004

Colbath et al.

2004/0167416 A1

8/2004

Lee

2004/0207530 A1

10/2004

Nielsen

2004/0210165 A1

10/2004

Marmaropoulos et al.

2004/0236202 A1

11/2004

Burton

2004/0243435 A1

12/2004

Williams

2004/0256453 A1

12/2004

Lammle

2004/0260188 A1

12/2004

Syed et al.

2004/0260192 A1

12/2004

Yamamoto

2005/0010139 A1

1/2005

Aminian et al.

2005/0043640 A1

2/2005

Chang

2005/0058701 A1

3/2005

Gross et al.

2005/0096513 A1

5/2005

Ozguz et al.

2005/0096717 A1

5/2005

Bishay et al.

2005/0101875 A1

5/2005

Semler et al.

2005/0108055 A1

5/2005

Ott et al.

2005/0113661 A1

5/2005

Nazeri

2005/0137485 A1

6/2005

Cao et al.

2005/0151640 A1

7/2005

Hastings

2005/0154267 A1

7/2005

Bardy

2005/0154294 A1

7/2005

Uchiyama et al.

2005/0182308 A1

8/2005

Bardy

2005/0182309 A1

8/2005

Bardy

2005/0215918 A1

9/2005

Frantz et al.

2005/0222513 A1

10/2005

Hadley et al.

2005/0228243 A1

10/2005

Bardy

2005/0245839 A1

11/2005

Stivoric et al.

2005/0261564 A1

11/2005

Ryu et al.

2005/0275416 A1

12/2005

Hervieux et al.

2006/0025696 A1

2/2006

Kurzweil et al.

2006/0025824 A1

2/2006

Freeman et al.

2006/0030767 A1

2/2006

Lang et al.

2006/0030781 A1

2/2006

Shennib

2006/0030904 A1

2/2006

Quiles

2006/0041201 A1

2/2006

Behbehani et al.

2006/0084883 A1

4/2006

Linker

2006/0100530 A1

5/2006

Kliot et al.

2006/0111642 A1

5/2006

Baura et al.

2006/0111943 A1

5/2006

Wu

2006/0122469 A1

6/2006

Martel

2006/0124193 A1

6/2006

Orr et al.

2006/0167502 A1

7/2006

Haefner

2006/0224072 A1

10/2006

Shennib

2006/0229522 A1

10/2006

Barr

2006/0235320 A1

10/2006

Tan et al.

2006/0253006 A1

11/2006

Bardy

2006/0264730 A1

11/2006

Stivoric et al.

2006/0264767 A1

11/2006

Shennib

2007/0003115 A1

1/2007

Patton et al.

2007/0029961 A1

2/2007

Harita et al.

2007/0038057 A1

2/2007

Nam et al.

2007/0050209 A1

3/2007

Yered

2007/0078324 A1

4/2007

Wijisiriwardana

2007/0078354 A1

4/2007

Holland

2007/0088406 A1

4/2007

Bennett et al.

2007/0088429 A1

4/2007

Thompson

2007/0089800 A1

4/2007

Sharma

2007/0093719 A1

4/2007

Nichols, Jr. et al.

2007/0100248 A1

5/2007

Van Dam et al.

2007/0100667 A1

5/2007

Bardy

2007/0123801 A1

5/2007

Goldberger et al.

2007/0131595 A1

6/2007

Jansson et al.

2007/0136091 A1

6/2007

McTaggart

2007/0142722 A1

6/2007

Chang

2007/0179357 A1

8/2007

Bardy

2007/0185390 A1

8/2007

Perkins et al.

2007/0203415 A1

8/2007

Bardy

2007/0203423 A1

8/2007

Bardy

2007/0208232 A1 *

9/2007

Kovacs A61B 5/14551
600/595

2007/0208233 A1

9/2007

Kovacs

2007/0208266 A1

9/2007

Hadley

2007/0225611 A1

9/2007

Kumar et al.

2007/0233198 A1

10/2007

Ghanem et al.

2007/0244405 A1

10/2007

Xue et al.

2007/0249946 A1

10/2007

Kumar et al.

2007/0255153 A1

11/2007

Kumar et al.

2007/0265510 A1

11/2007

Bardy

2007/0270678 A1

11/2007

Fadem

2007/0276270 A1

11/2007

Tran

2007/0276275 A1

11/2007

Proctor et al.

2007/0293738 A1

12/2007

Bardy

2007/0293739 A1

12/2007

Bardy

2007/0293740 A1

12/2007

Bardy

2007/0293741 A1

12/2007

Bardy

2007/0293742 A1

12/2007

Bardy

2007/0299325 A1

12/2007

Farrell et al.

2007/0299617 A1

12/2007

Willis

2008/0027337 A1

1/2008

Dugan

2008/0027339 A1

1/2008

Nagai et al.

US 12,310,735 B2

Page 5

(56)

References Cited

U.S. PATENT DOCUMENTS

2008/0051668	A1	2/2008	Bardy	2010/0280366	A1	11/2010	Arne et al.
2008/0058661	A1	3/2008	Bardy	2010/0298720	A1	11/2010	Potkay
2008/0088467	A1	4/2008	Al-Ali et al.	2010/0312188	A1	12/2010	Robertson et al.
2008/0091089	A1	4/2008	Guillory et al.	2010/0324384	A1	12/2010	Moon et al.
2008/0091097	A1	4/2008	Linti et al.	2011/0009729	A1	1/2011	Shin et al.
2008/0108890	A1	5/2008	Teng et al.	2011/0021937	A1 *	1/2011	Hugh A61B 5/0205
2008/0114232	A1	5/2008	Gazit				600/523
2008/0139953	A1 *	6/2008	Baker A61B 5/024	2011/0054285	A1	3/2011	Searle et al.
			600/509	2011/0054286	A1	3/2011	Crosby et al.
2008/0143080	A1	6/2008	Burr	2011/0060215	A1	3/2011	Tupin, Jr. et al.
2008/0177168	A1	7/2008	Callahan et al.	2011/0066041	A1	3/2011	Pandia et al.
2008/0194927	A1	8/2008	KenKnight et al.	2011/0077497	A1	3/2011	Oster et al.
2008/0208009	A1	8/2008	Shklarski	2011/0082842	A1	4/2011	Groseclose, Jr. et al.
2008/0208014	A1	8/2008	KenKnight et al.	2011/0105861	A1	5/2011	Derchak et al.
2008/0243012	A1	10/2008	Hisayuki et al.	2011/0112379	A1	5/2011	Li et al.
2008/0284599	A1	11/2008	Zdeblick et al.	2011/0125040	A1	5/2011	Crawford et al.
2008/0288026	A1 *	11/2008	Cross H01R 13/5224	2011/0144470	A1	6/2011	Mazar et al.
			607/60	2011/0160548	A1	6/2011	Forster
2008/0294024	A1	11/2008	Cosentino et al.	2011/0160601	A1 *	6/2011	Wang A61B 5/6841
2008/0306359	A1	12/2008	Zdeblick et al.				600/509
2008/0309481	A1	12/2008	Tanaka et al.	2011/0208076	A1	8/2011	Fong et al.
2008/0312522	A1	12/2008	Rowlandson et al.	2011/0224564	A1	9/2011	Moon et al.
2009/0009342	A1	1/2009	Karjalainen	2011/0237922	A1	9/2011	Parker, III et al.
2009/0012412	A1	1/2009	Wiesel	2011/0237924	A1 *	9/2011	McGusty A61B 5/335
2009/0012979	A1	1/2009	Bateni et al.				600/391
2009/0054737	A1	2/2009	Magar et al.	2011/0245699	A1	10/2011	Snell et al.
2009/0054952	A1	2/2009	Glukhovsky et al.	2011/0245711	A1	10/2011	Katra et al.
2009/0062670	A1	3/2009	Sterling et al.	2011/0288605	A1	11/2011	Kaib et al.
2009/0062897	A1	3/2009	Axelgaard	2011/0313305	A1	12/2011	Rantala
2009/0069867	A1	3/2009	KenKnight et al.	2012/0003933	A1	1/2012	Baker et al.
2009/0073991	A1	3/2009	Landrum et al.	2012/0029300	A1	2/2012	Paquet
2009/0076336	A1	3/2009	Mazar et al.	2012/0029306	A1	2/2012	Paquet et al.
2009/0076341	A1	3/2009	James et al.	2012/0029307	A1	2/2012	Paquet et al.
2009/0076342	A1	3/2009	Amurthur et al.	2012/0029314	A1	2/2012	Paquet et al.
2009/0076343	A1	3/2009	James et al.	2012/0029315	A1	2/2012	Raptis et al.
2009/0076346	A1	3/2009	James et al.	2012/0029316	A1	2/2012	Raptis et al.
2009/0076349	A1	3/2009	Libbus et al.	2012/0035432	A1	2/2012	Katra et al.
2009/0076363	A1	3/2009	Bly et al.	2012/0059668	A1	3/2012	Baldock et al.
2009/0076364	A1	3/2009	Libbus et al.	2012/0078127	A1	3/2012	McDonald et al.
2009/0076397	A1	3/2009	Libbus et al.	2012/0079127	A1	3/2012	Hadland
2009/0076401	A1	3/2009	Mazar et al.	2012/0088998	A1	4/2012	Bardy et al.
2009/0076559	A1	3/2009	Libbus et al.	2012/0088999	A1	4/2012	Bishay et al.
2009/0088652	A1	4/2009	Tremblay	2012/0089000	A1	4/2012	Bishay et al.
2009/0093687	A1	4/2009	Telfort et al.	2012/0089001	A1	4/2012	Bishay et al.
2009/0099469	A1	4/2009	Flores	2012/0089037	A1	4/2012	Bishay et al.
2009/0112116	A1	4/2009	Lee et al.	2012/0089412	A1	4/2012	Bardy et al.
2009/0131759	A1	5/2009	Sims et al.	2012/0089417	A1	4/2012	Bardy et al.
2009/0133047	A1	5/2009	Lee et al.	2012/0095352	A1	4/2012	Tran
2009/0156908	A1	6/2009	Belalcazar et al.	2012/0101358	A1	4/2012	Boettcher et al.
2009/0177073	A1	7/2009	Sonnenborg	2012/0101396	A1	4/2012	Solosko et al.
2009/0182204	A1	7/2009	Semler et al.	2012/0108993	A1	5/2012	Gordon et al.
2009/0216132	A1	8/2009	Orbach	2012/0165645	A1	6/2012	Russell et al.
2009/0264792	A1	10/2009	Mazar	2012/0172695	A1	7/2012	Ko et al.
2009/0270708	A1	10/2009	Shen et al.	2012/0179665	A1	7/2012	Baarman et al.
2009/0270747	A1	10/2009	Van Dam et al.	2012/0184207	A1	7/2012	Gaines
2009/0292194	A1	11/2009	Libbus et al.	2012/0215123	A1	8/2012	Kumar et al.
2009/0327715	A1	12/2009	Smith et al.	2012/0220835	A1	8/2012	Chung
2010/0007413	A1	1/2010	Herleikson et al.	2012/0232929	A1	9/2012	Experton
2010/0022897	A1	1/2010	Parker et al.	2012/0238910	A1	9/2012	Nordstrom
2010/0056877	A1	3/2010	Fein et al.	2012/0253847	A1	10/2012	Dell’Anno et al.
2010/0056881	A1	3/2010	Libbus et al.	2012/0265080	A1	10/2012	Yu et al.
2010/0076517	A1	3/2010	Imran	2012/0265738	A1	10/2012	Beckmann et al.
2010/0081913	A1	4/2010	Cross et al.	2012/0302906	A1	11/2012	Felix et al.
2010/0137694	A1	6/2010	Irazoqui et al.	2012/0306662	A1	12/2012	Vosch et al.
2010/0174229	A1	7/2010	Hsu et al.	2012/0323098	A1	12/2012	Moein et al.
2010/0177100	A1	7/2010	Carnes et al.	2012/0323132	A1	12/2012	Warner et al.
2010/0185063	A1	7/2010	Bardy	2012/0330126	A1	12/2012	Hoppe et al.
2010/0185076	A1	7/2010	Jeong et al.	2013/0041272	A1	2/2013	Guillén Arredondo et al.
2010/0191154	A1	7/2010	Berger et al.	2013/0077263	A1	3/2013	Oleson et al.
2010/0191310	A1	7/2010	Bly	2013/0079611	A1	3/2013	Besko
2010/0223020	A1	9/2010	Goetz	2013/0079618	A1	3/2013	Sandmore et al.
2010/0234697	A1	9/2010	Walter et al.	2013/0085347	A1	4/2013	Manicka et al.
2010/0234715	A1	9/2010	Shin et al.	2013/0085403	A1	4/2013	Gunderson et al.
2010/0234716	A1	9/2010	Engel	2013/0087609	A1	4/2013	Nichol et al.
2010/0268103	A1	10/2010	McNamara et al.	2013/0096395	A1	4/2013	Katra et al.
				2013/0116533	A1	5/2013	Lian et al.
				2013/0123651	A1	5/2013	Bardy
				2013/0124891	A1	5/2013	Donaldson
				2013/0131530	A1	5/2013	Brockway et al.

US 12,310,735 B2

Page 6

(56)

References Cited

U.S. PATENT DOCUMENTS

2013/0158361	A1	6/2013	Bardy
2013/0172763	A1	7/2013	Wheeler
2013/0197380	A1	8/2013	Oral et al.
2013/0225963	A1	8/2013	Kodandaramaiah et al.
2013/0225966	A1	8/2013	Macia Barber et al.
2013/0225967	A1	8/2013	Esposito
2013/0226018	A1	8/2013	Kumar et al.
2013/0231947	A1	9/2013	Shusterman
2013/0243105	A1	9/2013	Lei et al.
2013/0274565	A1	10/2013	Langer et al.
2013/0274584	A1	10/2013	Finlay et al.
2013/0275158	A1	10/2013	Fahey
2013/0324809	A1	12/2013	Lisogurski et al.
2013/0324855	A1	12/2013	Lisogurski et al.
2013/0324856	A1	12/2013	Lisogurski et al.
2013/0325081	A1	12/2013	Karst et al.
2013/0325359	A1	12/2013	Jarverud et al.
2013/0331665	A1	12/2013	Libbus et al.
2013/0338448	A1	12/2013	Libbus et al.
2013/0338472	A1	12/2013	Macia Barber et al.
2014/0002234	A1	1/2014	Alwan
2014/0005502	A1	1/2014	Klap et al.
2014/0012154	A1	1/2014	Mazar et al.
2014/0031663	A1	1/2014	Gallego
2014/0056452	A1	2/2014	Moss et al.
2014/0088399	A1	3/2014	Lian et al.
2014/0107509	A1	4/2014	Banet et al.
2014/0121557	A1	5/2014	Gannon et al.
2014/0140359	A1	5/2014	Kalevo et al.
2014/0148718	A1	5/2014	Stickney et al.
2014/0180027	A1	6/2014	Buller
2014/0189928	A1	7/2014	Oleson et al.
2014/0194760	A1	7/2014	Albert
2014/0206977	A1	7/2014	Bahney et al.
2014/0214134	A1	7/2014	Peterson
2014/0215246	A1	7/2014	Lee et al.
2014/0249852	A1	9/2014	Proud
2014/0280027	A1	9/2014	Cordes et al.
2014/0296651	A1	10/2014	Stone
2014/0297310	A1	10/2014	Collins, Jr.
2014/0330147	A1	11/2014	Ousdigian et al.
2014/0343390	A1	11/2014	Berzowska et al.
2014/0358193	A1	12/2014	Lyons et al.
2014/0364756	A1	12/2014	Brockway et al.
2015/0018660	A1	1/2015	Thomson et al.
2015/0022372	A1	1/2015	Vosch
2015/0048836	A1	2/2015	Guthrie et al.
2015/0065842	A1	3/2015	Lee et al.
2015/0087950	A1	3/2015	Felix et al.
2015/0094558	A1	4/2015	Russell
2015/0142090	A1	5/2015	Duijsens et al.
2015/0177175	A1	6/2015	Elder et al.
2015/0202351	A1	7/2015	Kaplan et al.
2015/0250422	A1	9/2015	Bay
2015/0257670	A1	9/2015	Ortega et al.
2015/0305676	A1	10/2015	Shoshani
2015/0335285	A1	11/2015	Poon et al.
2015/0359489	A1	12/2015	Baudenbacher et al.
2016/0029917	A1	2/2016	Baker et al.
2016/0135746	A1	5/2016	Kumar et al.
2016/0217691	A1	7/2016	Kadobayashi et al.
2018/0020931	A1	1/2018	Shusterman
2019/0021671	A1	1/2019	Kumar et al.
2019/0117068	A1	4/2019	Thomson et al.
2019/0223806	A1	7/2019	Bennet et al.
2021/0315504	A1	10/2021	Kumar et al.

FOREIGN PATENT DOCUMENTS

EP	2438851	4/2012
EP	2438852	4/2012
EP	2465415	6/2012
EP	2589333	5/2013
JP	H06319711	11/1994
JP	H11188015	7/1999

JP	2004121360	4/2004
JP	2004129788	4/2004
JP	2007082938	4/2007
JP	2009219554	10/2009
WO	9852463	11/1998
WO	0078213	12/2000
WO	0332192	4/2003
WO	WO 03/065926	A2 8/2003
WO	2006009767	1/2006
WO	2006014806	2/2006
WO	2007066270	6/2007
WO	2007092543	8/2007
WO	2008010216	1/2008
WO	WO 2008/005015	A1 1/2008
WO	2008057884	5/2008
WO	2008092098	7/2008
WO	2009036306	3/2009
WO	2009036313	3/2009
WO	2009036327	3/2009
WO	2009112976	9/2009
WO	2009112978	9/2009
WO	2009112979	9/2009
WO	2009142975	11/2009
WO	2010066507	6/2010
WO	2010105045	9/2010
WO	WO 2010/104952	A2 9/2010
WO	2011047207	4/2011
WO	2012040487	3/2012
WO	2012112407	8/2012
WO	2012140559	10/2012
WO	2012146957	11/2012

OTHER PUBLICATIONS

Chart AA-1 Invalidity Contentions: U.S. Pat. No. 11,445,967; Case No. 22-351-CJB (Delaware); Invalidity of U.S. Pat. No. 11,445,967 by International Publication No. WO 2010/104952 to Mazar (“Mazar”) and U.S. Pat. No. 11,116,447 (“Yang”); Oct. 25, 2023; 24 pages.

Chart C-1 Invalidity Contentions: U.S. Pat. No. 11,051,743; Case No. 22-351-CJB (Delaware); Invalidity of U.S. Pat. No. 11,051,743 by International Publication No. WO 2010/104952 to Mazar (“Mazar”) and U.S. Pat. No. 11,116,447 (“Yang”); Oct. 25, 2023; 32 pages.

Chart B-7 Invalidity Contentions: U.S. Pat. No. 11,051,743 and U.S. Pat. No. 11,445,967; Case No. 22-351-CJB (Delaware); A Patch Comprising Adhered Layers; Oct. 25, 2023; 16 pages.

Chart B-6 Invalidity Contentions: U.S. Pat. No. 11,051,743 and U.S. Pat. No. 11,445,967; Case No. 22-351-CJB (Delaware); Hydrocolloid Adhesives on a Portion of the Backing; Oct. 25, 2023; 5 pages.

Chart B-5 Invalidity Contentions: U.S. Pat. No. 11,051,743 and U.S. Pat. No. 11,445,967; Case No. 22-351-CJB (Delaware); Conversion of Electrocardiographic Signals From One Format to Another; Oct. 25, 2023; 6 pages.

Chart B-4 Invalidity Contentions: U.S. Pat. No. 11,051,743 and U.S. Pat. No. 11,445,967; The Case No. 22-351-CJB (Delaware); Rounded Outer Edge of Backing Ends; Oct. 25, 2023; 5 pages.

Chart B-3 Invalidity Contentions: U.S. Pat. No. 11,051,743 and U.S. Pat. No. 11,445,967; Case No. 22-351-CJB (Delaware); Flexible Circuit Comprising a Pair of Circuit Traces to Couple Electrodes; Oct. 25, 2023; 8 pages.

Chart B-2 Invalidity Contentions: U.S. Pat. No. 11,051,743 and U.S. Pat. No. 11,445,967; Case No. 22-351-CJB (Delaware); An Electrocardiogramactrode on Each End of the Backing; Oct. 25, 2023; 8 pages.

Chart B-1 Invalidity Contentions: U.S. Pat. No. 11,051,743 and U.S. Pat. No. 11,445,967; Case No. 22-351-CJB (Delaware); Elongated Strip With Narrowed Midsection; Oct. 25, 2023; 8 pages.

Chart AA-10 Invalidity Contentions: U.S. Pat. No. 11,445,967; Case No. 22-351-CJB (Delaware); Invalidity of U.S. Pat. No. 11,445,967 by WO 2003/065926 (“Ozguz”); Oct. 25, 2023; 6 pages.

Chart AA-9 Invalidity Contentions: U.S. Pat. No. 11,445,967; Case No. 22-351-CJB (Delaware); Invalidity of U.S. Pat. No. 11,445,967 by U.S. Pat. Pub. No. 2011/0009729 (“Shin”); Oct. 25, 2023; 6 pages.

US 12,310,735 B2

Page 7

(56)

References Cited

OTHER PUBLICATIONS

Chart AA-8 Invalidity Contentions: U.S. Pat. No. 11,445,967; Case No. 22-351-CJB (Delaware); Invalidity of U.S. Pat. No. 11,445,967 by WO 2008/005015 (“Shennib”); Oct. 25, 2023; 6 pages.

Chart AA-7 Invalidity Contentions: U.S. Pat. No. 11,445,967; Case No. 22-351-CJB (Delaware); Invalidity of U.S. Pat. No. 11,445,967 by U.S. Pat. No. 7,206,630 (“Tarler”); Oct. 25, 2023; 7 pages.

Chart AA-6 Invalidity Contentions: U.S. Pat. No. 11,445,967; Case No. 22-351-CJB (Delaware); Invalidity of U.S. Pat. No. 11,445,967 by U.S. Pat. No. 9,669,212 (“Mueller”); Oct. 25, 2023; 6 pages.

Chart AA-5 Invalidity Contentions: U.S. Pat. No. 11,445,967; Case No. 22-351-CJB (Delaware); Invalidity of U.S. Pat. No. 11,445,967 by U.S. Pat. No. 10,413,251 (“Golda”); Oct. 25, 2023; 6 pages.

Chart A-4 Invalidity Contentions: U.S. Pat. No. 11,445,967; Case No. 22-351-CJB (Delaware); Invalidity of U.S. Pat. No. 11,445,967 by U.S. Pat. Pub. No. 2011/0077497 (“Oster”); Oct. 25, 2023; 6 pages.

Chart A-3 Invalidity Contentions: U.S. Pat. No. 11,445,967; Case No. 22-351-CJB (Delaware); Invalidity of U.S. Pat. No. 11,445,967 by U.S. Pat. No. 10,327,660 (“Gallego”); Oct. 25, 2023; 7 pages.

Chart AA-2 Invalidity Contentions: U.S. Pat. No. 11,445,967; Case No. 22-351-CJB (Delaware); Invalidity of U.S. Pat. No. 11,445,967 by U.S. Pat. No. 11,116,447 (“Yang”); Oct. 25, 2023; 14 pages.

Chart AA-1 Invalidity Contentions: U.S. Pat. No. 11,445,967; Case No. 22-351-CJB (Delaware); Invalidity of U.S. Pat. No. 11,445,967 by International Publication No. WO 2010/104952 to Mazar (“Mazar”); Oct. 25, 2023; 13 pages.

Chart A-10 Invalidity Contentions: U.S. Pat. No. 11,051,743; Case No. 22-351-CJB (Delaware); Invalidity of U.S. Pat. No. 11,051,743 by WO 2003/065926 (“Ozguz”); Oct. 25, 2023; 12 pages.

Chart A-9 Invalidity Contentions: U.S. Pat. No. 11,051,743; Case No. 22-351-CJB (Delaware); Invalidity of U.S. Pat. No. 11,051,743 by U.S. Pat. Pub. No. 2011/0009729 (“Shin”); Oct. 25, 2023; 12 pages.

Chart A-8 Invalidity Contentions: U.S. Pat. No. 11,051,743; Case No. 22-351-CJB (Delaware); Invalidity of U.S. Pat. No. 11,051,743 by WO 2008/005015 (“Shennib”); Oct. 25, 2023; 12 pages.

Chart A-7 Invalidity Contentions: U.S. Pat. No. 11,051,743; Case No. 22-351-CJB (Delaware); Invalidity of U.S. Pat. No. 11,051,743 by U.S. Pat. No. 7,206,630 (“Tarler”); Oct. 25, 2023; 12 pages.

Chart A-6 Invalidity Contentions: U.S. Pat. No. 11,051,743; Case No. 22-351-CJB (Delaware); Invalidity of U.S. Pat. No. 11,051,743 by U.S. Pat. No. 9,669,212 (“Mueller”); Oct. 25, 2023; 11 pages.

Chart A-5 Invalidity Contentions: U.S. Pat. No. 11,051,743; Case No. 22-351-CJB (Delaware); Invalidity of U.S. Pat. No. 11,051,743 by U.S. Pat. No. 10,413,251 (“Golda”); Oct. 25, 2023; 11 pages.

Chart A-4 Invalidity Contentions: U.S. Pat. No. 11,051,743; Case No. 22-351-CJB (Delaware); Invalidity of U.S. Pat. No. 11,051,743 by U.S. Pat. Pub. No. 2011/0077497 (“Oster”); Oct. 25, 2023; 11 pages.

Chart A-3 Invalidity Contentions: U.S. Pat. No. 11,051,743; Case No. 22-351-CJB (Delaware); Invalidity of U.S. Pat. No. 11,051,743 by U.S. Pat. No. 10,327,660 (“Gallego”); Oct. 25, 2023; 12 pages.

Chart A-2 Invalidity Contentions: U.S. Pat. No. 11,051,743; Case No. 22-351-CJB (Delaware); Invalidity of U.S. Pat. No. 11,051,743 by U.S. Pat. No. 11,116,447 (“Yang”); Oct. 25, 2023; 19 pages.

Chart A-1 Invalidity Contentions: U.S. Pat. No. 11,051,743; Case No. 22-351-CJB (Delaware); Invalidity of U.S. Pat. No. 11,051,743 by International Publication No. WO 2010/104952 to Mazar (“Mazar”); Oct. 25, 2023; 19 pages.

Wolf, “The Data-Driven Life,” New York Times Magazine, Apr. 28, 2010, 13 pages.

Hill, “Adventures in Self-Surveillance: Fitbit, Tracking My Movement and Sleep,” Forbes, Feb. 25, 2011, 11 pages.

Mehen, “Open health with the quantified self,” Opensource.com, Aug. 25, 2011, 7 pages.

“23 Personal Tools to Learn More About Yourself,” Flowingdata.com, Sep. 18, 2008, 18 pages.

Puurtinen et al., “Estimation of ECG Signal of closely separated bipolar electrodes using thorax models,” Proceedings of the 26th

Annual International Conference of the IEEE EMBS pp. 801-804, San Francisco, Calif., USA, Sep. 1-5, 2004, 4 pages.

Trägårdh et al., How many ECG leads do we need? *Cardiol Clin.* Aug. 2006;24(3):317-30, vii. doi: 10.1016/j.ccl.2006.04.005. PMID: 16939826; 14 pages.

Toth et al., U.S. Appl. No. 61/832,131, filed Jun. 6, 2013, 82 pages.

Vishnubhotla, “Pre-processing of ECG signals for ambulatory use,” Jan. 2009; 5 pages.

Chaimanonart et al., “A wireless batteryless in vivo EKG and body temperature sensing microsystem with adaptive RF powering for genetically engineered mice monitoring,” Jul. 2009; 4 pages.

Saeed et al., “A Scalable Wireless Body Area Sensor Network for Health-Care Monitoring,” Jun. 2009, 4 pages.

Pandian et al., “Wireless Sensor Network for Wearable Physiological Monitoring,” *Journal of Networks*, vol. 3, No. 5, May 2008; 15 pages.

Mukala et al., “A Novel Zigbee-based Low-cost, Low-Power Wireless EKG system,” IEEE, May 2010; 4 pages.

Aventyn, Inc., “Vital Connect, Aventyn Launch Wearable Biosensor Platform for Mobile Patient Monitoring”, Dec. 12, 2013, 5 pages.

Anand et al., “Design of the Multi-Sensor Monitoring in Congestive Heart Failure (MUSIC) Study: Prospective Trial to Assess the Utility of Continuous Wireless Physiologic Monitoring in Heart Failure”, *Journal of Cardiac Failure*, vol. 17, No. 1, Jan. 1, 2011, pp. 11-16 (6 pages).

Cesario et al., “Arrhythmia Detection with a Low-Profile Wireless Adherent Cardiac Monitor: Results from the ADAM and EVE Studies”, *The Journal of Innovations in Cardiac Rhythm Management*, 2 (2011) Sep. 2011, pp. 476-482, (7 pages).

Corventis Nuvant, “Nuvant Mobile Cardiac Telemetry (MTC) System”, Corventis, 2009, last printed Jul. 18, 2024, <https://web.archive.org/web/20100127193736/http://corventis.com/AP/nuvant.asp>.

Corventis Avivo, “Avivo Mobile Patient Management System”, Corventis, 2008, last printed Jul. 18, 2024, <https://web.archive.org/web/20100118155329/http://www.corventis.com/AP/avivo.asp>.

IRhythm Zio XT Patch/Event Card, “Zio Patch”, iRhythm, 2011, last printed Jul. 18, 2024, <https://web.archive.org/web/20111017074139/http://irhythmtech.com/media/files/Z100A4020.04%20-%20ZIO%20PATCH%20DATA%20SHEET.pdf>.

International Preliminary Report on Patentability and Written Opinion, PCT/US2019/064331, Jun. 8, 2021.

First Examination Report, Communication pursuant to Article 94(3) EPC, 19 828 053.9-1113, dated Apr. 15, 2024.

Actigraphy/ Circadian Rhythm SOMNOwatch, URL <http://www.somnomedics.eu/news-events/publications/omnowatchtm_html> (Web page cached on Jan. 23, 2010).

Adams et al., U.S. Appl. No. 61/755,623, filed Jan. 23, 2013, 48 pages.

Alzaidi et al., “Smart Textiles Based Wireless ECG System,” May 2012; 5 pages.

Anand et al., “Design of the Multi-Sensor Monitoring in Congestive Heart Failure (MUSIC) Study: Prospective Trial to Assess the Utility of Continuous Wireless Physiologic Monitoring in Heart Failure”, *Journal of Cardiac Failure* (2011), 17(1), pp. 11-16.

Bardy Diagnostics, Inc. v. Vital Connect, Inc., Defendant’s Identification of Supplemental Prior Art References, C.A. No. 22-351 (CJV), May 22, 2024.

Bardy Diagnostics, Inc., Plaintiff v. *Vital Connect, Inc.*; The United States District Court for the District of Delaware; C.A. No. 22-351 (CJB); Vitalconnect’s Preliminary Invalidity Contentions; filed Oct. 25, 2023.

Cesario et al., “Arrhythmia Detection with a Low-Profile Wireless Adherent Cardiac Monitor: Results from the ADAM and EVE Studies”, *The Journal of Innovations in Cardiac Rhythm Management* (2011), pp. 476-482.

[CORRECTED] Chart C-2 Invalidity Contentions: U.S. Pat. No. 11,051,743; Case No. 22-351-CJB (Delaware); Invalidity of U.S. Pat. No. 11,051,743 by U.S. Pat. Pub. No. 2011/0077497 (“Oster”) and U.S. Pat. No. 11,116,447 (“Yang”); Oct. 25, 2023; 22 pages.

[CORRECTED] Chart CC-2 Invalidity Contentions: U.S. Pat. No. 11,445,967; Case No. 22-351-CJB (Delaware); Invalidity of U.S.

US 12,310,735 B2

Page 8

(56)

References Cited

OTHER PUBLICATIONS

Patent No. by U.S. Pat. Pub. No. 2011/0077497 (“Oster”) and U.S. Pat. No. 11,116,447 (“Yang”); Oct. 25, 2023; 16 pages.

Chen et al. “Monitoring Body Temperature of Newborn Infants at Neonatal Intensive Care Units Using Wearable Sensors,” *BodyNets* 2010, Corfu Island, Greece. Sep. 10-12, 1210.

Complaint from Case No. 1 :22-cv-00351-UNA, *Bardy Diagnostics, Inc.* (Plaintiff) v. *Vital Connect, Inc.* (Defendant), filed: Mar. 18, 2022, 182 pages.

Daoud et al. “Fall Detection Using Shimmer Technology and Multiresolution Analysis.” Aug. 2, 2013. URL: <https://decibel.ni.com/content/docs/DOC-26652>.

Dec. 26, 2022 Letter from Opposing Counsel, 1:22-cv-00351-CJB; *Bardy Diagnostics, Inc. v. Vital Connect, Inc.* D. Del.); and IPR2023-00381; *Vital Connect, Inc. v. Bardy Diagnostics, Inc.* (P.T.A.B.), Dec. 26, 2022.

Defendant’s Answer, Defenses, and Counterclaim from Case. No. 1:22-cv-00351-CFC, *Bardy Diagnostics, Inc.* (Plaintiff) v. *Vital Connect, Inc.* (Defendant), Filed May 25, 2022, 132 pages.

Defendant’s Opening Brief in Support of Its Motion to Dismiss for Failure to State a Claim from Case No. 1:22-v.00351-CFC, *Bardy Diagnostics, Inc.* (Plaintiff) v. *Vital Connect, Inc.* (Defendant), Filed: May 25, 2022, 18 pages.

Defendant’s Reply Brief in Support of Its Motion to Dismiss for Failure to State a Claim from Case No. 1 :22-cv-00351-CFC, *Bardy Diagnostics, Inc.* (Plaintiff) v. *Vital Connect, Inc.* (Defendant), Filed: Jun. 15, 2022, 93 pages.

Duttweiler et al., “Probability Estimation in Arithmetic and Adaptive-Huffman Entropy Coders,” *IEEE Transactions in Image Processing* vol. 4, No. 3, Mar. 1, 1995, pp. 237-246.

Epstein, Andrew E. et al.; ACC/AHA/HRS 2008 Guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities. *J. Am. Coll. Cardiol.* 2008; 51; e1-e62, 66 pages.

First Amended Complaint for Patent Infringement, 1:22-cv-00351-CJB, *Bardy Diagnostics, Inc. v. Vital Connect, Inc.* D. Del.), filed Jan. 10, 2023.

Fitbit Tracker, URL <<http://www.fitbit.com/>> (Web page cached on Sep. 10, 2008.).

Gravitz, Lauren, “When Your Diet Needs a Band-Aid,” *Technology Review*, MIT. (May 1, 2009).

Gupta et al., “An ECG Compression Technique for Telecardiology Application,” *India Conference (INDICON)*, 2011 Annual IEEE, Dec. 16, 2011, pp. 1-4.

Harland et al., “Electric Potential Probes—New Directions in the Remote Sensing of the Human Body”, *Measurement Science and Technology* (2002), vol. 13, pp. 163-169.

[http://www.gtec.at/Products/Software/g. BSanalyze-Specs-Features](http://www.gtec.at/Products/Software/g.BSanalyze-Specs-Features) (2014).

http://www.originlab.com/origin#Data_Exploration 2015.

<https://fccid.io/LF524950/User-Manual/User-Manual-1944573> © Medtronic, Inc. 2012.

<https://web.archive.org/web/20130831204020/http://www.biopac.com/research.asp?Catl0=37&Main=Software> (Aug. 2013).

Initial hands-on with sirdv activity tracker, URL <<http://www.dcrainmaker.com/2013/09/polar-loop-firstlook.html>> Sep. 17, 2013).

Invalidity of U.S. Pat. No. 11,051,743 by U.S. Pat. Pub. No. 2011/0077497 (“Oster”); Oct. 25, 2023; 11 pages.

IRhythm, Inc.v. Welch Allyn, Inc., Expert Declaration of Jason Heikenfeld for U.S. Pat. No. 8,214,007, U.S. Pat. No. 8,965,492, U.S. Pat. No. 9,155,484, and U.S. Pat. No. 10,159,422 dated Dec. 20, 2024. 516 pages.

IRhythm, Inc.v. Welch Allyn, Inc., Petition for Inter Partes Review Under 35 U.S.C. § 312 and 37 C.F.R. § 42.104, Case No. IPR2025-00363 for U.S. Pat. No. 10,159,422, dated Dec. 23, 2024. 94 pages.

IRhythm, Inc.v. Welch Allyn, Inc., Petition for Inter Partes Review Under 35 U.S.C. § 312 and 37 C.F.R. § 42.104, Case No. IPR2025-00374 for U.S. Pat. No. 8,965,492, dated Dec. 23, 2024. 86 pages.

IRhythm, Inc.v. Welch Allyn, Inc., Petition for Inter Partes Review Under 35 U.S.C. § 312 and 37 C.F.R. § 42.104, Case No. IPR2025-00376 for U.S. Pat. No. 9,155,484, dated Dec. 23, 2024. 106 pages.

IRhythm, Inc.v. Welch Allyn, Inc., Petition for Inter Partes Review Under 35 U.S.C. § 312 and 37 C.F.R. § 42.104, Case No. IPR2025-00377 for U.S. Pat. No. 8,214,007, dated Dec. 23, 2024. 88 pages.

IRhythm, Inc.v. Welch Allyn, Inc., Petition for Inter Partes Review Under 35 U.S.C. § 312 and 37 C.F.R. § 42.104, Case No. IPR2025-00378 for U.S. Pat. No. 8,214,007, dated Dec. 23, 2024. 95 pages.

Ivanov, G.G., “HRV Analysis Under the Usage of Different Electrocardiography Systems,” Apr. 15, 2008, (Apr. 15, 2008), XP55511209, Retrieved from the Internet: URL:[http://www.drkucera.eu/upload_doc/hrv_analysis_methodical_recommendations\)_pdf](http://www.drkucera.eu/upload_doc/hrv_analysis_methodical_recommendations)_pdf) [retrieved on Oct. 1, 2018].

Kligfield, Paul et al., Recommendations for the Standardization and Interpretation of the Electrocardiogram: Part I. *U. Am.Coll. Cardiol*; 2007; 49; 1109-27, 75 Pgs.

Knight et al., U.S. Appl. No. 60/786,502, filed Mar. 29, 2006, 8 pages.

Leonard, Dwayne C., “A Framework for the Creation of a Unified Electronic Medical Record Using Biometrics”, *Data Fusion and Belief Theory* (2007), <<https://dialong.proquest.com/professional/docview/304852676/17AEEF1F9382EF1C4E5/6?accountid=131444>> (last visited Aug. 27, 2021).

Libbus, “Adherent Cardiac Monitor With Wireless Fall Detection for Patients With Unexplained Syncope.” Abstracts t>f the First AMA-IEEE Medical Technology Conference on Individualized Healthcare. May 22, 2010.

Lieberman, Jonathan “How Telemedicine Is Aiding Prompt ECG Diagnosis in Primary Care,” *British Journal of Community Nursing*, vol. 13, No. 3, Mar. 1, 2008, pp. 123-126, XP009155082, ISSN: 1462-4753.

May 2, 2022 Letter From Counsel. 1:22-cv-00351-CFC. May 2, 2022.

May 24, 2022 Letter to Opposing Counsel. 1:22-cv-00351-CFC. May 24, 2022.

McManus et al., “A Novel Application for the Detection of an Irregular Pulse using an iPhone 4S in Patients with Atrial Fibrillation,” vol. 10(3), pp. 315-319 (Mar. 2013).

Nave et al., “ECG Compression Using Long-Term Prediction,” *IEEE Transactions on Biomedical Engineering*, IEEE Service Center, NY, USA, vol. 40, No. 9, Sep. 1, 1993, pp. 877-885.

Nike+ Fuel Band, URL <http://www.nike.com/us/en_us/c/nikeplus-fuelband> (Web page cached on Jan. 11, 2013).

Nov. 11, 2022, Letter from Opposing Counsel, 1 :22-cv-00351-CJB; *Bardy Diagnostics, Inc. v. Vital Connect, Inc.* D.Del.), Nov. 11, 2022.

Oct. 17, 2022 Letter to Opposing Counsel, *Bardy Diagnostics, Inc. v. Vital Connect, Inc.*, No. 22-cv-00351-CFC D. Del.), Oct. 17, 2022.

P. Libby et al., “Braunwald’s Heart Disease—A Textbook of Cardiovascular Medicine,” Chs_ 11, pp. 125-148 and 12, pp. 149-193 (8th ed_ 2008), American Heart Association.

Petition for Inter Partes Review of U.S. Pat. No. 11,051,743 Pursuant to 35 U.S.C. §§ 311-319 and 37 C.F.R. § 42, Case No. IPR2023-00381, *Vital Connect, Inc. v. Bardy Diagnostics, Inc.* (P.T.A.B.), Dec. 21, 2022, 875 pages.

Plaintiff’s Answer Brief in Opposition to Defendant’s Motion to Dismiss for Failure to State a Claim from Case No. 1:22-cv-00351-CFC, *Bardy Diagnostics, Inc.* (Plaintiff) v. *Vital Connect, Inc.* (Defendant), Filed Jun. 8, 2022, 25 pages.

Plaintiffs Answer to Defendant’s Counterclaim from Case No. 1 :22-cv-00351-CFC, *Bardy Diagnostics, Inc.* (Plaintiff) v. *Vital Connect, Inc.* (Defendant), Filed: Jun. 15, 2022, 5 pages.

Saadi et al. “Heart Rhythm Analysis Using ECG Recorded With a Novel Sternum Based Patch Technology—A Pilot Study_” *Cardio technix* 2013—Proceedings of the International Congress on Cardiovascular Technologies, Sep. 20, 2013.

Sapoznikov, Dan et al., “Comparison of Different Methodologies of Heart Rate Variability Analysis,” *Department of Cardiology, Hadasah University Hospital*, P.O.B. 12000, Ein Kerem, Jerusalem 91120, Israel (1993).

Sittig et al., “A Computer-Based Outpatient Clinical Referral System,” *International Journal of Medical Informatics*, Shannon, IR, vol. 55, No. 2, Aug. 1, 1999, pp. 149-158, XO004262434, ISSN: 1386-5056(99)00027-1.

US 12,310,735 B2

Page 9

(56)

References Cited

OTHER PUBLICATIONS

Skretting et al., “Improved Huffman Coding Using Recursive Splitting,” NORSIG, Jan. 1, 1999.

Sleepview, URL <<http://www.clevemed.com/sleepview/overview.shtml>> (Web page cached on Sep. 4, 2013).

Smith, Jawbone Up, URL <<http://www.businessinsider.com/fitbit-flex-vs-jawbone-up-2013-5?op=1>> (Jun. 1, 2013).

Varicrad-Kardi Software User’s Manual Rev_ 1.1, Jul. 8, 2009 (Jul. 8, 2009), XP002757888, retrieved from the Internet: URL:<http://www.ehrlich.tv/KARDiVAR-Software.pdf> [retrieved on May 20, 2016].

Voss, A. et al., “Linear and Nonlinear Methods for Analyses of Cardiovascular Variability in Bipolar Disorders,” *Bipolar Disorders*, vol. 8, No. 5 p. 1, Oct. 1, 2006, pp. 441-452, XP55273826, DK ISSN: 1398-5647, DOI: 10.1111/.1399-5618-2006.00364x.

Wallot et al., “Using Complexity Metrics With R-R Intervals and BPM Heart Rate Measures,” *Frontiers in Physiology*, vol. 4, Article 211, pp. 1-8, Aug. 13, 2013. 2013.

Zio Event Card, URL <<http://www.irhythmtech.com/zio-solution/zio-event/>> (Web page cached on Mar. 11, 2013).

Zio Patch System, URL <<http://www.irhythmtech.com/zio-solution/zio-system/index.html>> (Web page cached on Sep. 8, 2013).

Bardy Diagnostics, Inc., Plaintiff v. *iRhythm Technologies, Inc.*; The United States District Court for the District of Delaware; Complaint against iRhythm Technologies; filed Dec. 10, 2024.

Exhibits 1-13 for *Bardy Diagnostics, Inc.*, Plaintiff v. *iRhythm Technologies, Inc.*; The United States District Court for the District of Delaware; Complaint against iRhythm Technologies; filed Dec. 10, 2024.

Bardy Diagnostics, Inc., Plaintiff v. *iRhythm Technologies, Inc.*; The United States District Court for the District of Delaware; C.A. No. 24-1355-RGA; First Amended Complaint against iRhythm Technologies; filed Dec. 26, 2024.

Exhibits 1-15 for *Bardy Diagnostics, Inc.*, Plaintiff v. *iRhythm Technologies, Inc.*; The United States District Court for the District of Delaware; C.A. No. 24-1355-RGA; First Amended Complaint against iRhythm Technologies; filed Dec. 26, 2024.

Bardy Diagnostics, Inc., Plaintiff v. *iRhythm Technologies, Inc.*; The United States District Court for the District of Delaware; C.A. No. 24-1355 (JDW); Defendant iRhythm Technologies, Inc.’s Counterclaim and Answer to Plaintiff Bardy Diagnostics, Inc.’s First Amended Complaint; filed Mar. 3, 2025.

Exhibits 1-10 for *Bardy Diagnostics, Inc.*, Plaintiff v. *iRhythm Technologies, Inc.*; The United States District Court for the District of Delaware; C.A. No. 24-1355 (JDW); Defendant iRhythm Technologies, Inc.’s Counterclaim and Answer to Plaintiff Bardy Diagnostics, Inc.’s First Amended Complaint; filed Mar. 3, 2025.

Vital Connect, Inc. v. Bardy Diagnostics, Inc., USPTO Patent Trial & Appeal Board—Patent Owner’s Preliminary Response, Case No. IPR2023-00381 for U.S. Pat. No. 11,051,743, dated Apr. 24, 2023. 53 pages.

Vital Connect, Inc. v. Bardy Diagnostics, Inc., USPTO Patent Trial & Appeal Board—Decision Denying Institution of Inter Partes Review 35 U.S.C. § 314, Case No. IPR2023-00381 for U.S. Pat. No. 11,051,743, dated Jul. 11, 2023. 21 pages.

Vital Connect, Inc. v. Bardy Diagnostics, Inc., USPTO Patent Trial & Appeal Board—Order, Case No. IPR2023-00381 for U.S. Pat. No. 11,051,743, dated Oct. 3, 2023. 3 pages.

Vital Connect, Inc. v. Bardy Diagnostics, Inc., USPTO Patent Trial & Appeal Board—Declaration of Dr. Per Reinhall, Ph.D, Case No. IPR2023-00381 for U.S. Pat. No. 11,051,743, dated Apr. 21, 2023. 28 pages.

Bardy Diagnostics Statutory Disclaimer Under 35 U.S.C. 253(a) and 37 C.F.R. § 1.321(a) for U.S. Pat. No. 11,051,743, dated Apr. 21, 2023. 2 pages.

Defendant’s Answer to First Amended Complaint, Defenses, and Counterclaim, 1 :22-cv-00351-CJB, *Bardy Diagnostics, Inc. v. Vital Connect, Inc.* (D. Del.), filed Jan. 24, 2023 (227 pages).

* cited by examiner

Fig. 1.




Fig. 2.




Fig. 3.




Fig. 4.




Fig. 5.




Fig. 6.




Fig. 7.




Fig. 8.




Fig. 9.




Fig. 10.

100





Fig. 11.



US 12,310,735 B2

1

**EXTENDED WEAR AMBULATORY
ELECTROCARDIOGRAPHY MONITOR****PRIORITY CLAIM AND CROSS-REFERENCE
TO RELATED APPLICATIONS**

This application is a continuation of U.S. patent application Ser. No. 17/691,004, filed Mar. 9, 2022, titled EXTENDED WEAR AMBULATORY ELECTROCARDIOGRAPHY MONITOR, which is a continuation of U.S. patent application Ser. No. 16/684,386, filed Nov. 14, 2019, titled EXPENDED WEAR AMBULATORY ELECTROCARDIOGRAPHY AND PHYSIOLOGICAL SENSOR MONITOR, which is a continuation of U.S. patent application Ser. No. 15/676,896, filed Aug. 14, 2017, titled EXTENDED WEAR AMBULATORY ELECTROCARDIOGRAPHY AND PHYSIOLOGICAL SENSOR MONITOR, which is a continuation of U.S. patent application Ser. No. 14/080,725, filed Nov. 14, 2013, titled EXTENDED WEAR AMBULATORY ELECTROCARDIOGRAPHY AND PHYSIOLOGICAL SENSOR MONITOR, which claims priority to U.S. Provisional Patent App. No. 61/882,403, filed Sep. 25, 2013, titled LONG-TERM WEARABLE PHYSIOLOGICAL MONITOR. The entire contents of these applications are incorporated by reference herein in their entirety and relied upon.

FIELD

This application relates in general to electrocardiographic monitoring and, in particular, to an extended wear ambulatory electrocardiography monitor.

BACKGROUND

The heart emits electrical signals as a by-product of the propagation of the action potentials that trigger depolarization of heart fibers. An electrocardiogram (ECG) measures and records such electrical potentials to visually depict the electrical activity of the heart over time. Conventionally, a standardized set format 12-lead configuration is used by an ECG machine to record cardiac electrical signals from well-established traditional chest locations. Electrodes at the end of each lead are placed on the skin over the anterior thoracic region of the patient's body to the lower right and to the lower left of the sternum, on the left anterior chest, and on the limbs. Sensed cardiac electrical activity is represented by PQRSTU waveforms that can be interpreted post-ECG recordation to derive heart rate and physiology. The P-wave represents atrial electrical activity. The QRSUTU components represent ventricular electrical activity.

An ECG is a tool used by physicians to diagnose heart problems and other potential health concerns. An ECG is a snapshot of heart function, typically recorded over 12 seconds, that can help diagnose rate and regularity of heartbeats, effect of drugs or cardiac devices, including pacemakers and implantable cardioverter-defibrillators (ICDs), and whether a patient has heart disease. ECGs are used in-clinic during appointments, and, as a result, are limited to recording only those heart-related aspects present at the time of recording. Sporadic conditions that may not show up during a spot ECG recording require other means to diagnose them. These disorders include fainting or syncope; rhythm disorders, such as tachyarrhythmias and bradyarrhythmias; apneic episodes; and other cardiac and related

2

disorders. Thus, an ECG only provides a partial picture and can be insufficient for complete patient diagnosis of many cardiac disorders.

Diagnostic efficacy can be improved, when appropriate, through the use of long-term extended ECG monitoring. Recording sufficient ECG and related physiology over an extended period is challenging, and often essential to enabling a physician to identify events of potential concern. A 30-day observation day period is considered the "gold standard" of ECG monitoring, yet achieving a 30-day observation day period has proven unworkable because such ECG monitoring systems are arduous to employ, cumbersome to the patient, and excessively costly. Ambulatory monitoring in-clinic is implausible and impracticable. Nevertheless, if a patient's ECG could be recorded in an ambulatory setting, thereby allowing the patient to engage in activities of daily living, the chances of acquiring meaningful information and capturing an abnormal event while the patient is engaged in normal activities becomes more likely to be achieved.

For instance, the long-term wear of ECG electrodes is complicated by skin irritation and the inability ECG electrodes to maintain continual skin contact after a day or two. Moreover, time, dirt, moisture, and other environmental contaminants, as well as perspiration, skin oil, and dead skin cells from the patient's body, can get between an ECG electrode, the non-conductive adhesive used to adhere the ECG electrode, and the skin's surface. All of these factors adversely affect electrode adhesion and the quality of cardiac signal recordings. Furthermore, the physical movements of the patient and their clothing impart various compressional, tensile, and torsional forces on the contact point of an ECG electrode, especially over long recording times, and an inflexibly fastened ECG electrode will be prone to becoming dislodged. Notwithstanding the cause of electrode dislodgment, depending upon the type of ECG monitor employed, precise re-placement of a dislodged ECG electrode maybe essential to ensuring signal capture at the same fidelity. Moreover, dislodgment may occur unbeknownst to the patient, making the ECG recordings worthless. Further, some patients may have skin that is susceptible to itching or irritation, and the wearing of ECG electrodes can aggravate such skin conditions. Thus, a patient may want or need to periodically remove or replace ECG electrodes during a long-term ECG monitoring period, whether to replace a dislodged electrode, reestablish better adhesion, alleviate itching or irritation, allow for cleansing of the skin, allow for showering and exercise, or for other purpose. Such replacement or slight alteration in electrode location actually facilitates the goal of recording the ECG signal for long periods of time.

Conventionally, Holter monitors are widely used for long-term extended ECG monitoring. Typically, they are often used for only 24-48 hours. A typical Holter monitor is a wearable and portable version of an ECG that include cables for each electrode placed on the skin and a separate battery-powered ECG recorder. The cable and electrode combination (or leads) are placed in the anterior thoracic region in a manner similar to what is done with an in-clinic standard ECG machine. The duration of a Holter monitoring recording depends on the sensing and storage capabilities of the monitor, as well as battery life. A "looping" Holter monitor (or event) can operate for a longer period of time by overwriting older ECG tracings, thence "recycling" storage in favor of extended operation, yet at the risk of losing event data. Although capable of extended ECG monitoring, Holter monitors are cumbersome, expensive and typically only available by medical prescription, which limits their usability.

US 12,310,735 B2

3

ity. Further, the skill required to properly place the electrodes on the patient's chest hinders or precludes a patient from replacing or removing the precordial leads and usually involves moving the patient from the physician office to a specialized center within the hospital or clinic.

The ZIO XT Patch and ZIO Event Card devices, manufactured by iRhythm Tech., Inc., San Francisco, CA, are wearable stick-on monitoring devices that are typically worn on the upper left pectoral region to respectively provide continuous and looping ECG recording. The location is used to simulate surgically implanted monitors. Both of these devices are prescription-only and for single patient use. The ZIO XT Patch device is limited to a 14-day monitoring period, while the electrodes only of the ZIO Event Card device can be worn for up to 30 days. The ZIO XT Patch device combines both electronic recordation components, including battery, and physical electrodes into a unitary assembly that adheres to the patient's skin. The ZIO XT Patch device uses adhesive sufficiently strong to support the weight of both the monitor and the electrodes over an extended period of time and to resist disadherance from the patient's body, albeit at the cost of disallowing removal or relocation during the monitoring period. Moreover, throughout monitoring, the battery is continually depleted and battery capacity can potentially limit overall monitoring duration. The ZIO Event Card device is a form of downsized Holter monitor with a recorder component that must be removed temporarily during baths or other activities that could damage the non-waterproof electronics. Both devices represent compromises between length of wear and quality of ECG monitoring, especially with respect to ease of long term use, female-friendly fit, and quality of atrial (P-wave) signals.

Therefore, a need remains for an extended wear continuously recording ECG monitor practicably capable of being worn for a long period of time in both men and women and capable of recording atrial signals reliably.

A further need remains for a device capable of recording signals ideal for arrhythmia discrimination, especially a device designed for atrial activity recording.

SUMMARY

Physiological monitoring can be provided through a wearable monitor that includes two components, a flexible extended wear electrode patch and a removable reusable monitor recorder. The wearable monitor sits centrally (in the midline) on the patient's chest along the sternum oriented top-to-bottom. The placement of the wearable monitor in a location at the sternal midline (or immediately to either side of the sternum), with its unique narrow "hourglass"-like shape, benefits long-term extended wear by removing the requirement that ECG electrodes be continually placed in the same spots on the skin throughout the monitoring period. Instead, the patient is free to place an electrode patch anywhere within the general region of the sternum. In addition, power is provided through a battery provided on the electrode patch, which avoids having to either periodically open the housing of the monitor recorder for the battery replacement, which also creates the potential for moisture intrusion and human error, or to recharge the battery, which can potentially take the monitor recorder off line for hours at a time. In addition, the electrode patch is intended to be disposable, while the monitor recorder is a reusable component. Thus, each time that the electrode patch is replaced, a fresh battery is provided for the use of the monitor recorder.

4

One embodiment provides an extended wear electrocardiography and physiological sensor monitor recorder that includes a sealed housing configured to be removably secured into a receptacle on an electrode patch that has a battery electrically interfaced to a pair of electrical pads on the receptacle. The sealed housing also includes a set of electrical contacts that protrude from a bottom surface and correspond with further electrical pads on the receptacle. Electronic circuitry is provided within the sealed housing and includes a micro-controller operable to execute under micro-programmable control, an electrographic front end circuit electrically interfaced to the micro-controller and operable to sense electrocardiographic signals through electrocardiographic electrodes provided on the electrode patch, and a flash memory electrically interfaced with the micro-controller and operable to store samples of the electrocardiographic signals.

A further embodiment provides an electrocardiography monitor. A sealed housing includes one end wider than an opposite end of the sealed housing. Electronic circuitry is provided within the sealed housing. The electronic circuitry includes an electrographic front end circuit to sense electrocardiographic signals and a micro-controller interfaced to the electrocardiographic front end circuit to sample the electrocardiographic signals. A buzzer within the housing outputs feedback to a wearer of the sealed housing.

A still further embodiment provides an extended wear electrocardiography and physiological sensor monitor that includes an electrode patch having a flexible backing formed of an elongated strip and a pair of electrocardiographic electrodes conductively exposed on a contact surface of each end of the elongated strip. A receptacle is adhered to an outward-facing side of the elongated strip opposite the contact surface and includes a plurality of electrical pads. A battery is electrically interfaced to a pair of the electrical pads on the receptacle. A flexible circuit is affixed on each end of the elongated strip and includes a pair of circuit traces electrically coupled to the pair of electrocardiographic electrodes and another pair of the electrical pads. An electrocardiography monitor includes a sealed housing configured to be removably secured into the receptacle on the electrode patch and has a set of electrical contacts that protrude from a bottom surface and correspond with further electrical pads on the receptacle. Electronic circuitry is provided within the sealed housing and includes a micro-controller operable to execute under micro-programmable control, an electrographic front end circuit electrically interfaced to the micro-controller and operable to sense electrocardiographic signals through the electrocardiographic electrodes provided on the electrode patch, and a flash memory electrically interfaced with the micro-controller and operable to store samples of the electrocardiographic signals.

The monitoring patch is especially suited to the female anatomy. The narrow longitudinal midsection can fit nicely within the intermammary cleft of the breasts without inducing discomfort, whereas conventional patch electrodes are wide and, if adhered between the breasts, would cause chafing, irritation, frustration, and annoyance, leading to low patient compliance.

The foregoing aspects enhance ECG monitoring performance and quality facilitating long-term ECG recording, critical to accurate arrhythmia diagnosis.

In addition, the foregoing aspects enhance comfort in women (and certain men), but not irritation of the breasts, by placing the monitoring patch in the best location possible for optimizing the recording of cardiac signals from the atrium, another feature critical to proper arrhythmia diagnosis.

5

Still other embodiments will become readily apparent to those skilled in the art from the following detailed description, wherein are described embodiments by way of illustrating the best mode contemplated. As will be realized, other and different embodiments are possible and the embodiments' several details are capable of modifications in various obvious respects, all without departing from their spirit and the scope. Accordingly, the drawings and detailed description are to be regarded as illustrative in nature and not as restrictive.

BRIEF DESCRIPTION OF THE DRAWINGS

FIGS. 1 and 2 are diagrams showing, by way of examples, an extended wear electrocardiography and physiological sensor monitor, including a monitor recorder in accordance with one embodiment, respectively fitted to the sternal region of a female patient and a male patient.

FIG. 3 is a perspective view showing an extended wear electrode patch with a monitor recorder in accordance with one embodiment inserted.

FIG. 4 is a perspective view showing the monitor recorder of FIG. 3.

FIG. 5 is a perspective view showing the extended wear electrode patch of FIG. 3 without a monitor recorder inserted.

FIG. 6 is a bottom plan view of the monitor recorder of FIG. 3.

FIG. 7 is a top view showing the flexible circuit of the extended wear electrode patch of FIG. 3 when mounted above the flexible backing.

FIG. 8 is a functional block diagram showing the component architecture of the circuitry of the monitor recorder of FIG. 3.

FIG. 9 is a functional block diagram showing the circuitry of the extended wear electrode patch of FIG. 3.

FIG. 10 is a flow diagram showing a monitor recorder-implemented method for monitoring ECG data for use in the monitor recorder of FIG. 3.

FIG. 11 is a graph showing, by way of example, a typical ECG waveform.

DETAILED DESCRIPTION

Physiological monitoring can be provided through a wearable monitor that includes two components, a flexible extended wear electrode patch and a removable reusable monitor recorder. FIGS. 1 and 2 are diagrams showing, by way of examples, an extended wear electrocardiography and physiological sensor monitor 12, including a monitor recorder 14 in accordance with one embodiment, respectively fitted to the sternal region of a female patient 10 and a male patient 11. The wearable monitor 12 sits centrally (in the midline) on the patient's chest along the sternum 13 oriented top-to-bottom with the monitor recorder 14 preferably situated towards the patient's head. In a further embodiment, the orientation of the wearable monitor 12 can be corrected post-monitoring, as further described infra. The electrode patch 15 is shaped to fit comfortably and conformal to the contours of the patient's chest approximately centered on the sternal midline 16 (or immediately to either side of the sternum 13). The distal end of the electrode patch 15 extends towards the Xiphoid process and, depending upon the patient's build, may straddle the region over the Xiphoid process. The proximal end of the electrode patch 15, located under the monitor recorder 14, is below the

6

manubrium and, depending upon patient's build, may straddle the region over the manubrium.

The placement of the wearable monitor 12 in a location at the sternal midline 16 (or immediately to either side of the sternum 13) significantly improves the ability of the wearable monitor 12 to cutaneously sense cardiac electric signals, particularly the P-wave (or atrial activity) and, to a lesser extent, the QRS interval signals in the ECG waveforms that indicate ventricular activity. The sternum 13 overlies the right atrium of the heart and the placement of the wearable monitor 12 in the region of the sternal midline 13 puts the ECG electrodes of the electrode patch 15 in a location better adapted to sensing and recording P-wave signals than other placement locations, say, the upper left pectoral region. In addition, placing the lower or inferior pole (ECG electrode) of the electrode patch 15 over (or near) the Xiphoid process facilitates sensing of right ventricular activity and provides superior recordation of the QRS interval.

During use, the electrode patch 15 is first adhered to the skin along the sternal midline 16 (or immediately to either side of the sternum 13). A monitor recorder 14 is then snapped into place on the electrode patch 15 to initiate ECG monitoring. FIG. 3 is a perspective view showing an extended wear electrode patch 15 with a monitor recorder 14 in accordance with one embodiment inserted. The body of the electrode patch 15 is preferably constructed using a flexible backing 20 formed as an elongated strip 21 of wrap knit or similar stretchable material with a narrow longitudinal mid-section 23 evenly tapering inward from both sides. A pair of cut-outs 22 between the distal and proximal ends of the electrode patch 15 create a narrow longitudinal midsection 23 or "isthmus" and defines an elongated "hourglass"-like shape, when viewed from above.

The electrode patch 15 incorporates features that significantly improve wearability, performance, and patient comfort throughout an extended monitoring period. During wear, the electrode patch 15 is susceptible to pushing, pulling, and torqueing movements, including compressional and torsional forces when the patient bends forward, and tensile and torsional forces when the patient leans backwards. To counter these stress forces, the electrode patch 15 incorporates strain and crimp reliefs, such as described in commonly-assigned U.S. Patent, entitled "Extended Wear Electrocardiography Patch," U.S. Pat. No. 9,545,204, issued on Jan. 17, 2017, the disclosure of which is incorporated by reference. In addition, the cut-outs 22 and longitudinal midsection 23 help minimize interference with and discomfort to breast tissue, particularly in women (and gynecomasitic men). The cut-outs 22 and longitudinal midsection 23 further allow better conformity of the electrode patch 15 to sternal bowing and to the narrow isthmus of flat skin that can occur along the bottom of the intermammary cleft between the breasts, especially in buxom women. The cut-outs 22 and longitudinal midsection 23 help the electrode patch 15 fit nicely between a pair of female breasts in the intermammary cleft. Still other shapes, cut-outs and conformities to the electrode patch 15 are possible.

The monitor recorder 14 removably and reusable snaps into an electrically non-conductive receptacle 25 during use. The monitor recorder 14 contains electronic circuitry for recording and storing the patient's electrocardiography as sensed via a pair of ECG electrodes provided on the electrode patch 15, as further described infra beginning with reference to FIG. 8. The non-conductive receptacle 25 is provided on the top surface of the flexible backing 20 with a retention catch 26 and tension clip 27 molded into the

7

non-conductive receptacle **25** to conformably receive and securely hold the monitor recorder **14** in place.

The monitor recorder **14** includes a sealed housing that snaps into place in the non-conductive receptacle **25**. FIG. **4** is a perspective view showing the monitor recorder **14** of FIG. **3**. The sealed housing **50** of the monitor recorder **14** intentionally has a rounded isosceles trapezoidal-like shape **52**, when viewed from above, such as described in commonly-assigned U.S. Design Patent, entitled “Electrocardiography Monitor,” No. D717955, issued on Nov. 18, 2014, the disclosure of which is incorporated by reference. The edges **51** along the top and bottom surfaces are rounded for patient comfort. The sealed housing **50** is approximately 47 mm long, 23 mm wide at the widest point, and 7 mm high, excluding a patient-operable tactile-feedback button **55**. The sealed housing **50** can be molded out of polycarbonate, ABS, or an alloy of those two materials. The button **55** is waterproof and the button’s top outer surface is molded silicon rubber or similar soft pliable material. A retention detent **53** and tension detent **54** are molded along the edges of the top surface of the housing **50** to respectively engage the retention catch **26** and the tension clip **27** molded into non-conductive receptacle **25**. Other shapes, features, and conformities of the sealed housing **50** are possible.

The electrode patch **15** is intended to be disposable. The monitor recorder **14**, however, is reusable and can be transferred to successive electrode patches **15** to ensure continuity of monitoring. The placement of the wearable monitor **12** in a location at the sternal midline **16** (or immediately to either side of the sternum **13**) benefits long-term extended wear by removing the requirement that ECG electrodes be continually placed in the same spots on the skin throughout the monitoring period. Instead, the patient is free to place an electrode patch **15** anywhere within the general region of the sternum **13**.

As a result, at any point during ECG monitoring, the patient’s skin is able to recover from the wearing of an electrode patch **15**, which increases patient comfort and satisfaction, while the monitor recorder **14** ensures ECG monitoring continuity with minimal effort. A monitor recorder **14** is merely unsnapped from a worn out electrode patch **15**, the worn out electrode patch **15** is removed from the skin, a new electrode patch **15** is adhered to the skin, possibly in a new spot immediately adjacent to the earlier location, and the same monitor recorder **14** is snapped into the new electrode patch **15** to reinitiate and continue the ECG monitoring.

During use, the electrode patch **15** is first adhered to the skin in the sternal region. FIG. **5** is a perspective view showing the extended wear electrode patch **15** of FIG. **3** without a monitor recorder **14** inserted. A flexible circuit **32** is adhered to each end of the flexible backing **20**. A distal circuit trace **33** and a proximal circuit trace (not shown) electrically couple ECG electrodes (not shown) to a pair of electrical pads **34**. The electrical pads **34** are provided within a moisture-resistant seal **35** formed on the bottom surface of the non-conductive receptacle **25**. When the monitor recorder **14** is securely received into the non-conductive receptacle **25**, that is, snapped into place, the electrical pads **34** interface to electrical contacts (not shown) protruding from the bottom surface of the monitor recorder **14**, and the moisture-resistant seal **35** enables the monitor recorder **14** to be worn at all times, even during bathing or other activities that could expose the monitor recorder **14** to moisture.

In addition, a battery compartment **36** is formed on the bottom surface of the non-conductive receptacle **25**, and a pair of battery leads (not shown) electrically interface the

8

battery to another pair of the electrical pads **34**. The battery contained within the battery compartment **35** can be replaceable, rechargeable or disposable.

The monitor recorder **14** draws power externally from the battery provided in the non-conductive receptacle **25**, thereby uniquely obviating the need for the monitor recorder **14** to carry a dedicated power source. FIG. **6** is a bottom plan view of the monitor recorder **14** of FIG. **3**. A cavity **58** is formed on the bottom surface of the sealed housing **50** to accommodate the upward projection of the battery compartment **36** from the bottom surface of the non-conductive receptacle **25**, when the monitor recorder **14** is secured in place on the non-conductive receptacle **25**. A set of electrical contacts **56** protrude from the bottom surface of the sealed housing **50** and are arranged in alignment with the electrical pads **34** provided on the bottom surface of the non-conductive receptacle **25** to establish electrical connections between the electrode patch **15** and the monitor recorder **14**. In addition, a seal coupling **57** circumferentially surrounds the set of electrical contacts **56** and securely mates with the moisture-resistant seal **35** formed on the bottom surface of the non-conductive receptacle **25**.

The placement of the flexible backing **20** on the sternal midline **16** (or immediately to either side of the sternum **13**) also helps to minimize the side-to-side movement of the wearable monitor **12** in the left- and right-handed directions during wear. To counter the dislodgment of the flexible backing **20** due to compressional and torsional forces, a layer of non-irritating adhesive, such as hydrocolloid, is provided at least partially on the underside, or contact surface of the flexible backing **20**, but only on the distal end **30** and the proximal end **31**. As a result, the underside, or contact surface of the longitudinal midsection **23** does not have an adhesive layer and remains free to move relative to the skin. Thus, the longitudinal midsection **23** forms a crimp relief that respectively facilitates compression and twisting of the flexible backing **20** in response to compressional and torsional forces. Other forms of flexible backing crimp reliefs are possible.

Unlike the flexible backing **20**, the flexible circuit **32** is only able to bend and cannot stretch in a planar direction. The flexible circuit **32** can be provided either above or below the flexible backing **20**. FIG. **7** is a top view showing the flexible circuit **32** of the extended wear electrode patch **15** of FIG. **3** when mounted above the flexible backing **20**. A distal ECG electrode **38** and proximal ECG electrode **39** are respectively coupled to the distal and proximal ends of the flexible circuit **32**. A strain relief **40** is defined in the flexible circuit **32** at a location that is partially underneath the battery compartment **36** when the flexible circuit **32** is affixed to the flexible backing **20**. The strain relief **40** is laterally extendable to counter dislodgment of the ECG electrodes **38**, **39** due to tensile and torsional forces. A pair of strain relief cutouts **41** partially extend transversely from each opposite side of the flexible circuit **32** and continue longitudinally towards each other to define in ‘S’-shaped pattern, when viewed from above. The strain relief respectively facilitates longitudinal extension and twisting of the flexible circuit **32** in response to tensile and torsional forces. Other forms of circuit board strain relief are possible.

ECG monitoring and other functions performed by the monitor recorder **14** are provided through a micro controlled architecture. FIG. **8** is a functional block diagram showing the component architecture of the circuitry **60** of the monitor recorder **14** of FIG. **3**. The circuitry **60** is externally powered through a battery provided in the non-conductive receptacle **25** (shown in FIG. **5**). Both power and raw ECG signals,

US 12,310,735 B2

9

which originate in the pair of ECG electrodes **38, 39** (shown in FIG. 7) on the distal and proximal ends of the electrode patch **15**, are received through an external connector **65** that mates with a corresponding physical connector on the electrode patch **15**. The external connector **65** includes the set of electrical contacts **56** that protrude from the bottom surface of the sealed housing **50** and which physically and electrically interface with the set of pads **34** provided on the bottom surface of the non-conductive receptacle **25**. The external connector includes electrical contacts **56** for data download, microcontroller communications, power, analog inputs, and a peripheral expansion port. The arrangement of the pins on the electrical connector **65** of the monitor recorder **14** and the device into which the monitor recorder **14** is attached, whether an electrode patch **15** or download station (not shown), follow the same electrical pin assignment convention to facilitate interoperability. The external connector **65** also serves as a physical interface to a download station that permits the retrieval of stored ECG monitoring data, communication with the monitor recorder **14**, and performance of other functions.

Operation of the circuitry **60** of the monitor recorder **14** is managed by a microcontroller **61**. The micro-controller **61** includes a program memory unit containing internal flash memory that is readable and writeable. The internal flash memory can also be programmed externally. The microcontroller **61** draws power externally from the battery provided on the electrode patch **15** via a pair of the electrical contacts **56**. The microcontroller **61** connects to the ECG front end circuit **63** that measures raw cutaneous electrical signals and generates an analog ECG signal representative of the electrical activity of the patient's heart over time.

The circuitry **60** of the monitor recorder **14** also includes a flash memory **62**, which the micro-controller **61** uses for storing ECG monitoring data and other physiology and information. The flash memory **62** also draws power externally from the battery provided on the electrode patch **15** via a pair of the electrical contacts **56**. Data is stored in a serial flash memory circuit, which supports read, erase and program operations over a communications bus. The flash memory **62** enables the microcontroller **61** to store digitized ECG data. The communications bus further enables the flash memory **62** to be directly accessed externally over the external connector **65** when the monitor recorder **14** is interfaced to a download station.

The circuitry **60** of the monitor recorder **14** further includes an actigraphy sensor **64** implemented as a 3-axis accelerometer. The accelerometer may be configured to generate interrupt signals to the microcontroller **61** by independent initial wake up and free fall events, as well as by device position. In addition, the actigraphy provided by the accelerometer can be used during post-monitoring analysis to correct the orientation of the monitor recorder **14** if, for instance, the monitor recorder **14** has been inadvertently installed upside down, that is, with the monitor recorder **14** oriented on the electrode patch **15** towards the patient's feet, as well as for other event occurrence analyses.

The microcontroller **61** includes an expansion port that also utilizes the communications bus. External devices, separately drawing power externally from the battery provided on the electrode patch **15** or other source, can interface to the microcontroller **61** over the expansion port in half duplex mode. For instance, an external physiology sensor can be provided as part of the circuitry **60** of the monitor recorder **14**, or can be provided on the electrode patch **15** with communication with the micro-controller **61** provided over one of the electrical contacts **56**. The physiology sensor

10

can include an SpO₂ sensor, blood pressure sensor, temperature sensor, respiratory rate sensor, glucose sensor, airflow sensor, volumetric pressure sensing, or other types of sensor or telemetric input sources. In a further embodiment, a wireless interface for interfacing with other wearable (or implantable) physiology monitors, as well as data offload and programming, can be provided as part of the circuitry **60** of the monitor recorder **14**, or can be provided on the electrode patch **15** with communication with the microcontroller **61** provided over one of the electrical contacts **56**.

Finally, the circuitry **60** of the monitor recorder **14** includes patient-interfaceable components, including a tactile feedback button **66**, which a patient can press to mark events or to perform other functions, and a buzzer **67**, such as a speaker, magnetic resonator or piezoelectric buzzer. The buzzer **67** can be used by the microcontroller **61** to output feedback to a patient such as to confirm power up and initiation of ECG monitoring. Still other components as part of the circuitry **60** of the monitor recorder **14** are possible.

While the monitor recorder **14** operates under micro control, most of the electrical components of the electrode patch **15** operate passively. FIG. 9 is a functional block diagram showing the circuitry **70** of the extended wear electrode patch **15** of FIG. 3. The circuitry **70** of the electrode patch **15** is electrically coupled with the circuitry **60** of the monitor recorder **14** through an external connector **74**. The external connector **74** is terminated through the set of pads **34** provided on the bottom of the non-conductive receptacle **25**, which electrically mate to corresponding electrical contacts **56** protruding from the bottom surface of the sealed housing **50** to electrically interface the monitor recorder **14** to the electrode patch **15**.

The circuitry **70** of the electrode patch **15** performs three primary functions. First, a battery **71** is provided in a battery compartment formed on the bottom surface of the non-conductive receptacle **25**. The battery **71** is electrically interfaced to the circuitry **60** of the monitor recorder **14** as a source of external power. The unique provisioning of the battery **71** on the electrode patch **15** provides several advantages. First, the locating of the battery **71** physically on the electrode patch **15** lowers the center of gravity of the overall wearable monitor **12** and thereby helps to minimize shear forces and the effects of movements of the patient and clothing. Moreover, the housing **50** of the monitor recorder **14** is sealed against moisture and providing power externally avoids having to either periodically open the housing **50** for the battery replacement, which also creates the potential for moisture intrusion and human error, or to recharge the battery, which can potentially take the monitor recorder **14** off line for hours at a time. In addition, the electrode patch **15** is intended to be disposable, while the monitor recorder **14** is a reusable component. Each time that the electrode patch **15** is replaced, a fresh battery is provided for the use of the monitor recorder **14**, which enhances ECG monitoring performance quality and duration of use. Finally, the architecture of the monitor recorder **14** is open, in that other physiology sensors or components can be added by virtue of the expansion port of the microcontroller **61**. Requiring those additional sensors or components to draw power from a source external to the monitor recorder **14** keeps power considerations independent of the monitor recorder **14**. Thus, a battery of higher capacity could be introduced when needed to support the additional sensors or components without effecting the monitor recorders circuitry **60**.

Second, the pair of ECG electrodes **38, 39** respectively provided on the distal and proximal ends of the flexible circuit **32** are electrically coupled to the set of pads **34**

US 12,310,735 B2

11

provided on the bottom of the non-conductive receptacle **25** by way of their respective circuit traces **33**, **37**. The signal ECG electrode **39** includes a protection circuit **72**, which is an inline resistor that protects the patient from excessive leakage current.

Last, in a further embodiment, the circuitry **70** of the electrode patch **15** includes a cryptographic circuit **73** to authenticate an electrode patch **15** for use with a monitor recorder **14**. The cryptographic circuit **73** includes a device capable of secure authentication and validation. The cryptographic device **73** ensures that only genuine, non-expired, safe, and authenticated electrode patches **15** are permitted to provide monitoring data to a monitor recorder **14**.

The monitor recorder **14** continuously monitors the patient's heart rate and physiology. FIG. **10** is a flow diagram showing a monitor recorder-implemented method **100** for monitoring ECG data for use in the monitor recorder **14** of FIG. **3**. Initially, upon being connected to the set of pads **34** provided with the non-conductive receptacle **25** when the monitor recorder **14** is snapped into place, the microcontroller **61** executes a power up sequence (step **101**). During the power up sequence, the voltage of the battery **71** is checked, the state of the flash memory **62** is confirmed, both in terms of operability check and available capacity, and microcontroller operation is diagnostically confirmed. In a further embodiment, an authentication procedure between the microcontroller **61** and the electrode patch **15** are also performed.

Following satisfactory completion of the power up sequence, an iterative processing loop (steps **102-109**) is continually executed by the microcontroller **61**. During each iteration (step **102**) of the processing loop, the ECG frontend **63** (shown in FIG. **8**) continually senses the cutaneous ECG electrical signals (step **103**) via the ECG electrodes **38**, **29** and is optimized to maintain the integrity of the P-wave. A sample of the ECG signal is read (step **104**) by the microcontroller **61** by sampling the analog ECG signal output front end **63**. FIG. **11** is a graph showing, by way of example, a typical ECG waveform **110**. The x-axis represents time in approximate units of tenths of a second. The y-axis represents cutaneous electrical signal strength in approximate units of millivolts. The P-wave **111** has a smooth, normally upward, that is, positive, waveform that indicates atrial depolarization. The QRS complex usually begins with the downward deflection of a Q wave **112**, followed by a larger upward deflection of an R-wave **113**, and terminated with a downward waveform of the S wave **114**, collectively representative of ventricular depolarization. The T wave **115** is normally a modest upward waveform, representative of ventricular depolarization, while the U wave **116**, often not directly observable, indicates the recovery period of the Purkinje conduction fibers.

Sampling of the R-to-R interval enables heart rate information derivation. For instance, the R-to-R interval represents the ventricular rate and rhythm, while the P-to-P interval represents the atrial rate and rhythm. Importantly, the PR interval is indicative of atrioventricular (AV) conduction time and abnormalities in the PR interval can reveal underlying heart disorders, thus representing another reason why the P-wave quality achievable by the extended wear ambulatory electrocardiography and physiological sensor monitor described herein is medically unique and important. The long-term observation of these ECG indicia, as provided through extended wear of the wearable monitor **12**, provides valuable insights to the patient's cardiac function and overall well-being.

12

Each sampled ECG signal, in quantized and digitized form, is temporarily staged in buffer (step **105**), pending compression preparatory to storage in the flash memory **62** (step **106**). Following compression, the compressed ECG digitized sample is again buffered (step **107**), then written to the flash memory **62** (step **108**) using the communications bus. Processing continues (step **109**), so long as the monitoring recorder **14** remains connected to the electrode patch **15** (and storage space remains available in the flash memory **62**), after which the processing loop is exited and execution terminates. Still other operations and steps are possible.

While the invention has been particularly shown and described as referenced to the embodiments thereof, those skilled in the art will understand that the foregoing and other changes in form and detail may be made therein without departing from the spirit and scope.

What is claimed is:

1. An electrocardiography monitor, comprising:
 - a battery;
 - a non-conductive receptacle configured to house the battery;
 - a housing comprising rounded edges along a top surface, wherein the housing engages the non-conductive receptacle and the non-conductive receptacle is configured to receive the housing, wherein the battery is positioned between the housing and a bottom surface of the non-conductive receptacle;
 - a patient feedback button located on the top surface of the housing;
 - an electrographic front end circuit to sense electrocardiographic signals;
 - a distal electrocardiography electrode coupled to a distal end of a flexible circuit and a proximal electrocardiography electrode coupled to a proximal end of the flexible circuit, wherein the flexible circuit is coupled to a flexible backing and the flexible backing is configured to adhere to skin of a patient's chest; and
 - a microcontroller secured by the housing, wherein the microcontroller is interfaced to the electrocardiographic front end circuit to sample the electrocardiographic signals.
2. The electrocardiography monitor according to claim 1, comprising:
 - a seal coupling surrounding electrical contacts, wherein the electrical contacts protrude from the bottom surface of the housing to connect to the battery to power the microcontroller.
3. The electrocardiography monitor according to claim 1, further comprising:
 - electrical contacts to establish an electrical connection with the distal electrocardiography electrode and the proximal electrocardiography electrode for sensing the electrocardiographic signals.
4. The electrocardiography monitor according to claim 1, wherein the housing is shaped for placement over the battery.
5. The electrocardiography monitor according to claim 1, further comprising:
 - circuitry for an actigraphy sensor.
6. The electrocardiography monitor according to claim 5, wherein the actigraphy sensor generates interrupt signals to the microcontroller based on a position of the housing.
7. The electrocardiography monitor according to claim 1, wherein the housing comprises polycarbonate, ABS, or an alloy of polycarbonate and ABS.

US 12,310,735 B2

13

8. The electrocardiography monitor according to claim 1, further comprising:

flash memory configured to store the electrocardiographic signals.

9. The electrocardiography monitor according to claim 1, further comprising:

an expansion port via which an external device interfaces to the microcontroller.

10. The electrocardiography monitor according to claim 9, wherein the external device comprises a physiological sensor.

11. An electrocardiography monitor assembly, comprising:

a battery compartment formed on a bottom surface of a non-conductive receptacle, wherein a battery is located in the battery compartment;

a housing comprising rounded edges along a top surface, wherein the non-conductive receptacle is configured to receive the housing and wherein the battery compartment is positioned between the housing and the bottom surface of the non-conductive receptacle;

an electrographic front end circuit to sense electrocardiographic signals;

a distal electrocardiography electrode coupled to a distal end of a flexible circuit and a proximal electrocardiography electrode coupled to a proximal end of the flexible circuit, wherein the flexible circuit is coupled to a flexible backing and the flexible backing is configured to adhere to skin of a patient's chest;

a microcontroller secured by the housing, wherein the microcontroller is interfaced to the electrocardiographic front end circuit to sample the electrocardiographic signals memory; and

a backing configured to receive the housing.

14

12. The electrocardiography monitor assembly according to claim 11, comprising:

a seal coupling surrounding electrical contacts.

13. The electrocardiography monitor assembly according to claim 11, further comprising:

electrical contacts to establish an electrical connection with the distal electrocardiography electrode and the proximal electrocardiography electrode for sensing the electrocardiographic signals.

14. The electrocardiography monitor assembly according to claim 11, wherein the housing is shaped to fit over the battery.

15. The electrocardiography monitor assembly according to claim 11, further comprising:

circuitry for an actigraphy sensor comprised within the housing.

16. The electrocardiography monitor assembly according to claim 15, wherein the actigraphy sensor generates interrupt signals to the microcontroller based on a position of the housing.

17. The electrocardiography monitor assembly according to claim 11, wherein the housing comprises polycarbonate, ABS, or an alloy of polycarbonate and ABS.

18. The electrocardiography monitor assembly according to claim 11, further comprising:

flash memory configured to store the electrocardiographic signals.

19. The electrocardiography monitor assembly according to claim 11, further comprising:

an expansion port comprised in the circuitry via which an external device interfaces to the microcontroller.


20. The electrocardiography monitor assembly according to claim 19, wherein the external device comprises a physiological sensor.

* * * * *

Exhibit 18


Claim Chart for U.S. Patent No. 12,285,261 (“the ’261 Patent”)



The Accused Instrumentalities include, but are not necessarily limited to, the Next-Generation Zio Monitor by iRhythm (the “Zio Monitor”). The Accused Instrumentalities infringe at least the claims of the ’261 Patent charted below either directly under 35 U.S.C. § 271(a), or indirectly under 35 U.S.C. §§ 271(b)–(c). The Accused Instrumentalities infringe such claims literally and/or under the doctrine of equivalents.

<u>Claim 1</u>	<u>Accused Instrumentalities</u>
1[pre]. A moisture-resistant electrocardiography monitor, comprising:	<p><i>To the extent the preamble is deemed to be a limitation, the Accused Instrumentalities include a moisture-resistant electrocardiography monitoring device in accordance with this claim. The Zio Monitor satisfies 1[pre] because the Zio Monitor is an ECG monitor that is moisture-resistant.</i></p>  <p>(https://s201.q4cdn.com/653785554/files/doc_downloads/V4_-_iRhythm_ESG_Report_2023.pdf)</p>

<u>Claim 1</u>	<u>Accused Instrumentalities</u>
	<p>ZIO MONITOR SYSTEM</p> <p>The Zio Monitor System is the next generation of the Zio XT System, and is a prescription-only, remote ECG monitoring system that consists of the Zio Monitor patch that records the electric signal from the heart continuously for up to 14 days and the ZEUS System, which supports the capture and analysis of ECG data recorded by the Zio Monitor patch at the end of the wear period, including specific arrhythmia events detected by the ZEUS algorithm.</p> <p>(https://s201.q4cdn.com/653785554/files/doc_downloads/V4_-_iRhythm_ESG_Report_2023.pdf)</p> <p>The Zio patches include the following features:</p> <ul style="list-style-type: none">• patented flexible, lightweight, wire-free design;• unobtrusive and inconspicuous profile;• proprietary adhesive backing designed to keep the Zio patch securely in place for the duration of the prescribed wear period;• water-resistant functionality, allowing patients to shower, sleep, and perform normal daily activities, including moderate exercise; <p>(https://go.irhythmtech.com/hubfs/LB10117.01%20-%20ZIO%20MONITOR%20INSTRUCTIONS%20FOR%20USE%2c%20PRINTED%20(2).pdf)</p>

<u>Claim 1</u>	<u>Accused Instrumentalities</u>
	<ul style="list-style-type: none">• An improved form-factor for a better patient wear experience – it is 23% thinner^{3,4}, 62% lighter^{3,4}, 72% smaller³⁻⁵ and weighs less than a pencil.⁶• Continued high patient compliance with prescribed wear time – Zio monitor demonstrates 99% patient compliance with prescribed wear times⁷ to help healthcare providers make the right diagnosis the first time.• Other features that make it easy to wear and allow patients to go about their daily lives⁸ – it is breathable, has a hydrocolloid adhesive and a waterproof housing^{9,10}, and requires no device or adhesive manipulation or battery change during the entire wear and monitoring period of up to 14 days. <p>(https://investors.irhythmtech.com/news/news-details/2023/iRhythm-Launches-Next-Generation-Zio-Monitor-and-Enhanced-Zio-Service-Its-Smallest-Lightest-and-Thinnest-Cardiac-Monitor/default.aspx)</p>


<u>Claim 1</u>	<u>Accused Instrumentalities</u>
<p>1[a]. an electrocardiography monitor recorder, comprising:</p>	<p><i>The Accused Instrumentalities include an electrocardiography monitor recorder.</i> The Zio Monitor satisfies 1[a] because the Zio Monitor includes an electrocardiography monitor recorder device. In an example, the Zio Monitor records patient ECG signals.</p> <p>ZIO MONITOR SYSTEM The Zio Monitor System is the next generation of the Zio XT System, and is a prescription-only, remote ECG monitoring system that consists of the Zio Monitor patch that records the electric signal from the heart continuously for up to 14 days and the ZEUS System, which supports the capture and analysis of ECG data recorded by the Zio Monitor patch at the end of the wear period, including specific arrhythmia events detected by the ZEUS algorithm.</p> <p>(https://s201.q4cdn.com/653785554/files/doc_downloads/V4_-_iRhythm_ESG_Report_2023.pdf)</p> <div data-bbox="659 954 1268 1235">  </div> <p>Next-generation Zio® monitor Long-Term Continuous Monitoring Service</p> <p>Introducing the Zio monitor—designed to be lighter, smaller, and thinner, while building on the high performance of Zio XT.⁵⁻⁸</p> <p>(https://www.irhythmtech.com/providers/zio-service/zio-monitors)</p>

<u>Claim 1</u>	<u>Accused Instrumentalities</u>
<p>1[b]. a wearable housing molded out of one or more materials and sealed against moisture;</p>	<p><i>The Accused Instrumentalities include a wearable housing molded out of one or more materials and sealed against moisture.</i> The Zio Monitor satisfies 1[b] because the Zio Monitor includes a wearable housing. The wearable housing is molded out of one or more materials.</p> <div data-bbox="850 425 1671 941"></div> <p>(https://s201.q4cdn.com/653785554/files/doc_downloads/V4_-_iRhythm_ESG_Report_2023.pdf)</p> <div data-bbox="974 1032 1545 1312"></div> <p>(https://www.irhythmtech.com/providers/zio-service/zio-monitors)</p>



<u>Claim 1</u>	<u>Accused Instrumentalities</u>
	<ul style="list-style-type: none"> • An improved form-factor for a better patient wear experience – it is 23% thinner^{3,4}, 62% lighter^{3,4}, 72% smaller³⁻⁵ and weighs less than a pencil.⁶ • Continued high patient compliance with prescribed wear time – Zio monitor demonstrates 99% patient compliance with prescribed wear times⁷ to help healthcare providers make the right diagnosis the first time. • Other features that make it easy to wear and allow patients to go about their daily lives⁸ – it is breathable, has a hydrocolloid adhesive and a waterproof housing^{9,10}, and requires no device or adhesive manipulation or battery change during the entire wear and monitoring period of up to 14 days. <p>(https://investors.irhythmtech.com/news/news-details/2023/iRhythm-Launches-Next-Generation-Zio-Monitor-and-Enhanced-Zio-Service-Its-Smallest-Lightest-and-Thinnest-Cardiac-Monitor/default.aspx)</p> <p>The Zio patches include the following features:</p> <ul style="list-style-type: none"> • patented flexible, lightweight, wire-free design; • unobtrusive and inconspicuous profile; • proprietary adhesive backing designed to keep the Zio patch securely in place for the duration of the prescribed wear period; • water-resistant functionality, allowing patients to shower, sleep, and perform normal daily activities, including moderate exercise; <p>(https://go.irhythmtech.com/hubfs/LB10117.01%20-%20ZIO%20MONITOR%20INSTRUCTIONS%20FOR%20USE%2c%20PRINTED%20(2).pdf)</p>


<u>Claim 1</u>	<u>Accused Instrumentalities</u>
<p>1[c]. a plurality of electrical contacts protruding from the wearable housing;</p>	<p><i>The Accused Instrumentalities include a plurality of electrical contacts protruding from the wearable housing.</i> The Zio Monitor satisfies 1[c] because the Zio Monitor includes a wearable housing with a plurality of electrical contacts.</p> <div data-bbox="756 423 1764 938"></div> <p>(Zio Monitor Teardown)</p>

<u>Claim 1</u>	<u>Accused Instrumentalities</u>
	<div data-bbox="915 310 1612 876"></div> <p data-bbox="632 894 949 930">(Zio Monitor Teardown)</p>



<u>Claim 1</u>	<u>Accused Instrumentalities</u>
	<div data-bbox="856 310 1663 933"></div> <p data-bbox="632 954 949 987">(Zio Monitor Teardown)</p>

<u>Claim 1</u>	<u>Accused Instrumentalities</u>
1[d]. a seal coupling positioned on the wearable housing and surrounding the electrical contacts; and	<p><i>The Accused Instrumentalities include a seal coupling positioned on the wearable housing and surrounding the electrical components.</i> The Zio Monitor satisfies 1[d] because the Zio Monitor includes a seal coupling positioned on the wearable housing. The seal coupling surrounds the electrical components.</p> <p>The Zio patches include the following features:</p> <ul style="list-style-type: none">• patented flexible, lightweight, wire-free design;• unobtrusive and inconspicuous profile;• proprietary adhesive backing designed to keep the Zio patch securely in place for the duration of the prescribed wear period;• water-resistant functionality, allowing patients to shower, sleep, and perform normal daily activities, including moderate exercise; <p>(https://s201.q4cdn.com/653785554/files/doc_downloads/V4_-_iRhythm_ESG_Report_2023.pdf)</p>


<u>Claim 1</u>	<u>Accused Instrumentalities</u>
	<div data-bbox="806 310 1713 773">A top-down view of a Zio Monitor device. It is a blue, oval-shaped patch with a central silver circular electrode labeled 'ZIO'. On the left, white text reads 'Instructions' followed by 'Peel clear backings (underside). Apply to chest with arrow pointing up.' and a white arrow pointing upwards. On the right, a white label reads 'DO NOT REMOVE THIS BLUE LAYER UNTIL MONITOR IS APPLIED.' There are small white double arrow symbols (» and «) near the top and bottom edges.</div> <p data-bbox="632 792 949 824">(Zio Monitor Teardown)</p> <div data-bbox="806 862 1713 1325">A bottom-up view of the Zio Monitor device, showing the clear adhesive backings and the internal components. The central silver electrode is visible, with the text 'DAA3737EP' and 'R' printed on it. The device is surrounded by a clear adhesive layer with a yellowish tint.</div> <p data-bbox="632 1344 949 1377">(Zio Monitor Teardown)</p>

<u>Claim 1</u>	<u>Accused Instrumentalities</u>
	<div data-bbox="655 310 1869 781">A photograph of the Zio Monitor packaging. It consists of a blue oval-shaped backing with a white arrow pointing upwards and the word "Instructions" in white. Below the arrow, the text reads: "Peel clear backings (underside). Apply to chest with arrow pointing up." To the right of the arrow is a circular opening showing the monitor's adhesive. To the right of the opening is a white label that reads: "DO NOT REMOVE THIS BLUE LAYER UNTIL MONITOR IS APPLIED." To the right of the label is a white circular cap with the "ZIO" logo embossed on it.</div> <div data-bbox="625 795 953 836"><p>(Zio Monitor Teardown)</p></div> <div data-bbox="655 868 1869 1302">A photograph of the Zio Monitor's internal components. The monitor is a circular device with a black PCB. It features a grid of gold-colored solder pads, a QR code, and various electronic components including a microcontroller, capacitors, and resistors. The monitor is shown from the underside, revealing the adhesive layer.</div> <div data-bbox="625 1318 953 1359"><p>(Zio Monitor Teardown)</p></div>

<u>Claim 1</u>	<u>Accused Instrumentalities</u>
1[e]. electronic circuitry provided within the wearable housing, the electronic circuitry further comprising:	<p><i>The Accused Instrumentalities include an electronic circuitry provided within the wearable housing.</i> The Zio Monitor satisfies 1[e] because the Zio Monitor includes electronic circuitry provided within the wearable housing.</p> <p>ZIO MONITOR SYSTEM</p> <p>The Zio Monitor System is the next generation of the Zio XT System, and is a prescription-only, remote ECG monitoring system that consists of the Zio Monitor patch that records the electric signal from the heart continuously for up to 14 days and the ZEUS System, which supports the capture and analysis of ECG data recorded by the Zio Monitor patch at the end of the wear period, including specific arrhythmia events detected by the ZEUS algorithm.</p> <p>(https://s201.q4cdn.com/653785554/files/doc_downloads/V4_-_iRhythm_ESG_Report_2023.pdf)</p>

<u>Claim 1</u>	<u>Accused Instrumentalities</u>
	<div data-bbox="886 310 1633 690">A blue, oval-shaped Zio Monitor packaging. It features a central silver circular cap with the 'ZIO' logo. To the left, white text reads 'Instructions' with a white arrow pointing upwards, followed by 'Peel clear backings (underside). Apply to chest with arrow pointing up.' To the right, white text reads 'DO NOT REMOVE THIS BLUE LAYER UNTIL MONITOR IS APPLIED.' Double arrow symbols are positioned above and below the central cap.</div> <p data-bbox="632 711 949 743">(Zio Monitor Teardown)</p> <div data-bbox="919 779 1602 1320">A photograph of the internal circuit board of a Zio Monitor. The board is populated with various electronic components, including a large black integrated circuit at the top labeled '2RF17 NW944', a smaller chip labeled '+MAX3266B 2248 341AB', and numerous surface-mount components like resistors and capacitors. A gold-colored curved component is visible on the left side.</div> <p data-bbox="632 1341 949 1373">(Zio Monitor Teardown)</p>


<u>Claim 1</u>	<u>Accused Instrumentalities</u>
<p>1[f]. an electrocardiographic front end circuit under a control of a micro-controller and adapted to sense cardiac electrical potential differentials through electrocardiographic electrodes via some of the electrical contacts, which are provided to the micro-controller as an analog signal;</p>	<p><i>The Accused Instrumentalities include an electrocardiographic front end circuit under a control of a micro-controller and adapted to sense cardiac electrical potential differentials through electrocardiographic electrodes via some of the electrical contacts, which are provided to the micro-controller as an analog signal.</i> The Zio Monitor satisfies 1[f] because the Zio Monitor comprises a micro-controller adapted to sense cardiac electrical potential differentials through electrocardiographic electrodes.</p> <div data-bbox="919 529 1604 1075" data-label="Image"> </div> <p>(Zio Monitor Teardown)</p>

<u>Claim 1</u>	<u>Accused Instrumentalities</u>
	<p data-bbox="724 308 1197 357">Example of Zio monitor</p> <div data-bbox="787 397 1228 868">  </div> <div data-bbox="1270 406 1795 917"> <ul style="list-style-type: none"> ① Electrode – acquires ECG data ② Adhesive wings – adheres the Zio monitor to the upper-left chest ③ Light – momentarily flashes green when activated and orange in the event of an error. After activation, you will not see any lights. Refer to Troubleshooting - flashing lights on page 17. ④ Zio button – activates the Zio monitor. The patient presses this button when a symptom is felt. ⑤ Clear plastic backings – remove from back of Zio monitor and discard before applying to the chest. </div> <p data-bbox="630 941 1890 1015">(https://go.irhythmtech.com/hubfs/LB10117.01%20-%20ZIO%20MONITOR%20INSTRUCTIONS%20FOR%20USE%2c%20PRINTED%20(2).pdf)</p>






<u>Claim 1</u>	<u>Accused Instrumentalities</u>
	<p>Day: From a technical viewpoint what we did was really to leverage a lot of advances not just in microprocessor efficiency, which is certainly part of it in terms of miniaturization as well as energy efficiency, but also we really challenged ourselves to figure out how to effectively fit in the smallest possible form factor, which for us was motivated a lot by the size of our battery, which is just a standard, easily available, and fortunately easily recyclable coin cell battery. We challenged ourselves to figure out how to miniaturize the device down to the level of one of those coin cells instead of the two that the Zio XT device uses. And that became feasible by the advances in microelectronic microprocessor efficiency and size as well through its miniaturization. But it also required a lot of really complicated dynamics from an electrical engineering perspective to figure out how to get all the components of a wearable medical device and a biosensor onto that small form factor. So, miniaturization was focused on very clever ways of handling some of the larger components, which for example involved moving some of the big resistors that are required on the device to the more flexible part of the patch instead of on the actual printed circuit board in the housing. And this is a patented feature that we've already received a patent on it and we're pursuing more around it, but it was the idea that these three big resistors are not too big in terms of the homage that they have but also in terms of the size that they are. So, if you put them on the circuit board, they are these pretty big components, so we realized pretty early on that we couldn't really do that and still fit the design constraints. So, we innovated a different way, which was to integrate it into the ECG tracings themselves.</p> <p>(https://www.mddionline.com/cardiovascular/behind-the-design-how-irhythm-built-its-new-zio-monitor)</p>

Claim 1

Accused Instrumentalities





(MAX30003 Datasheet)

Claim 1	Accused Instrumentalities
	<div><div><div><div></div><div><div> Evaluation Kit Available</div><div> Design Resources</div><div> Tools and Models</div><div> Support</div></div></div><div>Click here to ask an associate for production status of specific part numbers.</div><div>Ultra-Low Power, Single-Channel Integrated Biopotential (ECG, R-to-R Detection) AFE</div><div>MAX30003</div><div>General Description</div><div>The MAX30003 is a complete, biopotential, analog front-end solution for wearable applications. It offers high performance for clinical and fitness applications, with ultra-low power for long battery life. The MAX30003 is a single biopotential channel providing ECG waveforms and heart rate detection.</div><div>The biopotential channel has ESD protection, EMI filtering, internal lead biasing, DC leads-off detection, ultra-low power leads-on detection during standby mode, and extensive calibration voltages for built-in self-test. Soft power-up sequencing ensures no large transients are injected into the electrodes. The biopotential channel also has high input impedance, low noise, high CMRR, programmable gain, various low-pass and high-pass filter options, and a high resolution analog-to-digital converter. The biopotential channel is DC coupled, can handle large electrode voltage offsets, and has a fast recovery mode to quickly recover from overdrive conditions, such as defibrillation and electrosurgery.</div><div>The MAX30003 is available in a 28-pin TQFN and 30-bump wafer-level package (WLP), operating over the 0°C to +70°C commercial temperature range.</div><div>(MAX30003 Datasheet)</div></div></div>

<u>Claim 1</u>	<u>Accused Instrumentalities</u>
	<p>Benefits and Features</p> <ul style="list-style-type: none">• Clinical-Grade ECG AFE with High-Resolution Data Converter<ul style="list-style-type: none">• 15.5 Bits Effective Resolution with 5μV_{P-P} Noise• Better Dry Starts Due to Much Improved Real World CMRR and High Input Impedance<ul style="list-style-type: none">• Fully Differential Input Structure with CMRR > 100dB• Offers Better Common-Mode to Differential Mode Conversion Due to High Input Impedance<ul style="list-style-type: none">• High Input Impedance > 500MΩ for Extremely Low Common-to-Differential Mode Conversion• Minimum Signal Attenuation at the Input During Dry Start Due to High Electrode Impedance• High DC Offset Range of \pm650mV (1.8V, typ) Allows to Be Used with Wide Variety of Electrodes• High AC Dynamic Range of 65mV_{P-P} Will Help the AFE Not Saturate in the Presence of Motion/Direct Electrode Hits• Longer Battery Life Compared to Competing Solutions<ul style="list-style-type: none">• 85μW at 1.1V Supply Voltage• Leads-On Interrupt Feature Allows to Keep μC in Deep Sleep Mode with RTC Off Until Valid Lead Condition is Detected<ul style="list-style-type: none">• Lead-On Detect Current: 0.7μA (typ) <p>(MAX30003 Datasheet)</p>

<u>Claim 1</u>	<u>Accused Instrumentalities</u>
	<ul style="list-style-type: none">• Built-In Heart Rate Detection with Interrupt Feature Eliminates the Need to Run HR Algorithm on the μController<ul style="list-style-type: none">• Robust R-R Detection in High Motion Environment at Extremely Low Power• Configurable Interrupts Allows the μC Wake-Up Only on Every Heart Beat Reducing the Overall System Power• High Accuracy Allows for More Physiological Data Extractions• 32-Word FIFO Allows You to Wake Up μController Every 256ms with Full ECG Acquisition• High-Speed SPI Interface• Shutdown Current of 0.5μA (typ) <p>(MAX30003 Datasheet)</p>

<u>Claim 1</u>	<u>Accused Instrumentalities</u>
1[g]. the micro-controller configured to sample the analog signal; and	<i>See element 1[f] for this limitation.</i>

<u>Claim 1</u>	<u>Accused Instrumentalities</u>
<p>1[h]. a memory electrically interfaced with the micro-controller and operable to store the samples; and</p>	<p><i>The Accused Instrumentalities include a memory electrically interfaced with the micro-controller and operable to store the samples.</i> The Zio Monitor satisfies 1[h] because the Zio Monitor includes a memory electrically interfaced with the micro-controller and operable to store the samples.</p> <div data-bbox="1003 423 1520 836"></div> <p>(Zio Monitor Teardown)</p> <div data-bbox="1003 924 1520 1325"></div> <p>(Zio Monitor Teardown)</p>



<u>Claim 1</u>	<u>Accused Instrumentalities</u>
	<p data-bbox="930 313 1253 347">General Description</p> <p data-bbox="930 354 1591 610">DARWIN is a new breed of low-power microcontrollers built to thrive in the rapidly evolving Internet of Things (IoT). They are smart, with the biggest memories in their class and a massively scalable memory architecture. They run forever, thanks to wearable-grade power technology. They are durable enough to withstand the most advanced cyberattacks. DARWIN microcontrollers are designed to run any application imaginable—in places where you would not dream of sending other microcontrollers.</p> <p data-bbox="930 623 1591 792">Generation UB microcontrollers are designed to handle the increasingly complex applications demanded by today's advanced battery-powered devices and wirelessly connected devices, while providing robust hardware security and Bluetooth® 5 Low Energy (Bluetooth LE) radio connectivity.</p> <p data-bbox="930 805 1591 1203">The MAX32665/MAX32666 UB class microcontrollers are advanced systems-on-chips featuring an Arm® Cortex®-M4 with FPU CPU for efficient computation of complex functions and algorithms with integrated power management. It also includes the newest generation Bluetooth 5 LE radio with support for long range (4x) and high throughput (2Mbps) and ADI's best-in-class hardware security suite trust protection unit (TPU). The devices offer large on-board memory with 1MB flash and 560KB SRAM. Split flash banks of 512KB each support seamless over-the-air upgrades, adding an additional degree of reliability. Memory scalability of data (SRAM) and code (Flash) space is supported by two SPI execute-in-place (SPIX) interfaces.</p> <p data-bbox="632 1224 942 1258">(MAX32666 Datasheet)</p>

<u>Claim 1</u>	<u>Accused Instrumentalities</u>
1[i]. an extended wear electrode patch, comprising:	<p><i>The Accused Instrumentalities include an extended wear electrode patch.</i> The Zio Monitor satisfies 1[i] because the Zio Monitor comprises an extended wear electrode patch. Specifically, the patch can be worn up to 14 days and the patch includes electrodes, which acquire ECG data.</p> <p>Product Description</p> <p>The Zio® ECG Monitoring System is an ambulatory Electrocardiogram (ECG) monitoring system. The Zio ECG Monitoring System consists of two components:</p> <p>(1) Zio monitor</p> <p>(2) proprietary algorithm software.</p> <p>The Zio monitor is a single-use ECG monitor that provides a continuous, single-channel recording for up to 14 days. The Zio monitor records ECG data without patient interaction, with the goal of improving patient compliance via simplicity of operation. Patients have the option of pressing a convenient button and filling out a log to document symptomatic events, which will support symptom-rhythm correlation in the diagnostic report.</p> <p>After conclusion of the wear period (up to 14 days), the patient removes the Zio monitor and returns it by mail to iRhythm for processing. After receipt, the data is analyzed by iRhythm's proprietary algorithm before a Certified Cardiographic Technician (CCT) reviews the results and generates a report of the key findings.</p> <p>(https://go.irhythmtech.com/hubfs/LB10117.01%20-%20ZIO%20MONITOR%20INSTRUCTIONS%20FOR%20USE%2c%20PRINTED%20(2).pdf)</p>

<u>Claim 1</u>	<u>Accused Instrumentalities</u>
	<p data-bbox="688 310 1192 363">Example of Zio monitor</p> <div data-bbox="751 407 1226 911"> </div> <ul style="list-style-type: none"> <li data-bbox="1276 418 1675 451">① Electrode – acquires ECG data <li data-bbox="1276 467 1808 532">② Adhesive wings – adheres the Zio monitor to the upper-left chest <li data-bbox="1276 548 1835 732">③ Light – momentarily flashes green when activated and orange in the event of an error. After activation, you will not see any lights. Refer to Troubleshooting - flashing lights on page 17. <li data-bbox="1276 748 1766 846">④ Zio button – activates the Zio monitor. The patient presses this button when a symptom is felt. <li data-bbox="1276 862 1814 959">⑤ Clear plastic backings – remove from back of Zio monitor and discard before applying to the chest. <p data-bbox="632 1003 1877 1073"> https://go.irhythmtech.com/hubfs/LB10117.01%20-%20ZIO%20MONITOR%20INSTRUCTIONS%20FOR%20USE%2c%20PRINTED%20(2).pdf </p>

<u>Claim 1</u>	<u>Accused Instrumentalities</u>
	<p>ZIO MONITOR SYSTEM</p> <p>The Zio Monitor System is the next generation of the Zio XT System, and is a prescription-only, remote ECG monitoring system that consists of the Zio Monitor patch that records the electric signal from the heart continuously for up to 14 days and the ZEUS System, which supports the capture and analysis of ECG data recorded by the Zio Monitor patch at the end of the wear period, including specific arrhythmia events detected by the ZEUS algorithm.</p> <p>(https://go.irhythmtech.com/hubfs/LB10117.01%20-%20ZIO%20MONITOR%20INSTRUCTIONS%20FOR%20USE%2c%20PRINTED%20(2).pdf)</p> <div><div>Zio MonitorZio XTZio AT</div><div>Long-term continuous monitoring service</div><div>The new Zio monitor is designed with patients in mind by providing a more breathable, inconspicuous, and comfortable wear experience so patients can go about their daily activities. ^{5,15,16}</div></div> <p>(https://www.irhythmtech.com/providers/zio-service/zio-monitors)</p>



<u>Claim 1</u>	<u>Accused Instrumentalities</u>
<p>1[j]. a flexible backing comprising a plurality of adhesive contact surfaces;</p>	<p><i>The Accused Instrumentalities include a flexible backing comprising a plurality of adhesive contact surfaces.</i> The Zio Monitor satisfies 1[j] because the Zio Monitor includes an adhesive flexible backing that sticks to the patient’s skin.</p> <p><u>The new Zio monitor:</u> The new Zio monitor is designed to be effortless to wear with increased adherence and better patient comfort. It’s small enough for patients to forget they are wearing it through exercise, showering, and sleeping. The new design is more than 50% lighter than the current generation, and includes a new breathable and waterproof outer layer. It also has an improved ‘stay-put’ adhesive and a more flexible design for a secure attachment. These refinements will allow for a more comfortable wear and, therefore, more complete, accurate diagnostic data.</p> <p>(https://www.irhythmtech.com/company/news/irhythm-technologies-continues-to-fuel-innovation-in-cardiac-monitoring-and-unveils-two-fda-clearances-for-superior-patient-care)</p> <p>The Zio patches include the following features:</p> <ul style="list-style-type: none"> • patented flexible, lightweight, wire-free design; • unobtrusive and inconspicuous profile; • proprietary adhesive backing designed to keep the Zio patch securely in place for the duration of the prescribed wear period; <p>(https://s201.q4cdn.com/653785554/files/doc_downloads/V4_-_iRhythm_ESG_Report_2023.pdf)</p>



<u>Claim 1</u>	<u>Accused Instrumentalities</u>
	<div data-bbox="806 293 1713 756">A photograph of a Zio Monitor, a blue, oval-shaped medical device. It features a central silver circular component with the 'ZIO' logo. To the left, white text reads 'Instructions' with a white arrow pointing upwards, followed by 'Peel clear backings (underside). Apply to chest with arrow pointing up.' To the right, a white rectangular label with black text reads 'DO NOT REMOVE THIS BLUE LAYER UNTIL MONITOR IS APPLIED.' The device has small white arrows on its top and bottom edges.</div> <p data-bbox="632 776 949 808">(Zio Monitor Teardown)</p> <div data-bbox="806 846 1713 1308">A photograph showing the internal components of a Zio Monitor. The device is open, revealing two yellow, circular, textured pads on the left and right sides. In the center is a silver circular component with a QR code and the text 'DAA3737EP' and 'RITHEM'. The entire assembly is encased in a clear plastic protective layer.</div> <p data-bbox="632 1328 949 1360">(Zio Monitor Teardown)</p>


<u>Claim 1</u>	<u>Accused Instrumentalities</u>
<p>1[k]. the electrocardiographic electrodes, each comprised on one of the adhesive contact surfaces;</p>	<p><i>The Accused Instrumentalities include electrocardiographic electrodes, where each of the electrocardiographic electrodes are comprised on one of the adhesive contact surfaces.</i> The Zio Monitor satisfies 1[k] because the Zio Monitor includes a plurality of adhesive contact surfaces and the electrodes are comprised on one of the adhesive contact surfaces.</p> <div data-bbox="865 461 1644 836" data-label="Image"> </div> <p>(Zio Monitor Teardown)</p> <div data-bbox="869 922 1650 1328" data-label="Image"> </div> <p>(Zio Monitor Teardown)</p>



<u>Claim 1</u>	<u>Accused Instrumentalities</u>
	<p data-bbox="699 313 1192 362">Example of Zio monitor</p> <div data-bbox="766 406 1228 901"> </div> <div data-bbox="1270 414 1816 941"> <ul style="list-style-type: none"> ① Electrode – acquires ECG data ② Adhesive wings – adheres the Zio monitor to the upper-left chest ③ Light – momentarily flashes green when activated and orange in the event of an error. After activation, you will not see any lights. Refer to Troubleshooting - flashing lights on page 17. ④ Zio button – activates the Zio monitor. The patient presses this button when a symptom is felt. ⑤ Clear plastic backings – remove from back of Zio monitor and discard before applying to the chest. </div> <p data-bbox="630 966 1885 1039">(https://go.irhythmtech.com/hubfs/LB10117.01%20-%20ZIO%20MONITOR%20INSTRUCTIONS%20FOR%20USE%2c%20PRINTED%20(2).pdf)</p>

<u>Claim 1</u>	<u>Accused Instrumentalities</u>
<p>1[1]. a receptacle affixed to a non-contacting surface of the flexible backing into which the wearable housing can be removably secured,</p>	<p><i>The Accused Instrumentalities include a receptacle affixed to a non-contacting surface of the flexible backing into which the wearable housing can be removably secured.</i> The Zio Monitor satisfies 1[1] because the Zio Monitor includes a receptacle affixed to a non-contacting surface of the flexible backing into which the wearable housing can be removably secured.</p> <div data-bbox="865 461 1644 834" data-label="Image"> </div> <p>(Zio Monitor Teardown)</p> <div data-bbox="871 922 1654 1328" data-label="Image"> </div> <p>(Zio Monitor Teardown)</p>

<u>Claim 1</u>	<u>Accused Instrumentalities</u>
	<div data-bbox="762 310 1759 696">A photograph of the Zio Monitor packaging, which is a blue oval-shaped sticker. The left side of the sticker has the word "Instructions" in white, followed by "Peel clear backings (underside). Apply to chest with arrow pointing up." and a white arrow pointing upwards. The right side of the sticker has a white label that reads "DO NOT REMOVE THIS BLUE LAYER UNTIL MONITOR IS APPLIED." in black capital letters. To the right of the sticker is a small, white, circular cap with the "ZIO" logo embossed on it.</div> <p data-bbox="632 716 947 748">(Zio Monitor Teardown)</p> <div data-bbox="762 786 1759 1141">A photograph of the Zio Monitor device after the blue layer has been removed. The device is a small, circular, silver-colored metal case. Inside the case, a black printed circuit board (PCB) is visible, featuring a grid of gold-colored pins and various electronic components. The device is resting on a white surface.</div> <p data-bbox="632 1161 947 1193">(Zio Monitor Teardown)</p>



<u>Claim 1</u>	<u>Accused Instrumentalities</u>
<p>1[m]. the receptacle comprising a compartment within which a component interfaced to the electronic circuitry is positioned via some of the electrical contacts,</p>	<p><i>The Accused Instrumentalities include a receptacle comprising a compartment within which a component interfaced to the electronic circuitry is positioned via some of the electrical contacts.</i> The Zio Monitor satisfies 1[m] because the Zio Monitor comprises a compartment within which a component is interfaced to the electronic circuitry.</p> <div data-bbox="898 479 1627 849">A photograph of the Zio Monitor's retail packaging. It is a blue, rounded rectangular box. On the left side, there is a white arrow pointing upwards with the word "Instructions" above it. Below the arrow, the text reads: "Peel clear backings (underside). Apply to chest with arrow pointing up." In the center of the box is a circular silver-colored cap with the word "ZIO" embossed on it. On the right side, there is a white rectangular label with the text: "DO NOT REMOVE THIS BLUE LAYER UNTIL MONITOR IS APPLIED." There are also small white double arrow symbols (» and «) near the top and bottom center of the box.</div> <p>(Zio Monitor Teardown)</p> <div data-bbox="898 938 1627 1308">A photograph showing the Zio Monitor after its packaging has been removed. The device consists of two circular, light-colored adhesive pads connected by a central silver-colored metal component. The pads have a grid of small, circular electrical contacts on their surface. The central component has some text and a logo on it, including the word "RHYTHM".</div> <p>(Zio Monitor Teardown)</p>


<u>Claim 1</u>	<u>Accused Instrumentalities</u>
	<div data-bbox="688 310 1835 781">A blue, oval-shaped Zio monitor is shown. It has a clear adhesive layer in the center. To the left of the adhesive layer is a white label with the word "Instructions" and an arrow pointing up. To the right is another white label that says "DO NOT REMOVE THIS BLUE LAYER UNTIL MONITOR IS APPLIED." A small white cap with the Zio logo is to the right of the monitor.</div> <p data-bbox="632 797 949 833">(Zio Monitor Teardown)</p> <div data-bbox="688 868 1835 1279">A close-up view of the Zio monitor's internal circuitry, showing a black PCB with various components and a QR code.</div> <p data-bbox="632 1295 949 1331">(Zio Monitor Teardown)</p>



<u>Claim 1</u>	<u>Accused Instrumentalities</u>
	<div data-bbox="963 310 1560 782"></div> <p data-bbox="632 803 949 841">(Zio Monitor Teardown)</p> <div data-bbox="963 873 1560 1333"></div> <p data-bbox="632 1352 949 1390">(Zio Monitor Teardown)</p>

<u>Claim 1</u>	<u>Accused Instrumentalities</u>				
<p>1[n]. wherein the component is a battery;</p>	<p><i>The Accused Instrumentalities include battery.</i> The Zio Monitor satisfies 1[n] because the Zio Monitor includes a battery as the component is interfaced to the electronic circuitry and positioned via some of the electrical contacts.</p> <p style="text-align: center;">Power specifications</p> <table border="0" style="margin-left: auto; margin-right: auto;"> <tr> <td style="padding-right: 40px;">Battery type</td> <td>1 lithium manganese dioxide coin cell</td> </tr> <tr> <td>Battery life</td> <td>> 14 days</td> </tr> </table> <p>(https://go.irhythmtech.com/hubfs/LB10117.01%20-%20ZIO%20MONITOR%20INSTRUCTIONS%20FOR%20USE%2c%20PRINTED%20(2).pdf)</p> <p style="text-align: center;">Precautions</p> <ul style="list-style-type: none"> • During storage and prior to prescription for a patient, do not exceed the temperature and humidity limitations for the Zio monitor. Devices exposed to environmental conditions outside the specified range may have degraded adhesive and battery performance. • Observe the temperature and humidity specifications for transportation and storage listed on the box and in the instructions for use. • Confirm the expiration date for the Zio monitor listed on the Zio box or pouch. Use of an expired device may cause a degradation of ECG signal quality and a low battery condition. Apply the device on or before expiration date. <p>(https://go.irhythmtech.com/hubfs/LB10117.01%20-%20ZIO%20MONITOR%20INSTRUCTIONS%20FOR%20USE%2c%20PRINTED%20(2).pdf)</p>	Battery type	1 lithium manganese dioxide coin cell	Battery life	> 14 days
Battery type	1 lithium manganese dioxide coin cell				
Battery life	> 14 days				



<u>Claim 1</u>	<u>Accused Instrumentalities</u>
	<p>The Zio Monitor, our newest model, is 72% smaller and 62% lighter relative to the previous generation. The Zio Monitor uses 1 coin-cell battery, as compared to the 2 used in Zio XT. This is the second-most environmentally impactful component of our devices (after the circuit board). While we recycle these batteries, this is still a meaningful reduction in impact.</p> <p>(https://s201.q4cdn.com/653785554/files/doc_downloads/V4_-_iRhythm_ESG_Report_2023.pdf)</p> <p>ZIO MONITOR SYSTEM</p> <p>The Zio Monitor System is the next generation of the Zio XT System, and is a prescription-only, remote ECG monitoring system that consists of the Zio Monitor patch that records the electric signal from the heart continuously for up to 14 days and the ZEUS System, which supports the capture and analysis of ECG data recorded by the Zio Monitor patch at the end of the wear period, including specific arrhythmia events detected by the ZEUS algorithm.</p> <p>(https://s201.q4cdn.com/653785554/files/doc_downloads/V4_-_iRhythm_ESG_Report_2023.pdf)</p>

<u>Claim 1</u>	<u>Accused Instrumentalities</u>
<p>1[o]. a plurality of electrical pads positioned on the receptacle,</p>	<p><i>The Accused Instrumentalities include a plurality of electrical pads positioned on the receptacle.</i> The Zio Monitor satisfies 1[o] because the Zio Monitor includes electrical pads, which are positioned on the receptacle.</p> <div data-bbox="896 425 1627 795">A photograph of the Zio Monitor packaging, which is a blue, oval-shaped blister pack. It features a central silver-colored circular cap with the 'ZIO' logo. To the left of the cap, there is a white arrow pointing upwards and the text 'Instructions Peel clear backings (underside). Apply to chest with arrow pointing up.' To the right of the cap, there is a white rectangular label with the text 'DO NOT REMOVE THIS BLUE LAYER UNTIL MONITOR IS APPLIED.' and two small white arrows pointing outwards.</div> <p>(Zio Monitor Teardown)</p> <div data-bbox="896 885 1627 1255">A photograph of the Zio Monitor after the blue packaging has been removed. It shows two large, circular, yellowish electrical pads on either side of a central silver-colored circular cap. The pads have a grid of small holes. The cap has some text on it, including 'DA3737E' and 'R5'. The entire device is set against a white background.</div> <p>(Zio Monitor Teardown)</p>

<u>Claim 1</u>	<u>Accused Instrumentalities</u>
	<div data-bbox="688 310 1835 781"></div> <p data-bbox="632 797 949 833">(Zio Monitor Teardown)</p> <div data-bbox="688 868 1835 1279"></div> <p data-bbox="632 1295 949 1331">(Zio Monitor Teardown)</p>

<u>Claim 1</u>	<u>Accused Instrumentalities</u>
	<div data-bbox="963 310 1560 782"></div> <p data-bbox="632 803 949 841">(Zio Monitor Teardown)</p> <div data-bbox="963 873 1560 1333"></div> <p data-bbox="632 1352 949 1390">(Zio Monitor Teardown)</p>

<u>Claim 1</u>	<u>Accused Instrumentalities</u>
<p>1[p]. each of the pads configured to interface with one of the electrical contacts when the wearable housing is secured within the receptacle; and</p>	<p><i>The Accused Instrumentalities include pads configured to interface with the electrical contacts when the earable housing is secured within the receptacle.</i> The Zio Monitor satisfies 1[p] because the Zio Monitor includes two pads configured to interface with the electrodes when the wearable housing is secured to the receptacle.</p> <div data-bbox="806 461 1713 924"></div> <p>(Zio Monitor Teardown)</p>



<u>Claim 1</u>	<u>Accused Instrumentalities</u>
	<div data-bbox="963 306 1560 781"></div> <p data-bbox="632 802 949 837">(Zio Monitor Teardown)</p> <div data-bbox="963 870 1560 1331"></div> <p data-bbox="632 1349 949 1385">(Zio Monitor Teardown)</p>

<u>Claim 1</u>	<u>Accused Instrumentalities</u>
	<div data-bbox="657 310 1869 781"></div> <p data-bbox="632 797 951 833">(Zio Monitor Teardown)</p>

<u>Claim 1</u>	<u>Accused Instrumentalities</u>
<p>1[q] a moisture-resistant seal formed on the receptacle and surrounding the electrical pads,</p>	<p><i>The Accused Instrumentalities include a moisture-resistant seal formed on the receptacle and surrounding the electrical pads.</i> The Zio Monitor satisfies 1[q] because the Zio Monitor includes two pads and a moisture-resistant seal formed on the receptacle and surrounding the electrical pads.</p> <p>The Zio patches include the following features:</p> <ul style="list-style-type: none"> • patented flexible, lightweight, wire-free design; • unobtrusive and inconspicuous profile; • proprietary adhesive backing designed to keep the Zio patch securely in place for the duration of the prescribed wear period; • water-resistant functionality, allowing patients to shower, sleep, and perform normal daily activities, including moderate exercise; <p>(https://go.irhythmtech.com/hubfs/LB10117.01%20-%20ZIO%20MONITOR%20INSTRUCTIONS%20FOR%20USE%2c%20PRINTED%20(2).pdf)</p> <ul style="list-style-type: none"> • An improved form-factor for a better patient wear experience – it is 23% thinner^{3,4}, 62% lighter^{3,4}, 72% smaller³⁻⁵ and weighs less than a pencil.⁶ • Continued high patient compliance with prescribed wear time – Zio monitor demonstrates 99% patient compliance with prescribed wear times⁷ to help healthcare providers make the right diagnosis the first time. • Other features that make it easy to wear and allow patients to go about their daily lives⁸ – it is breathable, has a hydrocolloid adhesive and a waterproof housing^{9,10}, and requires no device or adhesive manipulation or battery change during the entire wear and monitoring period of up to 14 days. <p>(https://investors.irhythmtech.com/news/news-details/2023/iRhythm-Launches-Next-Generation-Zio-Monitor-and-Enhanced-Zio-Service-Its-Smallest-Lightest-and-Thinnest-Cardiac-Monitor/default.aspx)</p>

<u>Claim 1</u>	<u>Accused Instrumentalities</u>
	 <p data-bbox="632 797 951 833">(Zio Monitor Teardown)</p>

<u>Claim 1</u>	<u>Accused Instrumentalities</u>
1[r] wherein the moisture-resistant seal mates the seal coupling when the wearable housing is secured within the receptacle.	<p><i>The Accused Instrumentalities include moisture-resistant seal, which mates with the seal coupling when the wearable housing is secured within the receptacle.</i> The Zio Monitor satisfies 1[r] because the Zio Monitor includes a moisture-resistant seal that mates the seal coupling when the wearable housing is secured within the receptacle.</p> <p>The Zio patches include the following features:</p> <ul style="list-style-type: none">• patented flexible, lightweight, wire-free design;• unobtrusive and inconspicuous profile;• proprietary adhesive backing designed to keep the Zio patch securely in place for the duration of the prescribed wear period;• water-resistant functionality, allowing patients to shower, sleep, and perform normal daily activities, including moderate exercise; <p>(https://s201.q4cdn.com/653785554/files/doc_downloads/V4_-_iRhythm_ESG_Report_2023.pdf)</p>

<u>Claim 1</u>	<u>Accused Instrumentalities</u>
	<div data-bbox="806 310 1717 773">A top-down view of a Zio Monitor Teardown. It is a blue, oval-shaped device with a central silver circular component labeled 'ZIO'. On the left, there is a white arrow pointing upwards and the text 'Instructions Peel clear backings (underside). Apply to chest with arrow pointing up.' On the right, there is a white rectangular label with the text 'DO NOT REMOVE THIS BLUE LAYER UNTIL MONITOR IS APPLIED.' and double arrow symbols (» and «) pointing towards the center.</div> <p data-bbox="632 792 949 824">(Zio Monitor Teardown)</p> <div data-bbox="806 862 1717 1325">A bottom-up view of the Zio Monitor Teardown. It shows the underside of the blue device, which is covered with a clear adhesive layer. The central silver component is visible, showing a QR code and the text 'DAA3737EP' and 'RITHEM'. The device is surrounded by a clear plastic protective layer.</div> <p data-bbox="632 1344 949 1377">(Zio Monitor Teardown)</p>


<u>Claim 1</u>	<u>Accused Instrumentalities</u>
	 <p data-bbox="632 797 951 833">(Zio Monitor Teardown)</p>

Exhibit 19

Claim Chart for U.S. Patent No. 12,310,735 (“the ’735 Patent”)



The Accused Instrumentalities include, but are not necessarily limited to, the Next-Generation Zio Monitor by iRhythm (the “Zio Monitor”). The Accused Instrumentalities infringe at least the claims of the ’735 Patent charted below either directly under 35 U.S.C. § 271(a), or indirectly under 35 U.S.C. §§ 271(b)–(c). The Accused Instrumentalities infringe such claims literally and/or under the doctrine of equivalents.



<u>Claim 1</u>	<u>Accused Instrumentalities</u>
<p>1[pre]. An electrocardiography monitor, comprising:</p>	<p><i>To the extent the preamble is deemed to be a limitation, the Accused Instrumentalities include an electrocardiography monitor in accordance with this claim.</i> The Zio Monitor satisfies 1[pre] because the Zio Monitor is an electrocardiography monitor.</p> <div data-bbox="814 667 1650 1201" data-label="Image"> </div> <p>Zio Monitor</p> <p>(https://s201.q4cdn.com/653785554/files/doc_downloads/V4_-_iRhythm_ESG_Report_2023.pdf)</p>


<u>Claim 1</u>	<u>Accused Instrumentalities</u>
	<p data-bbox="932 318 1199 342">ZIO MONITOR SYSTEM</p> <p data-bbox="932 355 1545 760">The Zio Monitor System is the next generation of the Zio XT System, and is a prescription-only, remote ECG monitoring system that consists of the Zio Monitor patch that records the electric signal from the heart continuously for up to 14 days and the ZEUS System, which supports the capture and analysis of ECG data recorded by the Zio Monitor patch at the end of the wear period, including specific arrhythmia events detected by the ZEUS algorithm.</p> <p data-bbox="583 781 1839 813">https://s201.q4cdn.com/653785554/files/doc_downloads/V4_-_iRhythm_ESG_Report_2023.pdf</p> <div data-bbox="640 850 1241 1131"></div> <p data-bbox="1339 850 1824 889">Next-generation Zio® monitor</p> <p data-bbox="1398 906 1766 927">Long-Term Continuous Monitoring Service</p> <p data-bbox="1312 967 1818 1057">Introducing the Zio monitor—designed to be lighter, smaller, and thinner, while building on the high performance of Zio XT.⁵⁻⁸</p> <p data-bbox="583 1154 1438 1187">https://www.irhythmtech.com/providers/zio-service/zio-monitors</p>



<u>Claim 1</u>	<u>Accused Instrumentalities</u>				
<p>1[a]. a battery;</p>	<p><i>The Accused Instrumentalities include a battery.</i> The Zio Monitor satisfies 1[a] because the Zio Monitor includes a battery.</p> <p>Power specifications</p> <table data-bbox="919 444 1558 552"> <tr> <td>Battery type</td><td>1 lithium manganese dioxide coin cell</td></tr> <tr> <td>Battery life</td><td>> 14 days</td></tr> </table> <p>(https://go.irhythmtech.com/hubfs/LB10117.01%20-%20ZIO%20MONITOR%20INSTRUCTIONS%20FOR%20USE%2c%20PRINTED%20(2).pdf)</p> <p>Precautions</p> <ul style="list-style-type: none"> • During storage and prior to prescription for a patient, do not exceed the temperature and humidity limitations for the Zio monitor. Devices exposed to environmental conditions outside the specified range may have degraded adhesive and battery performance. • Observe the temperature and humidity specifications for transportation and storage listed on the box and in the instructions for use. • Confirm the expiration date for the Zio monitor listed on the Zio box or pouch. Use of an expired device may cause a degradation of ECG signal quality and a low battery condition. Apply the device on or before expiration date. <p>(https://go.irhythmtech.com/hubfs/LB10117.01%20-%20ZIO%20MONITOR%20INSTRUCTIONS%20FOR%20USE%2c%20PRINTED%20(2).pdf)</p>	Battery type	1 lithium manganese dioxide coin cell	Battery life	> 14 days
Battery type	1 lithium manganese dioxide coin cell				
Battery life	> 14 days				

<u>Claim 1</u>	<u>Accused Instrumentalities</u>
	<p>The Zio Monitor, our newest model, is 72% smaller and 62% lighter relative to the previous generation. The Zio Monitor uses 1 coin-cell battery, as compared to the 2 used in Zio XT. This is the second-most environmentally impactful component of our devices (after the circuit board). While we recycle these batteries, this is still a meaningful reduction in impact.</p> <p>(https://s201.q4cdn.com/653785554/files/doc_downloads/V4_-_iRhythm_ESG_Report_2023.pdf)</p> <p>ZIO MONITOR SYSTEM</p> <p>The Zio Monitor System is the next generation of the Zio XT System, and is a prescription-only, remote ECG monitoring system that consists of the Zio Monitor patch that records the electric signal from the heart continuously for up to 14 days and the ZEUS System, which supports the capture and analysis of ECG data recorded by the Zio Monitor patch at the end of the wear period, including specific arrhythmia events detected by the ZEUS algorithm.</p> <p>(https://s201.q4cdn.com/653785554/files/doc_downloads/V4_-_iRhythm_ESG_Report_2023.pdf)</p>


<u>Claim 1</u>	<u>Accused Instrumentalities</u>
<p>1[b]. a non-conductive receptacle configured to house the battery;</p>	<p><i>The Accused Instrumentalities include a non-conductive receptacle configured to house a battery.</i></p> <p>The Zio Monitor satisfies 1[b] because the Zio Monitor includes a non-conductive receptacle configured to house a battery.</p> <div data-bbox="844 425 1633 824">A photograph of the Zio Monitor device, which is a blue, oval-shaped patch. It features a central silver circular component with the word "ZIO" embossed on it. To the left of the center, there is a white arrow pointing upwards and the text "Instructions Peel clear backings (underside). Apply to chest with arrow pointing up." To the right of the center, there is a white rectangular label with the text "DO NOT REMOVE THIS BLUE LAYER UNTIL MONITOR IS APPLIED." The device is shown against a plain white background.</div> <p>(Zio Monitor Teardown)</p> <div data-bbox="844 915 1633 1315">A photograph of the Zio Monitor device with its clear backings removed, revealing the internal components. The device is shown from a top-down perspective, showing the silver circular component in the center and the clear backings on either side. The backings are yellowish and have a grid of small holes. The device is shown against a plain white background.</div> <p>(Zio Monitor Teardown)</p>



<u>Claim 1</u>	<u>Accused Instrumentalities</u>
	<div data-bbox="667 310 1812 756">A photograph showing the Zio Monitor device, a small circular medical sensor, placed on a blue protective backing. The backing has white text instructions: 'Instructions Peel clear backings (underside). Apply to chest with arrow pointing up.' and a white arrow pointing upwards. To the right of the device, there is a white circular cap with the 'ZIO' logo. The device itself is partially covered by the backing, showing its metallic outer ring and internal components.</div> <p data-bbox="583 776 903 808">(Zio Monitor Teardown)</p> <div data-bbox="667 846 1812 1255">A close-up photograph of the Zio Monitor device, showing its internal components. The device is circular with a metallic outer ring. The central part is a black printed circuit board (PCB) with numerous gold-colored solder pads and various electronic components, including a small square chip and several resistors. The device is placed on a white surface.</div> <p data-bbox="583 1274 903 1307">(Zio Monitor Teardown)</p>



<u>Claim 1</u>	<u>Accused Instrumentalities</u>
<p>1[c]. a housing comprising rounded edges along a top surface,</p>	<p><i>The Accused Instrumentalities include wherein the sealed housing includes a housing comprising rounded edges along a top surface.</i> The Zio Monitor satisfies 1[c] because the Zio Monitor includes a housing comprising rounded edges along a top surface.</p> <div data-bbox="848 425 1629 917"></div> <p>Zio Monitor</p> <p>(https://s201.q4cdn.com/653785554/files/doc_downloads/V4_-_iRhythm_ESG_Report_2023.pdf)</p>


<u>Claim 1</u>	<u>Accused Instrumentalities</u>
	<div data-bbox="783 310 1692 773">A photograph of a Zio Monitor device, which is a blue, oval-shaped adhesive patch. The patch is shown with its top layer removed, revealing a silver-colored circular electrode in the center. The electrode has the word "ZIO" embossed on it. To the left of the electrode, there is a white arrow pointing upwards and the word "Instructions" in bold. Below the arrow, the text reads: "Peel clear backings (underside). Apply to chest with arrow pointing up." To the right of the electrode, there is a white rectangular label with the text: "DO NOT REMOVE THIS BLUE LAYER UNTIL MONITOR IS APPLIED." The patch is set against a light-colored background.</div> <p data-bbox="583 792 903 824">(Zio Monitor Teardown)</p> <div data-bbox="632 862 1843 1333">A photograph of a Zio Monitor device, similar to the one above, but with the top layer removed, revealing the internal components. The device is blue and oval-shaped. The internal components include a silver-colored circular electrode in the center, which has the word "ZIO" embossed on it. To the left of the electrode, there is a white arrow pointing upwards and the word "Instructions" in bold. Below the arrow, the text reads: "Peel clear backings (underside). Apply to chest with arrow pointing up." To the right of the electrode, there is a white rectangular label with the text: "DO NOT REMOVE THIS BLUE LAYER UNTIL MONITOR IS APPLIED." The device is set against a light-colored background.</div> <p data-bbox="583 1352 903 1385">(Zio Monitor Teardown)</p>


<u>Claim 1</u>	<u>Accused Instrumentalities</u>
<p>1[d]. wherein the housing engages the non-conductive receptacle and the non-conductive receptacle is configured to receive the housing,</p>	<p><i>The Accused Instrumentalities include a housing , which engages the non-conductive receptacle and the non-conductive receptacle is configured to receive the housing.</i> The Zio Monitor satisfies 1[d] because the Zio Monitor includes the housing engages the non-conductive receptacle and the non-conductive receptacle is configured to receive the housing.</p> <div data-bbox="913 446 1543 706"><p>The diagram shows a cross-section of a housing assembly. A central horizontal line represents the axis of symmetry. Above this line, a curved line labeled 714 represents the top flange of a housing. Below the line, a curved line labeled 716 represents the bottom flange. Between these two flanges, there is a shaded rectangular region labeled 718, which represents a non-conductive receptacle. The housing flanges are positioned such that they engage the receptacle. A reference numeral 700 with an arrow points to the entire housing assembly.</p></div> <p>FIG. 12F</p> <p>(https://patentimages.storage.googleapis.com/12/7b/34/ee9a6b3db2a824/US11399760.pdf)</p>

<u>Claim 1</u>	<u>Accused Instrumentalities</u>
	 <p>The diagram, labeled FIG. 15B, shows an exploded view of a medical device assembly. The components are arranged vertically and labeled with reference numerals: 640 (a circular ring), 120 (a small rectangular component), 632 (a small rectangular component), 610 (a large, irregularly shaped base plate with a grid of small holes), 332 (a circular component with a grid of small holes), 160 (a circular component), 650 (a circular component), 665 (a U-shaped component), and 645 (a circular component with internal structures). The components are shown in a perspective view, with lines indicating their relative positions and assembly order.</p> <p>FIG. 15B</p> <p>(https://patentimages.storage.googleapis.com/12/7b/34/ee9a6b3db2a824/US11399760.pdf)</p>


<u>Claim 1</u>	<u>Accused Instrumentalities</u>
<p>1[e]. wherein the battery is positioned between the housing and a bottom surface of the non-conductive receptacle;</p>	<p><i>The Accused Instrumentalities include a battery positioned between the housing and a bottom surface of the non-conductive receptacle.</i> The Zio Monitor satisfies 1[e] because the Zio Monitor includes a battery positioned between the housing and a bottom surface of the non-conductive receptacle.</p> <div data-bbox="846 423 1631 824">A photograph of the Zio Monitor device, which is a blue, oval-shaped patch. It features a central silver circular electrode with the 'ZIO' logo. To the left of the electrode is a white label with the word 'Instructions' in bold, followed by the text 'Peel clear backings (underside). Apply to chest with arrow pointing up.' and a white arrow pointing upwards. To the right of the electrode is another white label that reads 'DO NOT REMOVE THIS BLUE LAYER UNTIL MONITOR IS APPLIED.' The device has small white tabs at the top and bottom.</div> <p>(Zio Monitor Teardown)</p> <div data-bbox="846 914 1631 1317">A photograph showing the Zio Monitor device after the clear backings have been removed. The device is now transparent, revealing the internal components. A silver circular battery is visible in the center, with the text 'DAA3737EP' and 'RHYTHM' printed on it. The device is flanked by two yellowish, circular adhesive pads. The entire assembly is held within a clear plastic frame.</div> <p>(Zio Monitor Teardown)</p>


<u>Claim 1</u>	<u>Accused Instrumentalities</u>
	<div data-bbox="653 293 1820 748"></div> <p data-bbox="583 764 903 800">(Zio Monitor Teardown)</p> <div data-bbox="913 824 1543 1079"></div> <p data-bbox="1144 1109 1260 1144">FIG. 12F</p> <p data-bbox="583 1214 1749 1250">(https://patentimages.storage.googleapis.com/12/7b/34/ee9a6b3db2a824/US11399760.pdf)</p>


<u>Claim 1</u>	<u>Accused Instrumentalities</u>
	 <p data-bbox="1178 1127 1262 1153">FIG. 15B</p> <p data-bbox="583 1203 1745 1239">(https://patentimages.storage.googleapis.com/12/7b/34/ee9a6b3db2a824/US11399760.pdf)</p>

<u>Claim 1</u>	<u>Accused Instrumentalities</u>
<p>1[f]. a patient feedback button located on the top surface of the housing;</p>	<p><i>The Accused Instrumentalities include a patient feedback button located on the top surface of the housing.</i> The Zio Monitor satisfies 1[f] because the Zio Monitor includes a patient feedback button located on the top surface of the housing.</p> <p>Example of Zio monitor</p>  <ul style="list-style-type: none"> ① Electrode – acquires ECG data ② Adhesive wings – adheres the Zio monitor to the upper-left chest ③ Light – momentarily flashes green when activated and orange in the event of an error. After activation, you will not see any lights. Refer to Troubleshooting - flashing lights on page 17. ④ Zio button – activates the Zio monitor. The patient presses this button when a symptom is felt. ⑤ Clear plastic backings – remove from back of Zio monitor and discard before applying to the chest. <p>(https://go.irhythmtech.com/hubfs/LB10117.01%20-%20ZIO%20MONITOR%20INSTRUCTIONS%20FOR%20USE%2c%20PRINTED%20(2).pdf)</p>

<u>Claim 1</u>	<u>Accused Instrumentalities</u>
	<p>The Zio monitor is a single-use ECG monitor that provides a continuous, single-channel recording for up to 14 days. The Zio monitor records ECG data without patient interaction, with the goal of improving patient compliance via simplicity of operation. Patients have the option of pressing a convenient button and filling out a log to document symptomatic events, which will support symptom-rhythm correlation in the diagnostic report.</p> <p>(https://go.irhythmtech.com/hubfs/LB10117.01%20-%20ZIO%20MONITOR%20INSTRUCTIONS%20FOR%20USE%2c%20PRINTED%20(2).pdf)</p> <p>A “symptom” is anything unusual the patient feels or experiences.</p> <p>1. Press the button on your Zio monitor when you feel a symptom.</p> <ul style="list-style-type: none">• The light does not flash when the button is pressed.• If you forget to either press the button or log a symptom, the Zio monitor is recording the ECG data. <p>(https://go.irhythmtech.com/hubfs/LB10117.01%20-%20ZIO%20MONITOR%20INSTRUCTIONS%20FOR%20USE%2c%20PRINTED%20(2).pdf)</p>

<u>Claim 1</u>	<u>Accused Instrumentalities</u>
	<p data-bbox="743 310 1354 370">4. Activate Zio monitor</p> <hr data-bbox="743 394 1753 397"/>  <p data-bbox="747 748 1745 927"><ul style="list-style-type: none">• Press and release button:<ul style="list-style-type: none">a. Press and quickly release the button on the Zio monitor.b. Watch the light briefly flash green to indicate the Zio monitor is recording ECG data.</p> <p data-bbox="583 951 1837 1024">(https://go.irhythmtech.com/hubfs/LB10117.01%20-%20ZIO%20MONITOR%20INSTRUCTIONS%20FOR%20USE%2c%20PRINTED%20(2).pdf)</p>


<u>Claim 1</u>	<u>Accused Instrumentalities</u>
<p>1[g]. an electrographic front end circuit to sense electrocardiographic signals;</p>	<p><i>The Accused Instrumentalities include an electrographic front end circuit to sense electrocardiographic signals.</i> The Zio Monitor satisfies 1[g] because the Zio Monitor comprises an electrographic front end circuit to sense electrocardiographic signals.</p> <div data-bbox="898 423 1581 966"></div> <p>(Zio Monitor Teardown)</p>

<u>Claim 1</u>	<u>Accused Instrumentalities</u>
	<p data-bbox="701 310 1171 358">Example of Zio monitor</p> <div data-bbox="764 396 1772 911">  <ul style="list-style-type: none"> ① Electrode – acquires ECG data ② Adhesive wings – adheres the Zio monitor to the upper-left chest ③ Light – momentarily flashes green when activated and orange in the event of an error. After activation, you will not see any lights. Refer to Troubleshooting - flashing lights on page 17. ④ Zio button – activates the Zio monitor. The patient presses this button when a symptom is felt. ⑤ Clear plastic backings – remove from back of Zio monitor and discard before applying to the chest. </div> <p data-bbox="583 943 1837 1013">(https://go.irhythmtech.com/hubfs/LB10117.01%20-%20ZIO%20MONITOR%20INSTRUCTIONS%20FOR%20USE%2c%20PRINTED%20(2).pdf)</p>






<u>Claim 1</u>	<u>Accused Instrumentalities</u>
	<p>Day: From a technical viewpoint what we did was really to leverage a lot of advances not just in microprocessor efficiency, which is certainly part of it in terms of miniaturization as well as energy efficiency, but also we really challenged ourselves to figure out how to effectively fit in the smallest possible form factor, which for us was motivated a lot by the size of our battery, which is just a standard, easily available, and fortunately easily recyclable coin cell battery. We challenged ourselves to figure out how to miniaturize the device down to the level of one of those coin cells instead of the two that the Zio XT device uses. And that became feasible by the advances in microelectronic microprocessor efficiency and size as well through its miniaturization. But it also required a lot of really complicated dynamics from an electrical engineering perspective to figure out how to get all the components of a wearable medical device and a biosensor onto that small form factor. So, miniaturization was focused on very clever ways of handling some of the larger components, which for example involved moving some of the big resistors that are required on the device to the more flexible part of the patch instead of on the actual printed circuit board in the housing. And this is a patented feature that we've already received a patent on it and we're pursuing more around it, but it was the idea that these three big resistors are not too big in terms of the homage that they have but also in terms of the size that they are. So, if you put them on the circuit board, they are these pretty big components, so we realized pretty early on that we couldn't really do that and still fit the design constraints. So, we innovated a different way, which was to integrate it into the ECG tracings themselves.</p> <p>(https://www.mddionline.com/cardiovascular/behind-the-design-how-irhythm-built-its-new-zio-monitor)</p>

Claim 1

Accused Instrumentalities




(MAX30003 Datasheet)


<u>Claim 1</u>	<u>Accused Instrumentalities</u>
	<div data-bbox="869 315 1079 375">  </div> <div data-bbox="1304 315 1604 396">     </div> <div data-bbox="1178 402 1604 418"> <p>Click here to ask an associate for production status of specific part numbers.</p> </div> <div data-bbox="869 423 1604 472"> <p>Ultra-Low Power, Single-Channel Integrated Biopotential (ECG, R-to-R Detection) AFE MAX30003</p> </div> <div data-bbox="869 488 1234 529"> <h3>General Description</h3> </div> <div data-bbox="869 537 1604 740"> <p>The MAX30003 is a complete, biopotential, analog front-end solution for wearable applications. It offers high performance for clinical and fitness applications, with ultra-low power for long battery life. The MAX30003 is a single biopotential channel providing ECG waveforms and heart rate detection.</p> </div> <div data-bbox="869 748 1604 1195"> <p>The biopotential channel has ESD protection, EMI filtering, internal lead biasing, DC leads-off detection, ultra-low power leads-on detection during standby mode, and extensive calibration voltages for built-in self-test. Soft power-up sequencing ensures no large transients are injected into the electrodes. The biopotential channel also has high input impedance, low noise, high CMRR, programmable gain, various low-pass and high-pass filter options, and a high resolution analog-to-digital converter. The biopotential channel is DC coupled, can handle large electrode voltage offsets, and has a fast recovery mode to quickly recover from overdrive conditions, such as defibrillation and electrosurgery.</p> </div> <div data-bbox="869 1211 1604 1308"> <p>The MAX30003 is available in a 28-pin TQFN and 30-bump wafer-level package (WLP), operating over the 0°C to +70°C commercial temperature range.</p> </div> <div data-bbox="583 1325 894 1365"> <p>(MAX30003 Datasheet)</p> </div>



<u>Claim 1</u>	<u>Accused Instrumentalities</u>
	<p data-bbox="884 321 1272 354">Benefits and Features</p> <ul data-bbox="884 370 1598 1230" style="list-style-type: none"> <li data-bbox="884 370 1598 467">• Clinical-Grade ECG AFE with High-Resolution Data Converter <ul data-bbox="926 435 1566 467" style="list-style-type: none"> <li data-bbox="926 435 1566 467">• 15.5 Bits Effective Resolution with 5µV_{P-P} Noise <li data-bbox="884 483 1598 581">• Better Dry Starts Due to Much Improved Real World CMRR and High Input Impedance <ul data-bbox="926 548 1587 581" style="list-style-type: none"> <li data-bbox="926 548 1587 581">• Fully Differential Input Structure with CMRR > 100dB <li data-bbox="884 597 1598 727">• Offers Better Common-Mode to Differential Mode Conversion Due to High Input Impedance <ul data-bbox="926 662 1587 727" style="list-style-type: none"> <li data-bbox="926 662 1587 727">• High Input Impedance > 500MΩ for Extremely Low Common-to-Differential Mode Conversion <li data-bbox="884 743 1598 808">• Minimum Signal Attenuation at the Input During Dry Start Due to High Electrode Impedance <li data-bbox="884 824 1598 889">• High DC Offset Range of ±650mV (1.8V, typ) Allows to Be Used with Wide Variety of Electrodes <li data-bbox="884 906 1598 1003">• High AC Dynamic Range of 65mV_{P-P} Will Help the AFE Not Saturate in the Presence of Motion/Direct Electrode Hits <li data-bbox="884 1019 1598 1084">• Longer Battery Life Compared to Competing Solutions <ul data-bbox="926 1052 1325 1084" style="list-style-type: none"> <li data-bbox="926 1052 1325 1084">• 85µW at 1.1V Supply Voltage <li data-bbox="884 1101 1598 1230">• Leads-On Interrupt Feature Allows to Keep µC in Deep Sleep Mode with RTC Off Until Valid Lead Condition is Detected <ul data-bbox="926 1198 1409 1230" style="list-style-type: none"> <li data-bbox="926 1198 1409 1230">• Lead-On Detect Current: 0.7µA (typ) <p data-bbox="583 1255 894 1287">(MAX30003 Datasheet)</p>


<u>Claim 1</u>	<u>Accused Instrumentalities</u>
	<ul style="list-style-type: none">• Built-In Heart Rate Detection with Interrupt Feature Eliminates the Need to Run HR Algorithm on the μController<ul style="list-style-type: none">• Robust R-R Detection in High Motion Environment at Extremely Low Power• Configurable Interrupts Allows the μC Wake-Up Only on Every Heart Beat Reducing the Overall System Power• High Accuracy Allows for More Physiological Data Extractions• 32-Word FIFO Allows You to Wake Up μController Every 256ms with Full ECG Acquisition• High-Speed SPI Interface• Shutdown Current of 0.5μA (typ) <p>(MAX30003 Datasheet)</p>



<u>Claim 1</u>	<u>Accused Instrumentalities</u>
<p>1[h]. a distal electrocardiography electrode coupled to a distal end of a flexible circuit and a proximal electrocardiography electrode coupled to a proximal end of the flexible circuit,</p>	<p><i>The Accused Instrumentalities include a distal electrocardiography electrode coupled to a distal end of a flexible circuit and a proximal electrocardiography electrode coupled to a proximal end of the flexible circuit.</i> The Zio Monitor satisfies 1[h] because the Zio Monitor includes a flexible circuit with a distal and a proximal end. The distal end and the proximal end each include an electrocardiography electrode.</p> <p>Example of Zio monitor</p>  <p>The diagram illustrates the Zio monitor, a small, oval-shaped device with a flexible circuit. It is shown being applied to the upper-left chest. The device has two circular electrodes at opposite ends of the flexible circuit. A central button is labeled 'Zio'. The device is shown with adhesive wings and clear plastic backings. Numbered callouts (1-5) point to specific components: 1. Electrode, 2. Adhesive wings, 3. Light, 4. Zio button, and 5. Clear plastic backings.</p> <ul style="list-style-type: none"> ① Electrode – acquires ECG data ② Adhesive wings – adheres the Zio monitor to the upper-left chest ③ Light – momentarily flashes green when activated and orange in the event of an error. After activation, you will not see any lights. Refer to Troubleshooting - flashing lights on page 17. ④ Zio button – activates the Zio monitor. The patient presses this button when a symptom is felt. ⑤ Clear plastic backings – remove from back of Zio monitor and discard before applying to the chest. <p>(https://go.irhythmtech.com/hubfs/LB10117.01%20-%20ZIO%20MONITOR%20INSTRUCTIONS%20FOR%20USE%2c%20PRINTED%20(2).pdf)</p>



<u>Claim 1</u>	<u>Accused Instrumentalities</u>
	<div data-bbox="814 302 1661 737"></div> <p data-bbox="583 756 903 792">(Zio Monitor Teardown)</p>

<u>Claim 1</u>	<u>Accused Instrumentalities</u>
<p>1[i]. wherein the flexible circuit is coupled to a flexible backing and the flexible backing is configured to adhere to skin of a patient's chest; and</p>	<p><i>The Accused Instrumentalities include a flexible circuit, which is coupled to a flexible backing and the flexible backing is configured to adhere to skin of a patient's chest.</i> The Zio Monitor satisfies 1[i] because the Zio Monitor includes a flexible backing that is configured to adhere to the skin of a patient's chest. The flexible circuit is coupled to the flexible backing.</p> <div data-bbox="814 459 1654 993"></div> <p>Zio Monitor</p> <p>(https://s201.q4cdn.com/653785554/files/doc_downloads/V4_-_iRhythm_ESG_Report_2023.pdf)</p>


<u>Claim 1</u>	<u>Accused Instrumentalities</u>
	<div data-bbox="831 306 1646 698">A top-down view of a Zio Monitor device. It is a blue, oval-shaped patch with a central silver circular electrode labeled 'ZIO'. On the left, white text reads 'Instructions' with a white arrow pointing upwards, followed by 'Peel clear backings (underside). Apply to chest with arrow pointing up.' On the right, a white label reads 'DO NOT REMOVE THIS BLUE LAYER UNTIL MONITOR IS APPLIED.' There are small white arrows '»' and '«' near the top and bottom edges.</div> <p data-bbox="583 716 903 751">(Zio Monitor Teardown)</p> <div data-bbox="831 784 1656 1209">A bottom-up view of the Zio Monitor device, showing the clear adhesive backings on either side of the central silver electrode. The electrode has 'DAA3737E01' and 'PC' printed on it. The clear layers are held in place by white tabs.</div> <p data-bbox="583 1227 903 1263">(Zio Monitor Teardown)</p>


<u>Claim 1</u>	<u>Accused Instrumentalities</u>
	<p data-bbox="678 310 1167 362">Example of Zio monitor</p> <div data-bbox="743 406 1799 938"><p data-bbox="1249 414 1799 938"><ul style="list-style-type: none">① Electrode – acquires ECG data② Adhesive wings – adheres the Zio monitor to the upper-left chest③ Light – momentarily flashes green when activated and orange in the event of an error. After activation, you will not see any lights. Refer to Troubleshooting - flashing lights on page 17.④ Zio button – activates the Zio monitor. The patient presses this button when a symptom is felt.⑤ Clear plastic backings – remove from back of Zio monitor and discard before applying to the chest.</p></div> <p data-bbox="583 982 1837 1052">(https://go.irhythmtech.com/hubfs/LB10117.01%20-%20ZIO%20MONITOR%20INSTRUCTIONS%20FOR%20USE%2c%20PRINTED%20(2).pdf)</p>

<u>Claim 1</u>	<u>Accused Instrumentalities</u>
<p>1[j]. a microcontroller secured by the housing,</p>	<p><i>The Accused Instrumentalities include a microcontroller secured by the housing.</i> The Zio Monitor satisfies 1[j] because the Zio Monitor comprises a micro-controller secured by the housing.</p> <div data-bbox="829 388 1646 776">A photograph of the Zio Monitor packaging, which is a blue, oval-shaped blister pack. It features a central silver-colored circular cap with the 'ZIO' logo. To the left of the cap, there is a white arrow pointing upwards and the text 'Instructions Peel clear backings (underside). Apply to chest with arrow pointing up.' To the right of the cap, there is a white rectangular label with the text 'DO NOT REMOVE THIS BLUE LAYER UNTIL MONITOR IS APPLIED.' The packaging is shown against a light background.</div> <p>(Zio Monitor Teardown)</p> <div data-bbox="829 862 1646 1289">A photograph showing the Zio Monitor after the blue packaging has been removed. The device is a small, circular, silver-colored component with a central gold-colored contact point. It is surrounded by a clear, flexible, yellowish material that appears to be a protective layer or adhesive. The device is shown against a light background.</div> <p>(Zio Monitor Teardown)</p>

<u>Claim 1</u>	<u>Accused Instrumentalities</u>
	<div data-bbox="940 310 1535 781"></div> <div data-bbox="583 802 903 837">(Zio Monitor Teardown)</div> <div data-bbox="940 873 1535 1333"></div> <div data-bbox="583 1349 903 1385">(Zio Monitor Teardown)</div>

<u>Claim 1</u>	<u>Accused Instrumentalities</u>
	<p>General Description</p> <p>DARWIN is a new breed of low-power microcontrollers built to thrive in the rapidly evolving Internet of Things (IoT). They are smart, with the biggest memories in their class and a massively scalable memory architecture. They run forever, thanks to wearable-grade power technology. They are durable enough to withstand the most advanced cyberattacks. DARWIN microcontrollers are designed to run any application imaginable—in places where you would not dream of sending other microcontrollers.</p> <p>Generation UB microcontrollers are designed to handle the increasingly complex applications demanded by today's advanced battery-powered devices and wirelessly connected devices, while providing robust hardware security and Bluetooth® 5 Low Energy (Bluetooth LE) radio connectivity.</p> <p>The MAX32665/MAX32666 UB class microcontrollers are advanced systems-on-chips featuring an Arm® Cortex®-M4 with FPU CPU for efficient computation of complex functions and algorithms with integrated power management. It also includes the newest generation Bluetooth 5 LE radio with support for long range (4x) and high throughput (2Mbps) and ADI's best-in-class hardware security suite trust protection unit (TPU). The devices offer large on-board memory with 1MB flash and 560KB SRAM. Split flash banks of 512KB each support seamless over-the-air upgrades, adding an additional degree of reliability. Memory scalability of data (SRAM) and code (Flash) space is supported by two SPI execute-in-place (SPIX) interfaces.</p> <p>(MAX32666 Datasheet)</p>


<u>Claim 1</u>	<u>Accused Instrumentalities</u>
<p>1[k]. wherein the microcontroller is interfaced to the electrocardiographic front end circuit to sample the electrocardiographic signals.</p>	<p><i>The Accused Instrumentalities include a microcontroller that is interfaced to the electrocardiographic front end circuit to sample the electrocardiographic signals.</i> The Zio Monitor comprises a microcontroller that is interfaced to the electrocardiographic front end circuit to sample the electrocardiographic signals.</p> <div data-bbox="898 462 1579 1003">A photograph of a Zio Monitor circuit board, showing various electronic components including a microcontroller, capacitors, and other integrated circuits. The board is dark green and populated with numerous surface-mount components. A large black integrated circuit (IC) is visible in the upper center, labeled '2RF17 NW944'. Below it, another IC is labeled 'MAX3266B 2248 341AB'. To the right, a smaller IC is labeled 'MAX3102'. The board has a complex, irregular shape with several cutouts and mounting points.</div> <p>(Zio Monitor Teardown)</p>

<u>Claim 1</u>	<u>Accused Instrumentalities</u>
	<p data-bbox="701 310 1171 358">Example of Zio monitor</p> <div data-bbox="764 402 1772 914"><p data-bbox="1247 410 1772 914"><ul style="list-style-type: none">① Electrode – acquires ECG data② Adhesive wings – adheres the Zio monitor to the upper-left chest③ Light – momentarily flashes green when activated and orange in the event of an error. After activation, you will not see any lights. Refer to Troubleshooting - flashing lights on page 17.④ Zio button – activates the Zio monitor. The patient presses this button when a symptom is felt.⑤ Clear plastic backings – remove from back of Zio monitor and discard before applying to the chest.</p></div> <p data-bbox="583 943 1837 1016">(https://go.irhythmtech.com/hubfs/LB10117.01%20-%20ZIO%20MONITOR%20INSTRUCTIONS%20FOR%20USE%2c%20PRINTED%20(2).pdf)</p>






<u>Claim 1</u>	<u>Accused Instrumentalities</u>
	<p>Day: From a technical viewpoint what we did was really to leverage a lot of advances not just in microprocessor efficiency, which is certainly part of it in terms of miniaturization as well as energy efficiency, but also we really challenged ourselves to figure out how to effectively fit in the smallest possible form factor, which for us was motivated a lot by the size of our battery, which is just a standard, easily available, and fortunately easily recyclable coin cell battery. We challenged ourselves to figure out how to miniaturize the device down to the level of one of those coin cells instead of the two that the Zio XT device uses. And that became feasible by the advances in microelectronic microprocessor efficiency and size as well through its miniaturization. But it also required a lot of really complicated dynamics from an electrical engineering perspective to figure out how to get all the components of a wearable medical device and a biosensor onto that small form factor. So, miniaturization was focused on very clever ways of handling some of the larger components, which for example involved moving some of the big resistors that are required on the device to the more flexible part of the patch instead of on the actual printed circuit board in the housing. And this is a patented feature that we've already received a patent on it and we're pursuing more around it, but it was the idea that these three big resistors are not too big in terms of the homage that they have but also in terms of the size that they are. So, if you put them on the circuit board, they are these pretty big components, so we realized pretty early on that we couldn't really do that and still fit the design constraints. So, we innovated a different way, which was to integrate it into the ECG tracings themselves.</p> <p>(https://www.mddionline.com/cardiovascular/behind-the-design-how-irhythm-built-its-new-zio-monitor)</p>

Claim 1

Accused Instrumentalities



(MAX30003 Datasheet)

<u>Claim 1</u>	<u>Accused Instrumentalities</u>
	<div data-bbox="869 315 1079 375">  </div> <div data-bbox="1312 315 1602 396">     </div> <div data-bbox="1178 402 1602 418"> <p><small>Click here to ask an associate for production status of specific part numbers.</small></p> </div> <div data-bbox="867 422 1606 472"> <p>Ultra-Low Power, Single-Channel Integrated Biopotential (ECG, R-to-R Detection) AFE MAX30003</p> </div> <div data-bbox="867 487 1236 527"> <h3>General Description</h3> </div> <div data-bbox="863 532 1610 735"> <p>The MAX30003 is a complete, biopotential, analog front-end solution for wearable applications. It offers high performance for clinical and fitness applications, with ultra-low power for long battery life. The MAX30003 is a single biopotential channel providing ECG waveforms and heart rate detection.</p> </div> <div data-bbox="863 750 1610 1196"> <p>The biopotential channel has ESD protection, EMI filtering, internal lead biasing, DC leads-off detection, ultra-low power leads-on detection during standby mode, and extensive calibration voltages for built-in self-test. Soft power-up sequencing ensures no large transients are injected into the electrodes. The biopotential channel also has high input impedance, low noise, high CMRR, programmable gain, various low-pass and high-pass filter options, and a high resolution analog-to-digital converter. The biopotential channel is DC coupled, can handle large electrode voltage offsets, and has a fast recovery mode to quickly recover from overdrive conditions, such as defibrillation and electrosurgery.</p> </div> <div data-bbox="863 1209 1610 1310"> <p>The MAX30003 is available in a 28-pin TQFN and 30-bump wafer-level package (WLP), operating over the 0°C to +70°C commercial temperature range.</p> </div> <div data-bbox="577 1326 898 1362"> <p>(MAX30003 Datasheet)</p> </div>

<u>Claim 1</u>	<u>Accused Instrumentalities</u>
	<p data-bbox="884 321 1272 354">Benefits and Features</p> <ul data-bbox="884 370 1598 1230" style="list-style-type: none"> <li data-bbox="884 370 1598 467">• Clinical-Grade ECG AFE with High-Resolution Data Converter <ul data-bbox="926 435 1566 467" style="list-style-type: none"> <li data-bbox="926 435 1566 467">• 15.5 Bits Effective Resolution with 5µV_{P-P} Noise <li data-bbox="884 483 1598 581">• Better Dry Starts Due to Much Improved Real World CMRR and High Input Impedance <ul data-bbox="926 548 1587 581" style="list-style-type: none"> <li data-bbox="926 548 1587 581">• Fully Differential Input Structure with CMRR > 100dB <li data-bbox="884 597 1598 727">• Offers Better Common-Mode to Differential Mode Conversion Due to High Input Impedance <ul data-bbox="926 662 1598 727" style="list-style-type: none"> <li data-bbox="926 662 1598 727">• High Input Impedance > 500MΩ for Extremely Low Common-to-Differential Mode Conversion <li data-bbox="884 743 1598 808">• Minimum Signal Attenuation at the Input During Dry Start Due to High Electrode Impedance <li data-bbox="884 824 1598 889">• High DC Offset Range of ±650mV (1.8V, typ) Allows to Be Used with Wide Variety of Electrodes <li data-bbox="884 906 1598 1003">• High AC Dynamic Range of 65mV_{P-P} Will Help the AFE Not Saturate in the Presence of Motion/Direct Electrode Hits <li data-bbox="884 1019 1598 1084">• Longer Battery Life Compared to Competing Solutions <ul data-bbox="926 1052 1325 1084" style="list-style-type: none"> <li data-bbox="926 1052 1325 1084">• 85µW at 1.1V Supply Voltage <li data-bbox="884 1101 1598 1230">• Leads-On Interrupt Feature Allows to Keep µC in Deep Sleep Mode with RTC Off Until Valid Lead Condition is Detected <ul data-bbox="926 1198 1409 1230" style="list-style-type: none"> <li data-bbox="926 1198 1409 1230">• Lead-On Detect Current: 0.7µA (typ) <p data-bbox="583 1255 894 1287">(MAX30003 Datasheet)</p>

<u>Claim 1</u>	<u>Accused Instrumentalities</u>
	<ul style="list-style-type: none">• Built-In Heart Rate Detection with Interrupt Feature Eliminates the Need to Run HR Algorithm on the μController<ul style="list-style-type: none">• Robust R-R Detection in High Motion Environment at Extremely Low Power• Configurable Interrupts Allows the μC Wake-Up Only on Every Heart Beat Reducing the Overall System Power• High Accuracy Allows for More Physiological Data Extractions• 32-Word FIFO Allows You to Wake Up μController Every 256ms with Full ECG Acquisition• High-Speed SPI Interface• Shutdown Current of 0.5μA (typ) <p>(MAX30003 Datasheet)</p>